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Abstract
Cancer is the leading cause of death in the developed world and research is ongo-
ing both towards curing the disease and understanding the disease on a cellular
level. As most cancer cells proliferate very fast, mitosis has often been the tar-
get of anti-cancer agents. However, this does not aﬀord cancer speciﬁc drugs as
healthy cells are also aﬀected, albeit to a lower extent. An ideal anti-cancer drug
would target cancer cells speciﬁcally, thus obviating side eﬀects.
A diﬀerence between healthy and cancerous cells that is currently being explored
is the supernumerary centrosomes present in most cancer cells. Centrosomes are
the microtubule organizing centers during mitosis and here, one centrosome is
situated at each pole of the mitotic spindle. During anaphase, each sister chromo-
some will be pulled towards the centrosomes in bipolar mitosis. Supernumerary
centrosomes enable the cancer cells to undergo multipolar mitosis, introducing
chromosomal instability, which would make it unlikely to produce viable progeny.
The cancer cells circumvent multipolar mitosis by a mechanism called centroso-
mal clustering, where any numbers of centrosomes are gathered in two clusters,
thus making bipolar mitosis possible. A small molecule that could disrupt centro-
somal clustering and force the cells to undergo multipolar mitosis might possess
the ability to aﬀect cancer cells speciﬁcally.
Prior to the work in this PhD thesis, the fungal metabolite griseofulvin (1) was
identiﬁed as an anti-cancer compound in a bio-guided screen of fungal raw ex-
tracts in a phenotypic based assay. The assay was designed to identify compounds
that forced cancer cells to undergo multipolar mitosis and thus apoptosis, using
the cancer cell line SCC114 (squamous cell carcinoma cells). In this work two
structure activity relationship (SAR) studies have been completed. The ﬁrst in-
vestigated the anti-cancer SAR of griseofulvin analogs in the phenotypic based
assay and the other a growth inhibition SAR against the two dermatophytes Tri-
chophyton mentagrophytes and T. rubrum as well as toxicity against the cancer
cell line MDA231 (human breast adenocarcinoma).
The studies found a good correlation between the anti-cancer phenotypic IC50
values and the cytotoxicity values (R2 = 0.70). General trends showed that alter-
ations of positions 4, 5 and 6 of griseofulvin lower the activity, while elongation
of the 2’ position increases the activity. Bulkier substituents increased the activ-
ity even further with the 2’ benzyloxy analog (2) being the most potent. The
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Figure 1: The structures of griseofulvin (1), 2’-benzyloxy-2’-demethoxy-
griseofulvin (2), the 4’ oxime (3) of the latter and aurantiamine (4)
introduction of an oxime at the 4’ position increase the potency slightly in both
assays but did not show any cumulative eﬀect with the 2’ benzyloxy group (3).
After extensive synthesis of 2’ analogs, the benzyloxy (2) and benzyloxy oxime
(3) analogs were still the best lead compounds.
It is not possible to distinguish between the two aryl methoxy groups in grise-
ofulvin (1) by NMR. To unequivocally prove the position of the two possible
phenols and thus the methoxy groups, the two phenols were synthesized and dis-
tinguished by single crystal X-ray analysis. In 1H NMR, the 4-methoxy group
resonates upﬁeld from the 6-methoxy group. A quantitative yield was obtained for
the synthesis of the 4 phenol by treatment of 1 with MgI2, while the 6 phenol was
obtained in 29% yield by treatment of 1 with LiI in pyridine. (+)-Geodin shares
the same structural core as griseofulvin (1) and it was isolated from Aspergillus
terreus to be tested in the phenotype based assay. The compound showed no
induction of multipolar mitoses but was twice as potent in the cytotoxicity assay
compared to 1. The unknown absolute structure of (+)-Geodin was assigned by
single crystal X-ray analysis.
The compound aurantiamine (4) was isolated from Penicillium cavernicola and
found to induce multipolarity in SCC114 cancer cells with an IC50 of 40 ± 4
μM. This was further investigated by ﬂuorescence-activated cell sorting (FACS)
analysis showing M phase arrest in SCC114 cells and an increase in the G0 pop-
ulation indicating apoptosis. Further indications of apoptosis was observed using
Western blotting for the p85 fragment of poly (ADP-ribose) polymerase (PARP),
a downstream target of activated caspase 3.
In addition to the above mentioned studies, a novel technique for the introduction
of radioactive iodide to aryl groups was developed. This was used in scintigraphic
in vivo imaging to assess bio-distribution and half-life of a griseofulvin analog.
Treating an aryl trimethylsilyl precursor with 2 equiv. of thallium(III)triﬂuoro-
acetate in 30% TFA in MeCN for 2 minutes followed by addition of sodium 125I
or 131I aﬀords the radio labeled compound in over 95% radioactive yield. This
method is applicable for both ortho, meta and para TMS aryl precursors stable
in TFA/MeCN (3:7).
6
Dansk Resume´
Kræft for˚arsager de ﬂeste dødsfald i den udviklede del af verdenen og kræft-
forskning har derfor høj prioritet. Forskningen fokuserer b˚ade p˚a at ﬁnde midler,
der kan helbrede personer ramt af kræft, men ogs˚a p˚a at forst˚a hvordan kræft
udvikles. De ﬂeste lægemidler i dag er ikke speciﬁkt rettet mod kræftceller men
rammer cellernes mitose. Da kræftceller deler sig meget hurtigere end de ﬂeste
andre celler i et menneske, bliver kræftcellerne dog h˚ardere ramt end de raske
celler. Ikke desto mindre ønskes et ideelt lægemiddel, der dræber kræftceller og
kun kræftceller.
En m˚ade hvorp˚a at ﬁnde denne slags lægemidler er at se p˚a hvilke forskelle,
der er p˚a raske celler og kræft celler. En s˚adan forskel er de unormalt mange
centrosomer, der ﬁndes i kræftceller. I raske celler er der to centrosomer under
mitosen, hvor de virker som microtubuli organiserende centre. Under bipolær
mitose sørger de for delingen af datterkromosomerne ud i de to datter celler.
Kræftcellerne med mange centrosomer har muligheden for at gennemg˚a en mul-
tipolar mitose, hvilket højst sandsynligt ville resultere i ikke levedygtige datter
celler. Kræftcellerne undg˚ar dette ved hjælp af centrosomal klyngedannelse, hvor
alle centrosomer bliver klumpet sammen i to klynger, der s˚a kan fungere som
to poler som i en regulær bipolær mitose. Et molekyle, der kan inhibere denne
centrosomale klyngedannelse, kan potentielt virke speciﬁkt mod kræftceller.
Griseofulvin (1, se Figur 2) blev, forud for dette arbejde, identiﬁceret som et
anti-kræft stof i en screening af svampe r˚aekstrakter i et phenotype baseret as-
say. Dette assay er designet til at identiﬁcere molekyler, der kan f˚a kræftceller til
at gennemg˚a multipolar mitose. Der er blevet gennemført to struktur-aktivitet
sammenhængsundersøgelser i dette arbejde. Det første omhandlede anti-kræft
egenskaberne af griseofulvin analoger i det phenotype baserede assay, mens der i
det andet blev testet analoger mod to patogene svampe Trichophyton mentagro-
phytes og T. rubrum samt en cancer cellelinje.
Der var en god korrelation mellem de IC50 værdier, der blev fundet i det pheno-
type baserede assay, og toksisitets-assay’et mod kræftcellelinjen (R2 = 0.70). Ud
fra data kunne det konkluderes, at ændringer i positionerne 4, 5 og 6 generelt
resulterede i en lavere aktivitet, mens forlængelse af 2’ position øgede aktiviteten.
Større grupper øgede aktiviteten yderligere med en 2’ benzyloxy gruppe som den
mest aktive. En oxim i 4’ positionen øgede aktiviteten i begge assays, men en
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Figure 2: Strukturerne af griseofulvin (1), 2’-benzyloxy-2’-demethoxy-
griseofulvin (2), 4’ oximen (3) af den foreg˚aende samt aurantiamine (4)
analog med b˚ade en 2’ benzyloxy gruppe samt en 4’ oxim viste ikke akkumuleret
aktivitet. Efter grundig undersøgelse af 2’ positionens betydning kunne det kon-
kluderes at 2’-benzyloxy analogen samt versionen med en 4’-oxim stadig er de
mest potente.
De to methoxy-grupper i griseofulvin kan ikke skelnes ved hjælp af NMR. For at
bevise positionen af de to methoxy-grupper blev phenolerne af griseofulvin synte-
tiseret og positionen af disse blev bestemt ved hjælp af enkeltkrystal røntgenanal-
yse. P˚a denne m˚ade kunne positionen af methoxy grupperne ogs˚a bestemmes,
og 4-methoxy gruppen er upﬁeld fra 6-methoxy gruppe. 4-phenol analogen blev
syntetiseret i kvantitativt udbytte med MgI2. 6-phenolen blev syntetiseret med
LiI i pyridin i 29% udbytte.
(+)-Geodin har samme grundstruktur som 1 og blev derfor isoleret fra Aspergillus
terreus for at blive testet. Det viste sig at (+)-geodin ikke inducerede multipolære
mitoser i SCC114 kræftceller, dog var (+)-geodin dobbelt s˚a aktiv i toksicitets
assayet i forhold til griseofulvin (1). (+)-Geodin’s absolutte struktur var uk-
endt men blev bestemt ved hjælp af enkeltkrystal røntgenanalyse til at være R
ved spirocentret. Aurantiamine (4) blev isoleret fra Penicillium cavernicola og
inducerede multipolar mitose i SCC114 kræftceller med en IC50 p˚a 40 ± 4 μM. In-
dvirkningen af 4 p˚a SCC114 celler blev ogs˚a undersøgt med ﬂuorescens-aktiveret
celle-sortering (FACS), og der blev observeret en ophobning af celler i M fase
og en øget G0 population, hvilket kan indikere apoptose. Ved hjælp af Western
blotting efter p85 fragmentet af poly (ADP-ribose) polymerase (PARP) blev det
yderligere p˚avist, at cellerne lavede apoptose.
En ny teknik til at mærke aromatiske stoﬀer med radioaktivt iod blev udviklet.
Behandling af en aromatisk trimethylsilyl (TMS) forbindelse med 2 ækvivalenter
Tl(OOCCF3)3 i MeCN/TFA (7:3) efterfulgt af radioaktivt kalium iodid (
125I eller
131I) førte til det radioaktivt mærkede stof i over 95% udbytte. Denne metode er
brugbar for b˚ade aromatiske ortho-, meta- og para-aryl TMS grupper s˚a længe
de er stabile i MeCN/TFA (7:3).
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Thesis Outline
The work for this thesis entitled ”New principles for targeting cancer - a rational
small molecule approach” is based on the cooperation between the Center for
Microbial Biotechnology at the Department of Systems Biology and the Depart-
ment of Chemistry both at the Technical University of Denmark and the German
Cancer Research Center at the University of Heidelberg, Germany. The thesis
includes work performed at all three locations, in the ﬁelds of natural products
chemistry, organic chemistry and microbiology.
The thesis consists of nine chapters. Chapter 1 is a short introduction to cancer,
centrosomal clustering, and natural products as bioactive compounds. Chapter
2 is a review of the chemistry of griseofulvin, intented for submission to Chem-
ical Reviews upon further work. Chapter 3 is a published paper concerning
an anti-cancer structure-activity relationship study of griseofulvin analogs in a
phenotypical assay. Chapter 4 is a manuscript concerning the structure-activity
relationship study of griseofulvin analogs against two dermathophytes as well as
a cancer cell line in two growth inhibition assays, which has been submitted to
the Journal of Medicinal Chemistry.
Chapter 5 is a published paper distinguishing between the two aryl methoxy
groups of griseofulvin. Chapter 6 presents the work performed on the develop-
ment of a radiolabeling technique of aryl trimethylsilyl precursors. Chapter 7 is
a published paper concerning the isolation of (+)-geodin and the determination
of the absolute structure of (+)-geodin. Chapter 8 presents, the work concerning
the isolation of aurantiamine and the work performed with this natural prod-
uct at the German Cancer Research Center (DKFZ), University of Heidelberg.
Chapter 9 is the ﬁnal conclusion of the entire work.
A paper with the title ”GF-15, a novel inhibitor of centrosomal clustering, sup-
presses multiple myeloma growth in vitro and in vivo”, which has been submitted
to Blood is found in Appendix A. Co-author statements for all articles and drafts
in the thesis can be found in Appendix B. Supporting information of articles and
drafts can be seen in Appendix C-G. To restrain the number of pages in the Ap-
pendix most of the supporting information have been modiﬁed to only contain
the 1H and 13C NMR spectra of synthesized/isolated compounds. Full support-
ing information for a given article can be obtained at the appropriate journal
homepage.
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Chapter 1
Introduction
In developed countries the single highest cause of death for man is cancer and
in developing countries it is the second highest cause.1 Therefore the attention
to and funding for cancer research is massive and it has accelerated in the late
20th century with for example the National Cancer Act of 1971 in the United
States.2 The focus in cancer research is both on treating the disease3 as well as
understanding what goes on at the cell biology level.4
So what is cancer? In short it is cells that proliferate abnormally and are able to
invade other tissue. It involves the transformation from normal to fully malignant
cells through a number of mutations (see Figure 1.1). One mutation or combina-
tions of mutations aﬀord the cells with one or more of the malignant phenotypes
required for the cells to develop into being fully malignant. Some phenotypes
are: insensitivity to antigrowth signals, mitogen-independent growth, evasion of
apoptosis, immortalization, sustained angiogenesis and metastasis.5,6,7 It’s well
known that smoking increases the risk of lung cancer8 and another example of
an exogenic factor that is life style related is obesity, which increases the risk of
renal cancer.9 However, factors which people have no or little inﬂuence on, like
ethnicity and socioeconomic status10,11,12 also have a correlation with the risk of
developing cancer.
Cancer can be treated by chemotherapy,13 radiation therapy14 or surgery15 and
often involves a combination of these treatments.16 For chemotherapy a popular
drug target has been mitosis and although not truly cancer speciﬁc, anti-mitotic
drugs are expected to aﬀect malignant cells to a greater extent than healthy cells.
After all, uncontrolled cell growth and proliferation is a deﬁning phenotype of
most malignant cells and thus the eﬀect from disrupting mitosis should be greater
on the malignant cells than on healthy, slower proliferating cells.17 However, some
healthy cells also proliferate fast and the side eﬀects of chemotherapy often stem
from the drugs eﬀect on these cell types. An example is hair bulb cells that are
often aﬀected by cytotoxic anti-cancer drugs resulting in hair loss (alopecia).18
Anti-mitotic agents often target tubulin,19 with two major groups, those that
stabilize microtubules (e.g. Taxol R©,20 epothilones21) and those that destabi-
lize tubulin (e.g. the vinca alkaloids22). In both cases microtubule dynamics
are greatly reduced, aﬀecting mitosis23 and resulting in cellular M phase arrest
followed by apoptosis.24
The ideal anti-cancer drug would target malignant cells and malignant cells
only and thus potentially obviate the side eﬀects of chemotherapy. In order to
achieve this, diﬀerences between malignant cells and healthy cells must be ex-
plored and described. A diﬀerence in phenotype that is currently being explored
is the fact that centrosome ampliﬁcation25,26,27,28 is a common feature in human
17
2 Introduction
Figure 1.1: On top normal cells are depicted with one daughter cell showing
DNA damage. This cell will undergo apoptosis because of the many tumor sup-
pressor mechanisms present in the cell. On the bottom more cells with DNA
damage are shown, which for some reason are not forced to undergo apoptosis,
possibly because the damage has aﬀected some of the tumor suppressor genes.
This cell population can then acquire more mutations over time and end up with
enough cancer phenotypic characteristics to become fully malignant (called the
multistep process). Artwork originally created for the National Cancer Institute.
Reprinted with permission of the artist, Jeanne Kelly. Copyright 2011.
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cancer cells. If not for a phenomenon called centrosomal clustering,29 cancer cells
would undergo multipolar mitoses resulting in aneuploid daughter cells, which are
determined to undergo apoptosis. A schematic overview is depicted in Figure 1.2,
where a cell with supernumerary centrosomes undergoes bipolar mitosis with the
majority of the progeny undergoing apoptosis. There is an odd chance of a daugh-
ter cell surviving the multipolar mitosis and regaining chromosomal stability by
centrosomal clustering. This cell is now able to undergo bipolar mitosis and to
proliferate. A small molecule that inhibits centrosomal clustering would force this
initial survivor to continuous multipolar mitosis resulting in unviable progeny at
some point. Such a small molecule would potentially oﬀer a speciﬁc treatment of
cancer.30
1.1 Centrosomal Clustering
A centrosome (see Figure 1.3) consists of two centrioles surrounded by an elec-
tron dense matrix of protein aggregates, referred to as the pericentriolar material
(PCM).32 The centrosomes are microtubule organizing centers and are essential
for correct segregation of chromosomes in diploid cells during bipolar mitosis.33
During mitosis (see Figure 1.4) of healthy cells the two centrosomes34 are situated
at each pole of the mitotic spindle, and in anaphase one copy of each duplicated
chromosome will be pulled to each pole. This results in two daughter cells each
with one centrosome and one identical set of DNA after cytokinesis. During the
next cell cycle the centrosome and DNA will be duplicated exactly once.
Whereas normal cells contain two centrosomes during mitosis34 it is common
that malignant cells contain supernumerary centrosomes.25,26,27,28 Having more
than two centrosomes could facilitate multipolar mitosis, with subsequent aber-
rant chromosome segregation and the development of aneuploid daughter cells,
which most likely will undergo apoptosis.7,31
Centrosome ampliﬁcation can happen through a number of pathways (See Fig-
ure 1.5): faulty regulation of centrosome synthesis35, abrupted mitosis36, fusion
of two cells37, fragmentation of centrosomes into smaller fractions that are still
able to function as microtubule organizing centers38,39, over-expression of cer-
tain pericentriolar material proteins producing a-centriolar microtubule organiz-
ing centers35, de novo synthesis of centrosomes40,41 or decoupled DNA and cen-
trosome cycles.42 Regardless of the path to supernumerary centrosomes, it evokes
chromosomal instability upon the cancer cell, and thus a property to acquire more
mutations.
There are currently two models for loss and/or gain of chromosomes for cells
with supernumerary centrosomes. A regular multipolar mitosis with three or
more poles aﬀording aneuploid daughter cells (see Figure 1.6). In this case it is
most likely that tripolar mitosis aﬀords aneuploid but viable daughter cells.43 It is
also possible for cells with extra centrosomes to align in a pseudo bipolar fashion
(see Figure 1.6). In this case one centrosome could fail to align with the bipolar
axis while still being able to nucleate microtubules and capture chromosomes
at their kinetochores.7 During anaphase the misaligned centrosome would pull
chromosomes out of the bipolar axis and one daughter cell would receive extra
chromosomes while the other would have lost them (see Figure 1.6).
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Figure 1.2: (A) The number of centrosomes in a cancer cell is ampliﬁed, which
can occur through multiple possible pathways (see Figure 1.5). (B) The cell
now undergoes multipolar mitosis with most progeny receiving insuﬃcient DNA
to survive, leading to apoptosis (C), while it is possible that one cell receives
enough DNA to survive and re-enter the cell cycle (D). The cell needs to regain
chromosomal stability to be viable and this is achived by centrosomal clustering,
which enables the cancer cell to undergo bipolar mitosis despite its supernumer-
ary centrosomes (E). Reprinted by permission from Macmillan Publishers Ltd:
Oncogene31, copyright 2001.
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Figure 1.3: A simple presentation of the centrosome. A pair of centrioles per-
pendicular to each other embedded in a cloud of pericentriolar material (PCM).
The centrosomes function as the main microtubule organizing center in the cell.
Reprinted by permission from Macmillan Publishers Ltd: Oncogene35, copyright
2002.
Figure 1.4: The cell cycle of a healthy cell is depicted. DNA and centrosome
replication occur in S phase (not shown), during interphase. In prophase the
unordered DNA is folded into sister chromosomes and in metaphase the mitotic
spindle is assembled. Here the chromosomes are aligned in between the two
centrosomes at each pole. During anaphase each sister chromosome is pulled
towards a centrosome followed by telophase, where the contractile ring initiates
cytokinesis. After completed cytokinesis two identical daughter cells have been
formed, which can now proliferate further. Copyright c© 2008 from Molecular
Biology of the Cell by Bruce Alberts et al. Reproduced by permission of Garland
Science/Taylor & Francis Books, Inc.
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Figure 1.5: Four possible pathways to supernumerary centrosomes. (A) A cell
that has synthesized extra copies of centrosomes during a single cell cycle will
contain extra centrosomes. (B) Aberrant mitosis will leave the cell with two
sets of copied chromosomes and two centrosomes that will be duplicated in the
next cell cycle leading to multiple centrosomes in a single cell. (C) If splitting
of the two centrioles of one centrosome is unsupervised it could result in more
than two functional microtubule organizing centers. (D) Increased production
of pericentriolar material due to over expression could also result in more than
two functional microtubule organizing centers. Reprinted by permission from
Macmillan Publishers Ltd: Oncogene35, copyright 2002.
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Figure 1.6: Multipolar and pseudo-multipolar mitosis with cells harboring su-
pernumerary centrosomes are pictured. (A) Two tripolar metaphase spindles are
shown in (a), centrosomes are yellow, microtubules in red and DNA in blue. (b)
Three daughter cells from a tripolar mitosis are seen. These three cells should
show signiﬁcant alterations to their DNA content as compared to the mother
cell. (B) A cell with supernumerary centrosomes has aligned in a pseudo bipo-
lar fashion, but with a single centrosome out of alignment. During anaphase,
this centrosome will pull chromosomes out of the bipolar axis, which results in
aneuploid daughter cells as one will have lost and one gained chromosomes. (C)
A schematic presentation of the chromosome loss/gain pathway. Reprinted by
permission from Macmillan Publishers Ltd: Oncogene35, copyright 2002
23
8 Introduction
In a tripolar mitosis there are still only two copies of DNA and dividing the
genes between the three daughter cells would most likely render them all ane-
uploid leading to apoptosis. It is possible to imagine though, that during the
multitude of cell divisions in cancer cells, one daughter cell arising from a mul-
tipolar mitosis would receive a suﬃcient amount of DNA to survive. It is also
possible that mutations or genes missing will grant the cell a new cancer phe-
notype. Continual proliferation of this aneuploid cell is dependent on regaining
chromosomal stability, as continual multipolar mitoses would most likely result
in apoptosis at some point. An aneuploid daughter cell with supernumerary cen-
trosomes needs to acquire the ability to undergo bipolar mitosis and this can be
achieved by centrosomal clustering.29
As cancer cells need to cluster their centrosomes to undergo bipolar mitosis and
healthy cells do not, a small molecule that inhibits centrosomal clustering would
potentially be speciﬁc towards cancer cells. A phenotype based assay to search
for such small molecules was established by Prof. Dr. Alwin Kra¨mer MD, and Dr.
Blanka Rebacz from DKFZ, Germany.44 See section 1.6 for a short description
of the assay.
1.2 Natural Products with Anti-cancer Properties
Medicine derived from nature has most likely been used since before civilization
started, with the earliest known records from Egypt around 2900 BC.45 Today
almost 5000 years later, nature is still the major contributor of drugs to mankind.
In a period from January 1981 to October 2008, 1024 new anti-cancer drugs were
introduced on the market. Of those drugs only 37% were truly synthetic, the
rest were in some way inspired by nature.46 This indicates that looking for novel
bioactive compounds in nature is still a valid strategy.47
There is a vast pool from which natural products can be derived, compounds
have been isolated from plants,20 insects,48 bacteria,49 fungi,50 and marine or-
ganisms51 (See Figure 1.7 for examples of compounds). In the case of fungi, a raw
extract is produced by grinding the fungi and agar in a stomacher with an organic
solvent, which upon concentration aﬀords the raw extract. With a raw extract
available there are several approaches to the isolation of the natural products,
one method is to isolate every novel compounds from a given extract and then
possibly test them in various assays afterwards. Another method is the bioguided
search for natural products where an assay must be available to test raw extracts.
If the target is known, it is possible to do target oriented isolation. A number of
raw extracts can then be tested in the assay and hopefully one or more will show
activity. With an active raw extract the isolation of the bioactive compound can
begin, which is often an iterative process with retesting after each fractionation
step. The isolation will most likely be done on a (semi)preparative HPLC system
using various normal or reverse-phase chromatography methods. A third option
is to use explorative solid phase extraction (E-SPE),52 where more information
about the chemical properties of the target compound is obtained before isolation
starts. This is attained by using four orthogonal solid phase columns, utilizing
not only polarity but also charge and size of compounds. This method makes it
possible to plan an isolation strategy before making a larger raw extract.
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Going through the laborious eﬀorts to make large raw extracts followed by
isolation of known compounds is frustrating and can be a potential problem.53
With isolated bioactive natural products counted in the tenths of thousands,
natural product chemists face an ever increasing task in distinguishing between
novel and known compounds. Early dereplication (see section 1.3)) is vital to
natural product chemists and when working with microbial natural products
the process can be assisted by e.g. Antibase,54 which was developed by Prof.
Dr. Hartmut Laatsch. It is a program that enables the scientist to compare
physical properties, e.g. exact mass or UV spectra of a target natural product,
with compounds already available in the database. This search should indicate
whether the active compound is a known or novel compound and thus if isolation
of the compound should be completed.
A possible problem for bioactive natural products with suﬃcient potency to
go to clinic trials is availability. If isolation from nature only procures minimal
amounts, if fermentation is not viable or if total synthesis is too lengthy or ineﬃ-
cient, then availability becomes a bottleneck. This was the case with Taxol R© (1),
as it was not possible to make this very potent agent available for clinical trials
because of its scarce availability. It was not until the isolation of a precursor of
Taxol R© (1) from the needles of Taxus baccata that a semisynthetic route made
the compound available in larger quantities.55
When a bioactive secondary metabolite has been isolated and characterized, a
structure-activity relationship study can be performed pending availability. This
is done by altering various positions on the parent compound and subsequently
test the analogs in the assay used for the bioguided isolation or in other suit-
able assays. The modiﬁcations can be achieved by total synthesis of the parent
compound and analogs, or if enough of the parent compound can be isolated by
altering directly on the parent compound. This will yield information about the
important positions of the compound and improved potency could result in a new
lead compound. This lead compound will then be the basis of a new round of
optimization.
1.3 Dereplication
The earlier dereplication can be used to determine if an active fraction is due to a
novel or known compound, the more work and time can be saved. Running a raw
extract through a HPLC-DAD-HRMS systems will aﬀord a lot of information and
data, making the tentative assignment of a given compound in the raw extract
plausible. This setup will give a general idea of the polarity of a compound,
the UV spectrum aﬀords information about possible functional groups as well
as the conjugation of the compound, but most importantly the exact mass of a
compound will be of great help in the dereplication of a given raw extract.
When using MS to ﬁnd the exact mass of a compound, correct interpretation of
the MS data is pivotal. The assignment of [M+H]+ or [M-H]− can be complicated
by minor co-eluting compounds that ionize better than the target compound.
The use of adducts (e.g. [M+Na]+, [M+H+MeCN]+ and/or [M+NH4]
+) are of
great assistance to correct assignment of the molecular peak. By recognizing
the pattern of these adducts it is possible to assign [M+H]+ or [M-H]− with
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Figure 1.7: Four anti-cancer agents derived from four diﬀerent natural sources.
Taxol R© (1) (plant),20 Curacin A (2) (Cyanobacterium),56 bryostatin 157,58 (3)
(marine symbiot bacteria) and fumagillin (4) (fungi).59
conﬁdence.
There are however some limitations to this approach, compounds that do not
ionize in either negative or positive mode and does not have a UV chromophore
will not be detected, these could in turn be observed using a light scattering
detector.60
Depending on the accuracy on the MS equipment the observed mass of a com-
pound could be compatible with several molecular formulas. Even if very high
accuracy is obtained there are still diﬀerent compounds with the same molecular
formula. Using all information available: polarity, UC spectra, MS-MS, exact
mass it is often possible to discriminate between the hits in antibase acquired
from the exact mass.
1.4 Secondary Metabolites from Fungi
Secondary metabolites or natural products can be deﬁned as metabolites not
normally involved in primary metabolic processes. The discussion about why
secondary metabolites are produced at all, ended with the now accepted notion
that natural products evolve under the pressure of nature.61 Secondary metabo-
lites can be divided into diﬀerent classes depending on their biosynthetic origin,
namely polyketides, terpenes and alkaloids. Natural products can be one of these
types solely or any mix of these three. A chromatogram of a raw extract from
Aspergillus terreus can be seen in Figure 1.8, with each peak representing a
metabolite.
Secondary metabolites fulﬁlls some role in the life of the fungi producing them,
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Figure 1.8: HPLC-DAD chromatogram of a raw extract from Aspergillus ter-
reus, illustrating peaks corresponding to natural products. The known com-
pounds geodin and dihydro geodin have been assigned.
e.g. by interacting with other microorganisms like bacteria or other fungi. The
interaction with bacteria can be extremely helpful for man, as seen when fungi
entered the world stage as a source for anti-bacteria agents with the discovery
of penicillin.62,63 The interaction with other fungi makes it possible that some
of these bioactive compounds could have eﬀects on mammalian cells including
cancerous cells as both fungi and mammals are eukaryotic; the cell ﬁlaments actin
and tubulin are for example very conserved in eukaryote cells.64 An example of
a fungal metabolite which shows both anti-fungal65,66 and anti-cancer properties
is griseofulvin.67,68
Mycotoxins are bioactive compounds that are toxic to humans, these myco-
toxins interacts with humans, mostly through food sources69 or fungi infested
living quarters.70 Some of the more important mycotoxins are the aﬂatoxins71
and ochratoxin A.72 Aﬂatoxins are produced by fungi contaminating e.g. maize,
which can cause liver cancer in humans consuming the maize.73 Ochratoxin A is
found in many consumer products like coﬀee,74 wine75 and meat.76
1.5 Work ﬂow
Looking for bioactive natural products involves a number of disciplines and pro-
cesses (see Figure 1.9). The source of the secondary metabolites needs to be
handled, the production of a raw extract, testing of the raw extract in a given as-
say, dereplication to avoid isolating known compounds, isolating a possible novel
bioactive compound, structure elucidation and characterizing of the compound.
This can then be followed by a structure-activity relationship study of the com-
pound, which could result in a new lead compound.
1.6 Centrosomal Clustering Assay
The assay44 was designed to identify small molecules that inhibits centrosomal
clustering. The cell line initially used was an oral squamous cell carcinoma cell
line labeled SCC114, which was cloned to stably express green ﬂuorescent protein
(GFP)-α-tubulin. The cell line contained centrosome ampliﬁcation in 64.5% of
the cells but only 3.6% of mitotic cells harbored multipolar spindles. A large por-
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Figure 1.9: Starting from the left is the the source, in this case fungi, of natural
products. Narrowing down from the numerous compounds in a screen with raw
extract to a hit, in this case griseofulvin. In the case of griseofulvin tentative
identiﬁcation was achieved by dereplication of the initial raw extract. Had it been
a novel compound the process of isolation followed by structure elucidation should
have been completed. With the active compound characterized it is possible to do
a structure-activity relationship study. This can be done by e.g. total synthesis
or in the fortunate case of griseofulvin by modifying directly on the commerciable
availabe compound. A SAR study could aﬀord better analogs and a new lead
compound.
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tion of the cells with supernumerary centrosomes thus underwent bipolar mitosis
by centrosomal clustering.
For screening purposes the cells were grown to near conﬂuence and then treated
with raw extract at diﬀerent concentrations for 7 h, ﬁxed, and examined by ﬂuo-
rescence microscopy. Three hundred mitotic cells per well were examined, observ-
ing if the cells underwent single, bi or multipolar mitosis, with the readout being
the percentage of multipolar mitoses. BJ ﬁbroblasts was used as a noncancerous
control cell line to investigate the speciﬁcity of a given active extract.
The screening procedure was changed around July 2008 to use the untrans-
formed SCC114 cells. Cells were seeded and incubated for 24 h after which raw
extract or griseofulvin analogs were added at various concentrations. After ﬁx-
ation the cells were stained with Eg5 antibodies and evaluated by ﬂuorescence
microscopy. The number of cells counted per well was lowered to one hundred,
easing the laborious manual counting of cells. Around May 2010 the cell line
used for the assay was changed as the SCC114 cells had lost their centrosomal
ampliﬁcation. The SCC114 cells were replaced by a human cell line labeled
MDA-MB-231 (breast adenocarcinoma), which at present is the cell line used in
the assay.
1.7 Griseofulvin
During the initial screening by Assoc. Prof. Thomas Ostenfeld Larsen, Lisette
Knoth-Nielsen (technician) and Blanka Leber (PhD. student at the time), the
known natural product griseofulvin was tentatively identiﬁed as active in three
seperate raw extracts (Penicillium berlinense, IBT 18288 and 19440 and P.
faroense, IBT 22543). The eﬀect of griseofulvin was further investigated at DKFZ
and during my undergraduate work I synthesized three 2’ analogs showing in-
creased activity, which was included in the paper concerning the assay.44 A large
part of the work performed in this work is based on this discovery of griseofulvin
in the assay.
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Chapter 2
Chemistry of Griseofulvin
Griseofulvin (1, see Figure 2.1) was initially isolated from Penicillium griseo-
fulvum in 1939 by Oxford et al.1 and was later isolated from P. janczewskii as
”Curling Factor” by Brian et al.2,3 in 1946. The latter described the curling of
hyphae induced by 1.2,3 It was not until 1947 that it was proved that griseofulvin
(1) and ”Curling Factor” was the same compound.4,5 The analogous metabolites
7-bromo-7-dechloro-griseofulvin6 (2, 1954) and dechlorogriseofulvin7 (3, 1953)
were isolated by MacMillan.
The structure of the compound was investigated by means of IR and UV spec-
troscopy as well as degradation studies.8,9,10,11 The correct relative structure
for griseofulvin (1) was reported in 1952 by Grove et al.12 followed by a num-
ber of papers concerning the chemistry of 1 and synthesis of analogs (1952-
1957).13,14,15,16,17 The absolute structure of 1 was reported in 1959 by Macmil-
lan18 and has since been supported by a crystal structure.19 There are two pos-
sible epimers of griseofulvin, position 2 and 6’, but through the literature they
are both referred to as epigriseofulvin.
The anti-fungal properties of 1 have been known since 1958,20 but recently po-
tency againt cancer21 and hepatitis C infected cells22 have renewed the interest
in this compound making a review of griseofulvin relevant. In the following sec-
tions a number of subjects concerning griseofulvin will be described, including
total synthesis, analogs obtained by total synthesis and analog synthesis using 1
as starting material.
Figure 2.1: griseofulvin (1), 7-bromo-7-dechloro-griseofulvin (2) and dechloro-
griseofulvin (3).
35
20 Chemistry of Griseofulvin
2.1 Total Syntheses of Griseofulvin
Several diﬀerent strategies have been utilized in the total synthesis of racemic
griseofulvin and the synthesis of the natural product (+)-griseofulvin (1) was pub-
lished in 1990. The ﬁrst total synthesis was completed by Day et al. (1960)23,24
by oxidative cyclization of a benzophenone precursor (6, see Scheme 1), a strategy
based on earlier pondering on the biosynthesis of 1.25,26 The two arenes 2-chloro-
3,5-dimethoxyphenol11 (4) and 2-methoxy-4-((methoxycarbonyl)oxy)-6-methyl-
benzoic acid27 (5), with the latter treated with oxalyl chloride to aﬀord the acid
chloride were used as starting materials. The benzophenone (6) was prepared by
Fridel-Craft reaction of 4 and the acid chloride of 5 followed by alkaline treat-
ment. The formation of the spiro center was completed by radical formation using
potassium ferricyanide aﬀording (±)-dehydrogriseofulvin (7). The ﬁnal step was
hydrogenation of 7 with a preformed catalyst of 3% selenium and 5% rhodium
on charcoal aﬀording (±)-griseofulvin (1).
Scheme 1: (a) (COCl)2, benzene; (b) AlCl3, nitrobenzene; (c) 4M NaOH, ether,
nitrobenzene; (d) Na2CO3, K3Fe(CN)6, H2O; (e) 5% Rh/C containing 3% sele-
nium, H2, EtOH
The C ring of griseofulvin (1) was established by a Dieckmann cyclization in the
total synthesis by von A. Brossi et al. (1960) (see Scheme 2).28,29,30 The synthesis
of the substituted 3-coumarone 10 starts with 8, which was treated with methyl
2-bromoacetate to aﬀord 9 setting up the ﬁrst Dieckman cyclization yielding 10.
The 3-coumarone 11 was synthesized by Michael addition to 3-penten-2-one. A
second Dieckmann cyclization followed by treatment with diazomethane aﬀorded
2-epi-griseofulvin (12), which was isomerized with sodium methoxide to yield
(±)-griseofulvin (1).
Stork and Tomasz (1962)31,32 reported the use of a double Michael addition
to establish both stereocenters and the 2’ enol ether in a one-pot synthesis (see
Scheme 3). The key substrate in this synthesis was an alkoxyethynyl vinyl ketone
(14) used as a double Michael acceptor. 7-Chloro-4,6-dimethoxy-3-coumaranone
(13) was used as precursor and reaction with 14 and potassium t-butoxide in
36
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Scheme 2: (a) BrCH2COOMe, K2CO3, DMF; (b) Na, toluene, 100
◦C; (c)
3-penten-2-one, Triton B, MeOH; (d) NaOMe, MeOH; (e) CH2N2, MeOH; (f)
NaOMe, MeOH, 80 ◦C
diglyme/t-butyl alcohol aﬀorded (±)-griseofulvin (1).
Scheme 3: (a) t-BuOK, 2-methoxyethyl ether, t-BuOH
Utilizing a method described earlier for the synthesis of 6’-desmethyl-griseo-
fulvin33 and 7-dechloro-7-ﬂuoro-griseofulvin,34 Taub et al. (1962)35 36 used oxida-
tive cyclization to establish the spiro center of (±)-griseofulvin (1) (see Scheme
4). In the early communication the last step was introduction of the chloro sub-
stituent, making this a formal total synthesis of 1.35
The total synthesis as described in the full paper36 prepared the benzophenone
(6) from two aromatic precursors as by Day et al.23,24 The arene (15) destined
to become ring C of 1 diﬀered slightly as the phenol was protected by an acetyl
group and the acid instead of the acid chloride was used. The coupling with 1
was performed with in situ formation of the mixed anhydride from triﬂuoracetic
anhydride aﬀording both 6 and the ester 16. Transformation of 16 to the de-
sired benzophenone (6) was completed by mild hydrolysis followed by a Fries
rearrangement.
For the following ring closure to (±)-dehydrogriseofulvin (7) a number of succes-
ful methods were described. Quantitative yields was obtained using potassium
37
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ferricyanide, lead dioxide in ether/acetone or manganese dioxide in ether/ace-
tone. Hydrogenation to 1 was performed in ethyl acetate using 10% palladium
on charcoal as catalyst.
Danishefsky and Walker (1979)37 reported a total synthesis of 1 utilizing a Diels-
Scheme 4: (a) (F3CCO)2O; (b) 5% NaOH in aq. MeOH; (c) TiCl4, nitroben-
zene; (d) K3Fe(CN)6; or PbO2, ether, acetone; or MnO2, ether, acetone; (e) 10%
Pd/C, H2, EtOAc
Alder cycloaddition strategy (see Scheme 5), an improvement of the total syn-
thesis of (±)-2-epigriseofulvin by Danishefsky and Etheredge.38 The dienophile
(19) was synthesized from 17 through double intramolecular nucleophilic at-
tack aﬀording 18, followed by treatment with thiophenol and oxidation with m-
chloroperoxybenzoic acid. The dienophile reacted with the diene (20) in toluene
at 100-135 ◦C aﬀording (±)-dehydrogriseofulvin (7), which was hydrogenated to
(±)-griseofulvin (1).
A total synthesis of (±)-dechloro-dehydro-griseofulvin (22) was completed by
Sargent (1980)39 (see Scheme 6). Treating the precursor 21 with dry hydrogen
chloride and excess titanium tetrachloride in dichloromethane yielded 22 through
oxidative cyclization.
An improvement of the method by Stork and Thomas using double Michael ad-
dition was published by Yamato et al. (1990)40 (see Scheme 7). The 3-coumarone
(13) was reacted with an altered Michael acceptor (23) yielding 24 and through
treatment with activated alumina (±)-2’-demethoxy-2’-methylthio-griseofulvin
(25) was formed. Displacement of the thio ether was achieved by oxidizing sulfur
with m-chloroperoxybenzoic acid followed by treatment with sodium methoxide
aﬀording (±)-griseofulvin (1).
Pirrung et al. (1991)41 reported the ﬁrst total synthesis of (+)-griseofulvin (1)
(see Scheme 8). Reacting the triether 26, with Mander’s reagent followed by diazo
transfer aﬀorded 27, which upon treatment with 5% rhodium pivalate catalyst
yielded, through a sigmatropic rearrangement, the 3-coumarone 28. Conversion
to 29 followed by Dieckmann cyclisation and diazomethane treatment completed
the total synthesis of (+)-griseofulvin (1).
38
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Scheme 5: (a) NaH, THF, HMPA; (b) thiophenol, p-toluenesulfonic acid, ben-
zene; (c) m-CPBA, CH2Cl2; (d) toluene, 100-135
◦C (e) H2, 10% Pd/C, EtOH
Scheme 6: (a) HCl, TiCl4, CH2Cl2
Scheme 7: (a) t-BuOK, DMF, 0 ◦C; (b) activated alumina, Et2O (c) m-CPBA,
CH2Cl2, 0
◦C; (d) MeONa, MeOH, benzene, 0 ◦C
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Scheme 8: (a) LHMDS, NCCO2Me, THF, -78
◦C; (b) MsN3, Et3N; (c)
Rh2(piv)4, benzene; (d) O3, CH2Cl2, MeOH, (CH3)2S; (e) Ph3=C(CH3)CO2-t-
Bu, THF; (f) TFA; (g) diphenyl phosphorazidate, Et3N; toluene, then HCl/H2O;
(h) NaOMe, MeOH; (i) CH2N2, THF
40
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2.2 Total Syntheses of Griseofulvin Analogs
Ring A and B as well as position 6’ of griseofulvin (1) are not easily modiﬁed from
the natural product and therefore analogs of these types have been obtained by to-
tal synthesis. The syntheses have been completed using a number of the methods
developed for the total synthesis of griseofulvin. The strategies used are oxida-
tive cyclisation,42,43,44,45 Diels-Alder,38,46 double Michael addition,47 Dieckmann
cyclization,48 and the improved Michael addition method.49 The analogs synthe-
sized by means of total synthesis can be seen in Figure 2.2 and Table 2.1.
Figure 2.2: Racemic analogs synthesized through total synthesis. The structures
are shown in Table 2.1.
Compound R’ R” R”’ Reference
30 OMe H H 49
30 H OMe H 49
30 H H OMe 49
30 OMe OMe OMe 49
30 OMe Me OMe 49
30 OMe Cl OMe 49
31 OMe H H 49
31 H OMe H 49
31 H H OMe 49
31 OMe OMe OMe 49
31 OMe Me OMe 49
31 OMe Cl OMe 49
31 OMe COOEt OMe 48
32 Cl H OMe 44,50,34,51,35
32 H NO2 OMe
51
32 NO2 H OMe
51
Continued on next page
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Compound R’ R” R”’ Reference
32 H Me OMe 51
32 Cl Cl OMe 35
32 H Cl OMe 34
32 H Br OMe 34
32 H F OMe 34,44,45
32 H Cl OEt 47
32 Cl Cl Cl 35
33 - - - 51
34 Me H Cl 46,38,52
34 Et H Cl 46,52
34 H Et Cl 52
34 Me Me Cl 46
34 H H Cl 50,46,33,33
34 H Pr H 44
35 OMe H H 47
35 OEt H H 47
35 OMe Cl H 47
35 OEt Cl H 47
35 OMe H Cl 47
35 OEt H Cl 47
35 OEt Cl Me 47
36 OEt - - 47
36 O(CH2)2Ome - -
47
37 - - - 47
38 - - - 42
Table 2.1: Racemic griseofulvin analogs acquired through total synthesis. See
Figure 2.2 for structures.
Scheme 9: (a) R=CN: ethyl cyanoacetate, piperidine; R=COOH: diethyl mal-
onate, piperidine, HOAc, benzene; (b) H2, 10% Pd/C, EtOAc; (c) but-3-en-2-one,
1,2-dimethoxyethane, NaOMe; (d) NaOMe, MeOH; (e) ZnCl2, HCl, ether.
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Newman and Angier developed a novel strategy for the preparation of ring B
analogs, with a Hoesch condensation as the crucial step (See Scheme 9).53,54,55,56
In the ﬁrst step either a cyano or acid group was introduced, the former by con-
densation of 39 with ethyl cyanoacetate using catalytic amounts of piperidine,
which after hydrogenation using 10% palladium on charcoal, aﬀorded the nitrile
40. The latter was synthesized by treatment of 39 with diethyl malonate, piperi-
dine and acetic acid in benzene yielding the acid 41 after hydrogenation. Both
40 and 41 were then reacted further with the Michael acceptor but-3-en-2-one
using sodium methoxide as base yielding 42 and 43. A Dieckmann condensation
formed the destined ring C (44) and 45 by treatment with sodium methoxide in
methanol. The Hoesch condensation was performed by bubling hydrogen chloride
through a mixture of 44 or 45 and zinc chloride in ether, aﬀording a position 2
carbon analog of griseofulvin (46). The position 1 carbon and sulphur analogs of
griseofulvin can be seen in Figure 2.3 and Table 2.2.
Figure 2.3: Ring B analogs synthesized through total synthesis. The compounds
are shown in Table 2.2.
Compound R’ R” R”’ Reference
47 - - - 55
48 OH H H 53,54
48 OMe Me Cl 55
48 OH Me H 54
49 - - - 43
50 - - - 56
51 H - - 47
51 Cl - - 47
51 Me - - 47
Table 2.2: Ring B analogs prepared by total synthesis. See Figure 2.3 for
structures.
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2.3 Spectroscopic Studies of Griseofulvin and Analogs
Several articles do not contain synthesis of griseofulvin (1) or analogs thereof,
but instead describe spectroscopic studies. Page and Staniforth thouroughly in-
vestigated the infrared absorption of a total of 188 griseofulvin analogs.57,58 The
IR spectra were acquired in bromoform and very detailed absorption values are
listed for all compounds. The authors were able to distinguish between analogs
of the griseofulvin or isogriseofulvin form as well as between 1 and the position
2 epimer by IR.
A comprehensive study of the mass spectra of griseofulvin and analogs of griseo-
fulvin have been carried out by Ballantine and Fenwick.59 60 MHz 1H NMR was
used in a study by Arison et al.60 covering griseofulvin and 27 analogs, exploring
the at the time, new technique while assigning groups based on diﬀerences be-
tween the analogs. Another NMR study by Green et al.61 including 43 analogs
concluded that the assignment of the 4 and 6 methoxy groups by Arison et al. was
faulty. The assignment by Green et al. was conﬁrmed by Rønnest et al.62 by 2D
NMR and single crystal X-ray analysis of the 4 and 6 phenols of 1.
The conformation of griseofulvin and the 4’-alcohol analog of 1 in solution (CDCl3)
was determined by Levine and Hicks63,64 and they proceeded to investigate the
13C-NMR of griseofulvin and four analogs.65 NMR has also been used in the
study of the biosynthesis of griseofulvin using deuterium labeled analogs.66 Han-
sch and Lien67 used griseofulvin analogs in a larger modeling study of the LogP
value of anti-fungal agents. These values were later used by Juvale et al.68 in a
2D-QSAR study using the curling of hyphae by the analogs reported by Crosse
et al.69 It was concluded by Crosse et al. that there were no correlation between
the potency for curling of hyphae and the anti-fungal activity of analogs.
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2.4 Tables of Griseofulvin Analogs
Numerous analogs of griseofulvin have been synthesized. In the following tables
all occurrences in the literature, in either English or German, of griseofulvin and
analogs are shown.
2.4.1 Griseofulvin Analogs with Modiﬁcations at the 2’ Position
Figure 2.4: Griseofulvin analogs with modiﬁcations at the 2’ position. See Table
2.3.
Structure R Reference
52 H 57,58,61,70,71,72,73
52 Me 70
52 OEt 57,61,71,68,60,74,67,75
52 OPr 74,70,71,57,68,76,75,67
52 OiPr 57,75
52 OBu 57,68,76,71,67,75
52 OPentyl 75
52 OHexyl 57,75
52 OAll 57,68,67
52 OCH2-cy-propyl
57,75
52 O-cy-pentyl 57,75
52 OPh 57,68,75,67
52 OBn 57,68,75,67
52 O(4-Methyl-Bn) 75
52 O(CH2)2Bn
75
52 Biphenylmethoxy 75
52 1-Adamantylmethoxy 75
52 OC6H7O5Ac4-A
71
52 B 58,61
52 NH2
77,71,76
52 NHMe 77,61
52 NHEt 77
52 NC4H8
77
52 Cl 57,58,61,78,75
52 (CH2)2Br
79
52 (CH2)2
125I 79
52 SMe 58,78,61,80
52 SEt 78,80
52 SPr 78,80
Continued on next page
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Structure R Reference
52 SiPr 80
52 SBu 78
52 SAllyl 78
52 SPh 78
52 SC4H9
80
52 SBn 78,75
52 S(CH2)2OH
78
52 S(CH2)2-C
78
52 S-B 78
52 S(CH2)2NEt2
78
Table 2.3: Griseofulvin analogs with modiﬁcations at the 2’ position. See Figure
2.4. A is glucose, B is pyrrolidin-1-yl and C is phthalimido.
46
2.4 Tables of Griseofulvin Analogs 31
2.4.2 Griseofulvin Analogs with Modiﬁcations at the 2’ and 3’
position
Figure 2.5: Griseofulvin analogs with modiﬁcations at the 2’ and 3’ position.
See Table 2.4.
Structure R R’ Reference
53 OMe Me 57,61,74,68,67
53 OMe Pr 68,67
53 OMe All 68,74,67
53 OMe Bn 74,57,68,67
53 OMe CH2CH2COCH3
74
53 OMe NO2
81
53 OMe NHBn 81
53 OMe NHAc 81
53 OMe Cl 57,60,61,68,67,82
53 OMe Br 82,57,68,67
53 OMe I 82,57,68,67,75
53 OEt Bn 74,68,67
53 OEt Et 74,57,68,67
53 OEt Cl 82,68,67
53 OEt Br 82,68,67
53 OEt I 82,68,67
53 OPr Me 74
53 OPr Pr 74,68,67
53 OPr Bn 74,68,67
53 OPr Cl 82
53 OPr Br 82,68,67
53 OPr I 82,68,75,67
53 OBu Bn 74,68,67
53 OBu Cl 82
53 OBu Br 82
53 OBu I 82
53 O(CH2)3Br Bn
74
53 OBn Br 82
53 OBn Cl 82
53 OBn I 82,75
53 Cl Cl 57,78
53 Cl Br 57,78
53 Cl Bn 57,78
Continued on next page
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Structure R R’ Reference
53 Cl Pr 57,78
53 SMe Br 78
53 SMe Cl 78
53 SEt Cl 78
53 SPr Cl 78
53 SBu Cl 78
53 SAll Cl 78
53 SBn Cl 78
53 SMe Bn 78
53 SEt Bn 78
53 SPr Bn 78
53 SBu Bn 78
53 SAll Bn 78
53 SBn Bn 78
53 SMe Pr 78
53 SPr Pr 78
53 SBu Pr 78
53 SAll Pr 78
53 SBn Pr 78
Table 2.4: Griseofulvin analogs with modiﬁcations at the 2’ and 3’ position. See
Figure 2.5.
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2.4.3 Griseofulvin Analogs with Modiﬁcations at the 5’ Position
Figure 2.6: Griseofulvin analogs with modiﬁcations at the 5’ position. See Table
2.5.
Structure R Reference
54 Br 83,84,85
54 Cl 83
54 I 83
54 F 83
54 CHO 83,86,84
54 OH 87
54 COCO2Me
83
54 COCO2Et
83
54 OCOMe 84
54 SO2CH3
85
54 OMe 84
54 SMe 86
54 =CH2
86
54 CN 86
54 =NNHPh 86
54 CH=NNH(CH3)2
86
54 CH=NOH 86
54 NC4H8
86
54 N2
84
54 SPh 86
54 SCOCH3
86,84
54 NC5H10
86
54 Me 86
Table 2.5: Griseofulvin analogs with modiﬁcations at the 5’ position. See Figure
2.6.
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2.4.4 Griseofulvin Analogs with Modiﬁcations at the 4 Position
Figure 2.7: Griseofulvin analogs with modiﬁcations at the 4 position. See Table
2.6.
Structure R Reference
55 OH 75,62
55 Me 61
55 OEt 88,61,57,75
55 OPr 88
55 OiPr 88,61
55 OBu 88
55 OAc 61
55 All 68
55 CH2Ph
68
55 A 61
55 OH 81
55 OAll 88,67
55 OBn 88,75,67
55 O(CH2)2NMe2
88
55 O(CH2)2NEt2
88
55 OCH(Me)CH2NMe2
88
55 OCH2CONH-p-Cl-C6H4
88
55 OC2CONHCH2Ph
88
55 OCH2CH2NC4H8
88
55 OCH2CH2NC5H10
88
55 OCH2CH2N
+(Me)2(Et)Br
− 88
Table 2.6: Griseofulvin analogs with modiﬁcations at the 4 position. See Figure
2.7. A is pyrrolidin-1-yl
50
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2.4.5 Griseofulvin Analogs with Modiﬁcations at the 5 Position
Figure 2.8: Griseofulvin analogs with modiﬁcations at the 5 position. See Table
2.7.
Structure R Reference
56 Cl 58,61,88
56 Br 57,58,89,82
56 NO2
58,90,81,89,75
56 NH2
81,90,75
56 Pr 57,61
56 NHBn 75
Table 2.7: Griseofulvin analogs with modiﬁcations at the 5 position. See Figure
2.8.
2.4.6 Griseofulvin Analogs with Modiﬁcations at the 6 Position
Figure 2.9: Griseofulvin analogs with modiﬁcations at the 6 position. See Table
2.8.
Structure R Reference
57 OEt 57,68,88,67
57 OPr 68,88,67
57 OiPr 61,88
57 OBu 68,88
57 OAc 61
57 OAll 68,88,67
57 OBn 88
57 OC16H33
88
57 OCH2COOCH3
88
57 A 61
57 OH 81,91,62
Table 2.8: Griseofulvin analogs with modiﬁcations at the 6 position. See Figure
2.9. A is pyrrolidin-1-yl
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2.4.7 Griseofulvin Analogs with Modiﬁcations at Position 4 and
6
Figure 2.10: Griseofulvin analogs with modiﬁcations at positions 4 and 6. See
Table 2.9.
Structure R R’ Reference
58 SMe SMe 77,88
58 OEt OEt 57,61
Table 2.9: Griseofulvin analogs with modiﬁcations at positions 4 and 6. See
Figure 2.10.
2.4.8 Griseofulvin Analogs with Modiﬁcations at Position 5 and
7
Figure 2.11: Griseofulvin analogues with modiﬁcations at ring A. See Table
2.10.
Structure R R’ Reference
59 H F 60
59 NO2 H
81
59 All H 57
59 NHBn H 81
59 NH2 H
81
59 Cl H 57,60,82
59 H NH2
81
59 H NO2
81
Table 2.10: Griseofulvin analogs with modiﬁcations at position 5 and 7. See
Figure 2.11.
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2.4.9 Isogriseofulvin Analogs with Modiﬁcations at the 4’ Posi-
tion
Figure 2.12: Isogriseofulvin analogs with modiﬁcations at the 4’ position. See
Table 2.11.
53
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Structure R Reference
60 H 57,58,61
60 OMe 57,58,81,61,71
60 OEt 57,74,60,61,71
60 OPr 57,71,74
60 OiPr 57,60
60 OBu 57,71
60 OHexyl 57,71
60 OAll 57
60 OPh 57
60 OBn 57
60 A 58
60 B 58
60 C 58,61
60 NH2
77,78
60 NHMe 61,77
60 NHBu 77
60 NEt2
77
60 NC4H8
77
60 NC5H10
77
60 NC4H8O
77
60 NMe(CH2)2NEt2
77
60 NH(CH2)2NC4H8O
77
60 SMe 58,80
60 SEt 78,80
60 SPr 80
60 SiPr 80
60 SC4H9
80
60 SPh 78
60 SBn 78
60 S(CH2)2NEtCH3
78
60 O(CH2)2Br
79
60 Cl 78,58,57,61
Table 2.11: Isogriseofulvin analogs with modiﬁcations at the 4’ position. See
Figure 2.12. A is phthalimido, B is 2-(2-imidazolyl), C is pyrrolidin-1-yl
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2.4.10 Isogriseofulvin Analogs with Modiﬁcations at the 3’ and
4’ Positions
Figure 2.13: Isogriseofulvin analogs with modiﬁcations at the 3’ and 4’ position.
See Table 2.12.
Structure R R’ Reference
61 Me OMe 74,57,61
61 Me OMe 74
61 Bn OMe 74,57
61 (CH2)2COCH3 OMe
74
61 Cl OMe 78,61,82,57
61 Br OMe 82,57,61
61 I OMe 82,57
61 Et OEt 74,57
61 Bn OEt 74
61 Cl OEt 82
61 Br OEt 82
61 I OEt 82
61 Me OPr 74
61 Pr OPr 74
61 Bn OPr 74
61 Cl OPr 82
61 Br OPr 82
61 I OPr 82
61 Bn OBu 74
61 Cl OBu 82
61 Br OBu 82
61 I OBu 82
61 Bn OAll 74
61 Cl OAll 82
61 Br OAll 82
61 I OAll 82
61 Cl OBn 82
61 Br OBn 82
61 I OBn 82
61 Bn O(CH2)3Br
74
61 Cl NH2
78
61 Br NH2
78
61 Bn NH2
78
61 Pr NH2
78
Continued on next page
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Structure R R’ Reference
61 Cl Cl 57
61 Br Cl 78,57
61 Bn Cl 57
Table 2.12: Isogriseofulvin analogs with modiﬁcations at the 3’ and 4’ position.
See Figure 2.13.
2.4.11 Isogriseofulvin Analogs with Modiﬁcations at the 4, 5 and
6 Positions
Figure 2.14: Isogriseofulvin analogs with modiﬁcations at the 4, 5 and 6 posi-
tions. See Table 2.13.
Structure R R’ R” Reference
62 OMe H OEt 57
62 OEt H OEt 57
62 OEt Cl OMe 88
62 OPr Cl OMe 88
62 OiPr Cl OMe 88
62 OBu Cl OMe 88
62 OAll Cl OMe 88
62 OBn Cl OMe 88
Table 2.13: Isogriseofulvin analogs with modiﬁcations at the 4, 5 and 6 posi-
tions. See Figure 2.14.
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2.4.12 Analogs of both Griseofulvin and Isogriseofulvin with Mod-
iﬁcations at Ring A and C
Figure 2.15: Analogs of both griseofulvin and isogriseofulvin with modiﬁcations
at ring A and C. See Table 2.14.
Structure R R’ R” Reference
63 OEt OMe OEt 71
63 NC4H8 NC4H8 OMe
77
63 NC4H8 OMe NC4H8
77
63 OEt OMe OEt 57
63 OEt OEt OEt 57
64 OEt OMe OEt 57
64 OEt OEt OEt 57
64 OMe NC4H8 OMe
77
Table 2.14: Analogs of both griseofulvin and isogriseofulvin with modiﬁcations
at ring A and C. See Figure 2.15.
2.4.13 Griseofulvic Acid with Modiﬁcations at the 3’ Position
Figure 2.16: Analogs of griseofulvic acid with changes at the 3’ position. See
Table 2.15.
Structure R Reference
65 Me 58,74,89
65 Et 58
65 Pr 58
65 OPr 89
65 (CH2)2Ac
58,74
65 NO2
58,81,89
65 NH2
81
65 NHAc 58
65 NHBn 58,81
65 Bn 58,74
Continued on next page
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Structure R Reference
65 Cl 58,82
65 Br 82,58,78
65 I 58,82,89
65 A 61
Table 2.15: Analogs of griseofulvic acid with modiﬁcations at the 3’ position.
See Figure 2.16. A is the sodium salt of the enol form.
2.4.14 Disubstituted Griseofulvic Acid at the 3’ Position
Figure 2.17: Analogs of griseofulvic acid with changes at the 3’ position. See
Table 2.16.
Structure R R’ Reference
66 Cl Cl 82
66 Me Me 74,58,61,75
66 Bn Bn 74,58
Table 2.16: Analogs of griseofulvic acid with modiﬁcations at the 3’ position.
See Figure 2.17
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2.4.15 Griseofulvic Acid with Modiﬁcations at the 5, 7 and 3’
Positions
Figure 2.18: Analogs of griseofulvic acid with changes at the 5, 7 and 3’ posi-
tions. See Table 2.17.
Structure R R’ R” R”’ Reference
67 H H NH2 H
81
67 H H NHBn H 58,81
67 Cl Cl Cl H 58,82
67 Br Cl Br H 58,82
67 Cl Cl H H 82
67 Br Cl H H 82
67 Cl Cl Cl Cl 58,82
67 Br Cl Br Br 58,82
Table 2.17: Analogs of griseofulvic acid with modiﬁcations at the 5, 7 and the
3’ position. See Figure 2.18.
2.4.16 Griseofulvic Acid with Modiﬁcations at the 6 position
Figure 2.19: Analogs of griseofulvic acid with modiﬁcations at the 6 position.
See Table 2.18.
Structure R Reference
68 OH 58
68 OEt 58
68 OPr 58,88
68 OiPr 58,88
68 OBu 58,88
68 OC16H33
58,88
68 OAll 58,88
68 OBn 58,88
68 A 58
68 OCH2COOH
88
Continued on next page
59
44 BIBLIOGRAPHY
Structure R Reference
68 (CH2)2NEt2
88
Table 2.18: Analogs of griseofulvic acid with modiﬁcations at the 6 position.
See Figure 2.19. A is pyrrolidin-1-yl
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Centrosomal Clustering in Cancer Cells
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Griseofulvin was identiﬁed as an inhibitor of centrosomal clustering in a recently developed assay.
Centrosomal clustering is an important cellular event that enables bipolar mitosis for cancer cell lines harboring
supernumerary centrosomes. We report herein the synthesis and SAR of 34 griseofulvin analogues as inhibitors
of centrosomal clustering. The variations in the griseofulvin structure cover ﬁve positions, namely the 4, 5,
2′, 3′, and 4′ positions. Modiﬁcation of the 4 and 5 positions affords inactive molecules. The enol ether
must be at the 2′ position, and the 4′ position needs to be sp2 hybridized. The most active analogues were
the 2′-benzyloxy and 2′-(4-methylbenzyloxy) analogues as well as the oxime of the former with a 25-fold
increase of activity compared to griseofulvin. Comparison of the results obtained in this work with prior
reported growth inhibition data for dermatophytic fungi showed both similarities and differences.
Introduction
Griseofulvin (1, Figure 1) is a classic antifungal agent1,2 used
clinically for the treatment of dermatomycoses. Since the
isolation of griseofulvin in 1939,3 it has attracted a lot of
attention and more than a hundred papers describing analogue
synthesis as well as structure-activity relationship (SARa)
studies relating to antifungal activity have been published. Since
1950, more than 400 analogues have been disclosed covering
most positions and many have displayed signiﬁcantly increased
activity in published antifungal assays. More recently, griseof-
ulvin has been the object of increased interest due to its activity
toward a range of mammalian cancer cell lines.4 Griseofulvin
has been shown to be cytotoxic by itself but also to potentiate
the activity of another anticancer drug, nocodazole.5,6 The
cytotoxicity of three 2′ analogues in Chinese hamster V79 cells
has previously been reported by Oda.7
We have recently developed an assay8 to identify small
molecules that inhibit centrosomal clustering, a mechanism
necessary for successful bipolar mitoses in human cancer cell
lines with supernumerary centrosomes.9,10 Healthy mammalian
cells harbor two centrosomes during mitosis that function as
mitotic spindle poles to ensure accurate chromosome segrega-
tion, whereas the majority of human malignancies contain
multiple centrosomes. Supernumerary centrosomes can form
multipolar spindles leading to aberrant mitoses with consecutive
chromosome missegregation, eventually resulting in apoptosis.
In most human cancer cell lines, this spindle multipolarity is
overcome through centrosomal clustering, giving rise to two
functional spindle poles and thereby allowing for successful
mitosis.11 As this phenotype is speciﬁc to cancer cells, there is
a possibility that the compounds identiﬁed in our assay will
target cancer cells selectively without interfering with healthy
cells.
Microtubules are vital components of centrosomes, and
compounds interacting with the dynamics of tubulin polymer-
ization and depolymerization are a major category of anticancer
agents including vinca alkaloids and taxanes.12 Griseofulvin is
known to interact with tubulin,13 but the mode of action for
this inhibition is not fully understood although a few theories
have been proposed.4,5,14
We have tested 34 griseofulvin analogues in our assay, of
which nine are novel, affording the ﬁrst SAR study of this
compound class with regard to anticancer activity. The analogues
vary at ﬁve positions of the griseofulvin structure, namely the
4, 5, 2′, 3′, and 4′ positions. All analogues described in this
paper have been prepared from commercially available griseof-
ulvin in one to four synthetic steps.
Chemistry
The phenol 4 was synthesized by treatment of 1 with MgI2
in diethyl ether and toluene.15 Alkylation of 4 with either ethyl
or benzyl bromide using NaH as base afforded elongated
analogues 5 and 6 (Scheme 1). Nitration16 of 1 gave 7, which
could be reduced to the amine 8 with iron powder.17 Reductive
amination with benzaldehyde yielded analogue 9 (Scheme 1).
Two synthetic routes have been utilized for the preparation
of the 2′ enol ether analogues of 1. Direct camphorsulfonic acid
(CSA) mediated solvolysis of griseofulvic acid (2)18 afforded
* To whom correspondence should be addressed. Phone: +45 45252131.
Fax: +45 45933968. E-mail: mhc@kemi.dtu.dk.
† Department of Chemistry, Technical University of Denmark.
‡ Center for Microbial Biotechnology, Department of Systems Biology.
§ Clinical Cooperation Unit for Molecular Hematology/Oncology, Ger-
man Cancer Research Center (DKFZ) and Department of Internal Medicine
V, University of Heidelberg.
a Abbreviations: CSA, camphorsulphonic acid, DBU, diaza(1,3)bicyclo-
[5.4.0]undecane; NIS, N-iodosuccinimide; NOE, nuclear Overhauser effect;
SAR, structure-activity relationship; TESOTf, triethylsilyl triﬂuoromethane-
sulfonate.
Figure 1. Structures of griseofulvin 1, griseofulvic acid 2, and
isogriseofulvin 3.
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compounds 10-15 plus their 4′ enol ether isomers. Dioxane
was used as cosolvent for alcohols with higher boiling points,
leading to 16 and 17. This method was generally applicable to
the synthesis of analogues with straight chain vinyl ethers in
yields of 14-22% (Scheme 2).
Bulkier alcohols like benzyl alcohol and cyclopentanol led
to unsatisfactory yields of 2-4%. An attractive alternative was
the known19 route through the 2′ vinyl chloride 18, which relies
on a base mediated addition of the alcohol followed by
elimination of chloride (Scheme 3). Vinyl chloride 18 is
accessible by treatment of 2 with lithium chloride in phosphoryl
chloride. We found using dioxane as cosolvent convenient
because this allowed us to reduce the amount of phosphoryl
chloride to 5 equiv, greatly facilitating the workup procedure
and the scale-up to multigram amounts.
The addition of alcohols to 18 performed well in DMF, THF,
and dioxane with comparable yields and THF or dioxane was
used as solvent for all subsequent experiments. NaH and Cs2CO3
weretestedasbases,butintheend,diaza(1,3)bicyclo[5.4.0]undecane
(DBU) turned out to be the most efﬁcient base and it was used
for preparation of analogues 19-25 in yields of 2-93%
(Scheme 3).
The 4′ alcohol 26 was derived from 1 using a slight
modiﬁcation of a known method20 (Scheme 4). Analogue 27
was available by reduction of 1 with hydrogen catalyzed by
platinum on charcoal, an improvement of a published proce-
dure.21 The oximes 28 and 29 were derived from the parent
ketones by treatment with hydroxylamine hydrochloride in
ethanol and DMSO, a slight modiﬁcation of the method of
Delgado et al.17 and isolated as inseparable 1:1 mixtures of
geometrical isomers. In a similar fashion, the hydrazine 30 was
synthesized by heating 1 with N,N-dimethyl hydrazine and acetic
acid in toluene. The major product was the E analogue 30 with
the geometry distinguished by NOE in proton NMR. The H3′
proton of the two isomers showed two distinct signals in NMR.
No dipolar coupling between a hydrazine methyl group and H3′
could be observed for the pure analogue 30, but a strong NOE
was detected for the isomer.
3′,3′-Dimethyl griseofulvic acid (31) was derived from 2
treated with K2CO3 and MeI22 (Scheme 5). Analogue 32 was
synthesized from 2 by reaction with benzyl bromide, NaI, and
KOH.22 Treatment of 1 with N-iodosuccinimide (NIS) and
triethylsilyl triﬂate (TESOTf) afforded 33, and the 3′-iodo
analogues 34 and 35 were obtained using the same convenient
conditions. This type of compounds have previously been
prepared by treating 2 with iodine monochloride and 2 equiv
of KOAc,23 followed by reacting the intermediate with an excess
of an appropriate diazo alkane.24
Results and Discussion
Compounds 1-35 were evaluated for their ability to inhibit
centrosomal clustering in our cellular assay8 (Table 1). The
percentages of cells with multipolar spindles were measured in
triplicate at 14 different concentrations (100 μM to 12 nM),
and IC50 values were calculated with an IC50 of 24 μM for
griseofulvin (1). Analogues with IC50 values higher than 100
μM are regarded as inactive.
Scheme 1a
a (a) MgI2, toluene, Et2O; (b) RBr, tetrabutylammonium iodide, NaH,
DMF; (c) HNO3, Ac2O; (d) Fe, HOAc; (e) PhCHO, NaBH(OAc)3, CH2Cl2.
Scheme 2a
a (a) ROH, CSA, dioxane (16 and 17).
Scheme 3a
a (a) LiCl, POCl3, dioxane; (b) ROH, DBU, THF, or dioxane.
Scheme 4a
a (a) NaBH4, CeCl3, MeOH; (b) H2, Pt/C, EtOAc; (c) hydroxylamine,
NaOAc, EtOH, DMSO; (d) Me2NNH2, HOAc, toluene.
Scheme 5a
a (a) MeI, K2CO3, THF; (b) NaI, KOH, BnBr, H2O; (c) NIS, TESOTf,
CH2Cl2.
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At ring A, the 4 and 5 positions were altered. Elongation at
the 4 position resulted in no activity for either the ethyl (5) or
benzyl (6) ethers. Introduction of a nitro (7), amine (8), or benzyl
amine (9) group at the 5 position negates all activity, indicating
that bulkier groups at these two positions are not tolerated.
Compound 6 has previously been tested for growth inhibition
against dermatophytes (Epidermophyton ﬂoccosum, Trichophy-
ton interdigitale, T. persicolor, T. mentagrophytes, T. rubrum,
and Microsporum canis), and 7 and 8 have been tested against
the latter three in addition to T. terrestre and all three were
found to be less active than 1.17,25
The 2′, 3′, and 4′ positions of the C ring have been altered in
this study. Solvolysis of 2 with a given alcohol affords two
isomers with the enol ether positioned at either the 2′ or 4′
position. We have tested altogether 11 analogues with a 4′ enol
ether as in isogriseofulvin (3), including the isomers of 10-17
and 20, and all have been inactive (data not shown). This
strongly indicates that active analogues should have the enol
ether at the 2′ position. The activity of the 4′ enol ether isomers
of 3, 10, 13, and 19 toward a range of dermatophytes
(Trichophyton mentagrophytes, T. interdigitale, T. rubrum, T.
persicolor, Microsporum canis and Epidermophyton ﬂoccosum)
have been published and all showed lower activity than 1.25
Several analogues with modiﬁcations at the 2′ position have
been prepared, and elongation of the methoxy group in 1
(analogues 10-15) increases the activity, with a maximum
around 4 carbon atoms.
The activity can be further increased by the introduction of
bulkier groups. The cyclopropylmethoxy (16) and cyclopentoxy
(17) analogues have IC50 values of 1.8 and 1.3 μM, comparable
to the phenoxy (19) and benzylthio (21) analogues with 1.5 and
1.3 μM. The most active 2′ analogues are the benzyloxy (20)
and 4-methylbenzyloxy (23) compounds, both with an IC50 value
of 0.9 μM. While there is little difference between 19 and 20,
the phenylethoxy analogue 22 is signiﬁcantly less potent with
an IC50 value of 15 μM. The introduction of even bulkier groups
such as 4-biphenylmethoxy (24) and adamantylmethoxy (25)
affords IC50 values of 2.9 and 3.7 μM, higher than the most
active compounds but signiﬁcantly more potent than 1. Because
our assay is whole-cell based, transport over the cell membrane
potentially also inﬂuences the observed activity. The higher
lipophilicity of 24 and 25 could render this transport easier,
which would contribute to the observed increase in activity.
Growth inhibition data for the dermatophytes Trichophyton
mentagrophytes, T. interdigitale, T. rubrum, T. persicolor,
Microsporum canis, and Epidermophyton ﬂoccosum has been
published for compounds 10, 11, 13, 15, 19, and 20.25 The
activities for 10 and 11 were equal to or lower than 1, while 13
was more active against two strains (T. interdigitale, T.
persicolor) and similar or less toward the remaining strains.
Compound 15 showed increased activity against a single strain
(T. interdigitale), and 19 and 20 were inactive.
A different phenotype was seen for 18. Usually, cells are
attached to the dish by focal adhesions. Treatment with 18 led
to a detachment of the cell monolayer from the dish, but,
interestingly, the cell-cell contacts were not affected. Because
of this phenotype, induction of multipolar spindle formation
could not be analyzed.
The 4′ alcohol, griseofulvol (26), has no activity and neither
has the 2′-methoxy 4′-alcohol analogue (27). The 4′ position
of 1 was altered to an oxime (28), giving rise to an increase in
activity with an IC50 of 17 μM. To check for a possible
synergistic effect, the 2′ benzyloxy analogue 20 was also ﬁtted
with an oxime affording 29, but the activity did not exceed that
of 20 as the IC50 value remained at 0.9 μM. Introduction of a
hydrazine group at the 4′ position (30) led to a slight decrease
in activity with an IC50 of 27 μM. No activity was reported for
26 toward dermatophytes Trichophyton metagrophytes or T.
rubrum, but for 28, the activity toward those two strains and T.
terrestre and Microsporum canis was comparable to griseof-
ulvin.17
The results from the 4′ analogues indicate that this position
is important for the activity, as removal of the ketone renders
the compounds (26 and 27) inactive. Taken together with the
increase in activity for 28 and 29, it suggests that the 4′ position
should be sp2 hybridized.
Neither griseofulvic acid 2, the 3′,3′-dimethyl analogue 31,
nor 3′-benzyl griseofulvic acid (32) showed activity in our assay.
Introduction of iodine at the 3′ position had equivocal effects.
3′-Iodo griseofulvin (33) and 3′-iodo-2′-benzyloxy analogue 35
were inactive. For the 2′-propoxy-3′-iodo analogue 34, the IC50
found was 2.0 μM, only a factor two higher than the most active
compounds and lower than the 2′-propoxy analogue 11 itself.
In antifungal screens, 33 shows lower activity toward Tricho-
phyton mentagrophytes, T. interdigitale, T. rubrum, T. persi-
color, Microsporum canis, and Epidermophyton ﬂoccosum,
Table 1. Compounds Included in the Article and Their IC50 Values within a 95% Conﬁdence Interval
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where 34 has a lower activity against all save T. interdigitale,
where the activity is the same as 1.25
Conclusion
We report here for the ﬁrst time a collection of griseofulvin
analogues tested for inhibition of centrosomal clustering in
cancer cells. Of the 34 analogues tested, 13 were inactive, two
had decreased activity, and 18 displayed increased activity as
compared to griseofulvin, while one analogue showed a different
phenotype characterized by detachment of the cell monolayer
from the dish.
All modiﬁcations of the 4 and 5 positions resulted in no
activity, and thus these positions should not be altered. It appears
as if the 4′ position needs to be sp2 hybridized as reduction of
the ketone results in no activity, whereas introduction of either
an oxime (28 and 29) or a hydrazine (30) group leads to more
active analogues. A total of 11 4′ enol ether analogues have
been tested, and all were inactive. The two inactive analogues
31 and 32 also indicate that modiﬁcations must preserve the
conjugated system of 1 to be beneﬁcial.
The 2′ position has been explored the most, and elongation
at this position increases the activity while introducing bulkier
groups do so to an even larger extent. The optimal substituent
seems to be a benzyloxy group (20) with the possibility of
substitution on the aromatic ring. The phenylethoxy analogue
22 is 15 times less active than 20, and a longer tether is thus
not a viable option for increased activity.
The three iodo substituted analogues do not give a clear
picture of the effect of substitution at the 3′ position as the
activity varies. We speculate that the iodine changes the
conformation of the 2′ substituent and that the benzyloxy group
is shifted to a less desirable position, whereas the propyloxy
group is moved to a more favorable position.
While comparing the SAR data obtained in this work for
inhibition of centrosomal clustering with the growth inhibitory
effect against seven dermatophytic fungi, some similarities are
seen but also notable differences. Modiﬁcation of the 4 and 5
positions in the A ring renders the analogues inactive with regard
to both activities. For the C ring modiﬁcations, the 4′ enol ether
analogues displayed reduced or no activity in both types of
assay. When modifying the 2′ position, the activity toward
dermatophytes is retained for the ethyl and propyl analogues.
The butyl and hexyl analogues show increased activity toward
some fungal strains and lower toward others. The inhibition of
centrosomal clustering is increased for all straight chained 2′
analogues, compared to griseofulvin. With bulkier substituents
(19 and 20), lower activity is seen toward all dermatophyte
strains, while the inhibition of centrosomal clustering is
enhanced further.
Reduction of the 4′ ketone makes the analogue inactive both
toward dermatophytes and cancer. An oxime on the 4′ position
retains activity toward dermatophytes but increases the cen-
trosomal clustering inhibition. Compound 33 with substitution
in the 3′ position is less active in our assay as well as against
dermatophytes, while 34 has diminished antifungal activity but
is 12 times more potent than 1 in our assay.
The results described herein demonstrate that the activity of
griseofulvin as an inhibitor of centrosomal clustering can be
enhanced by structural modiﬁcations, which renders this com-
pound class interesting as potential anticancer agents. Further-
more, we have demonstrated that previously published data on
the antifungal activity of griseofulvin analogues does not
correlate directly to their activity in mammalian cells.
Experimental Section
Starting materials, reagents, and solvents were purchased from
Sigma-Aldrich Chemical Co. and used without further puriﬁcation.
Reactions involving air or moisture sensitive reagents were carried
out under N2, and ﬂasks were dried by ﬂame heating under reduced
pressure. DMF, CH2Cl2, dioxane, and toluene were dried over 3 Å
molecular sieves. Evaporation of solvents was done under reduced
pressure (in vacuo). Purity of all compounds was found to be greater
than 95% by LC-DAD-MS (see below).
NMR spectra were recorded using either a Varian Unity Inova
500 MHz spectrometer or a Varian Mercury 300 MHz spectrometer.
13C NMR spectra were recorded using either a Bruker AC 200 MHz
or a Varian Mercury 300 MHz. Chemical shifts were measured in
ppm and coupling constants in Hz, the ﬁeld is indicated in each
case. When CDCl3 was used as solvent, the residual peak was used
as internal reference at δ 7.27 for 1H NMR and δ 77.00 for 13C
NMR spectra. When DMSO-d6 was used, the values were δ 2.50
for 1H NMR and δ 39.43 for 13C NMR spectra.
IR spectra were recorded using a Perkin-Elmer 1600 series FTIR.
All melting points are uncorrected. TLC was performed on
aluminum sheets precoated with silica gel 60 F254 (Merck
1.05554.0001). Compounds were visualized by charring after
dipping in a solution of 1% KMnO4, 6.7% K2CO3, and 0.08%
NaOH in water. UV visualization was done using a model UVGL-
25 Mineralight lamp.
EIMS were recorded by direct inlet to a GCMS-QP5000 gas
chromatograph mass spectrometer from Shimadzu. High-resolution
LC-DAD-MS was performed on an Agilent 1100 system equipped
with a photodiode array detector (DAD) and coupled to a LCT
orthogonal time-of-ﬂight mass spectrometer (Waters-Micromass)
with a Z-spray electrospray ionization (ESI) source and a LockSpray
probe (M + H 556.2771) and controlled by MassLynx 4.0 software.
LC-MS calibration from m/z 100-900 was done with a PEG
mixture. Standard separation involved a LUNA 2 column with an
acetonitrile (50 ppm TFA) in water gradient starting from 15% to
100% over 25 min with a ﬂow rate of 0.3 mL/min. Microanalyses
were obtained from H. Kolbe, Mikroanalytisches Laboratorium,
Mu¨lheim/Ruhr, Germany.
For the determination of IC50 values, we tested the compounds
in our assay8 for centrosomal clustering based on SSC114 cells,
an oral squamous cell carcinoma cell line characteristic for this
phenotype. Despite the presence of supernumerary centrosomes in
64.5% of SCC114 cells, only 3.6% of the cells in mitosis harbor
multipolar spindles. The rest of the cell population cluster their
centrosomes and undergo bipolar mitoses, making this cell line an
ideal model system. SCC114 cells were grown in 96-well plates to
near conﬂuence and treated for 24 h with different griseofulvin
analogues. The compounds were tested in triplicate at 14 different
concentrations (100, 50, 25, 12.5, 6.3, 3.1, 2, 1, 0.4, 0.2, 0.1, 0.05,
0.02, and 0.01 μM). Cells were then ﬁxed and examined by
ﬂuorescence microscopy. Then 100 mitotic cells per well were
analyzed, with the percentage of mitotic cells with multipolar
spindles being the read-out. The relationship between readout and
the dose was described by a logistic model (eq 1):
p ) (1 + exp(-R - x))-1 (1)
where p is the percentage of mitotic cells with multipolar spindles
and x is the dose scaled according to x ) ln(dose + 1). The dose
axis was scaled to spread out the low concentration data. The IC50
values and the corresponding 95% conﬁdence intervals were
determined from the ﬁtted dose-response curves. The calculations
were performed in Matlab 7.0.4.365 (The Mathworks) using the
glmﬁt and glmVal functions.
(2S,6′R)-(7-Chloro-4,6-dimethoxy-5-benzylamino-benzofuran-3-
on)-2-spiro-1′-(2′-methoxy-6′-methyl-cyclohex-2′-ene-4′-one) (9). To
a solution of 5-amino griseofulvin 8 (120 mg, 0.327 mmol) and
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benzaldehyde (0.07 mL, 0.654 mmol) in CH2Cl2 (4 mL) was added
a solution of sodium triacetoxyborohydride (104 mg, 0.490 mmol)
in CH2Cl2 (4 mL) at 0 °C under nitrogen atmosphere. Acetic acid
(90% aq, 0.03 mL, 0.654 mmol) was added and the mixture was
stirred at 20 °C for 48 h. The mixture was washed with sat. aq
NaHCO3 (15 mL) and water (15 mL). The combined aqueous
phases were extracted with CH2Cl2 (3 × 30 mL). The combined
organic phases were dried (MgSO4) and concentrated. The residue
was puriﬁed by column chromatography (toluene:CH2Cl2:EtOAc
30:30:1) to afford the product 9. Yield: 26 mg (17%) (yellow
needles); Rf (EtOAc:heptane 5:2): 0.54; mp: 79-80 °C. IR (KBr,
cm-1) 1709, 1664. 1H NMR (CDCl3) δ 7.31-7.18 (5H, m), 5.52
(1H, s), 4.30 (2H, s), 3.90 (3H, s), 3.86 (3H, s), 3.60 (3H, s), 2.93
(1H, dd, J ) 16.1, 13.3 Hz), 2.85-2.75 (1H, m), 2.40 (1H, dd, J
) 16.1, 4.1 Hz), 0.89 (3H, d, J ) 6.5 Hz). 13C NMR (CDCl3) δ
196.8, 194.1, 171.1, 163.9, 156.8, 146.6, 140.2, 128.8 (2C), 128.2
(2C), 127.6, 110.2, 106.2, 105.2, 105.1, 90.1, 62.6, 60.5, 57.0, 51.5,
40.2, 36.8, 14.5. HRMS (ESI+) calcd for [C24H25ClNO6]+ 458.1370,
found 458.1371.
General Procedure for the Synthesis of Enol Ethers by Solvoly-
sis (16 and 17). CSA (0.1 mmol, 0.1 equiv) was added to a solution
of griseofulvic acid (0.6 mmol, 1 equiv), the appropriate alcohol
(3 mmol, 5 equiv), and 1,4-dioxane (3 mL). The mixture was stirred
at 100 °C for 6 h and then cooled to 20 °C. EtOAc (20 mL) was
added to the solution, and the mixture was washed with sat.
NaH2PO4 (20 mL) and then water (20 mL). The combined aqueous
phases were extracted with EtOAc (3 × 20 mL), dried (MgSO4),
and then concentrated. The residue was puriﬁed by column
chromatography (toluene:CH2Cl2:EtOAc 7:7:1) to afford the desired
product and the isomer. When possible the product was recrystal-
lized from EtOAc/Heptane.
(2S,6′R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1′-(2′-
cyclopropylmethoxy-6′-methyl-cyclohex-2′-en-4′-one) (16). Yield: 86
mg (4%) (white crystals); Rf (EtOAc:heptane 5:1): 0.51; mp:
190-191 °C. IR (KBr, cm-1) 1704, 1659, 1608. 1H NMR(500
MHz, CDCl3) δ 6.13 (1H, s), 5.47 (1H, s), 4.03 (3H, s), 3.98 (3H,
s), 3.65 (2H, d, J ) 6.5 Hz), 3.03 (1H, dd, J ) 16.7, 13.5 Hz),
2.83 (1H, ddq, J ) 13.5, 4.7, 6.6 Hz), 2.41 (1H, dd, J ) 16.7, 4.7
Hz), 1.05-0.98 (1H, m), 0.96 (3H, d, J ) 6.6 Hz), 0.50-0.43 (2H,
m), 0.22-0.13 (2H, m). 13C NMR (50 MHz, CDCl3) δ 197.0, 192.5,
169.9, 169.6, 164.4, 157.6, 105.0 (2C), 97.1, 90.8, 89.3, 73.2, 56.9,
56.3, 39.9, 36.2, 14.2, 9.0, 2.7 (2C). HRMS (ESI+) calcd for
[C20H22ClO6]+ 393.1105, found 393.1108. Anal. (C20H21ClO6): C,
H.
(2S,6′R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1′-
(2′-cyclopentoxy-6′-methyl-cyclohex-2′-en-4′-one) (17). Yield: 50 mg
(4%) (yellow oil); Rf (EtOAc:heptane 5:1): 0.50. IR (KBr, cm-1)
1705, 1652, 1615. 1H NMR (500 MHz, CDCl3) δ 6.11 (1H, s),
5.49 (1H, s), 4.56-4.51 (1H, m), 4.03 (3H, s), 3.97 (3H, s), 3.03
(1H, dd, J ) 16.7, 13.5 Hz), 2.82 (1H, ddq, J ) 13.5, 4.8, 6.7 Hz),
2.40 (1H, dd, J ) 16.7, 4.8 Hz), 1.79-1.72 (2H, m), 1.72-1.64
(2H, m), 1.58-1.44 (4H, m), 0.95 (3H, d, J ) 6.7 Hz). 13C NMR
(50 MHz, CDCl3) δ 197.1, 192.6, 169.6, 169.0, 164.3, 157.5, 105.8,
105.1, 97.0, 90.9, 89.2, 81.6, 56.8, 56.3, 39.8, 36.1, 32.1 (2C), 23.7
(2C) 14.2. HRMS (ESI+) calcd for [C21H24ClO6]+ 407.1261, found
407.1262.
General Procedure for the Synthesis of Enol Ethers by
Addition-Elimination (19-25). To a solution of 18 (0.65 mmol,
1 equiv) in 1,4-dioxane (3 mL, 0.2 M) was added the desired alcohol
(1.30 mmol, 2 equiv) and DBU (1.63 mmol, 2.5 equiv). The mixture
was heated to 100 °C and stirred for 12 h. The mixture was then
cooled to 20 °C, and excess reagent was quenched with sat. aq
NH4Cl (30 mL). The aqueous phase was extracted with EtOAc (3
× 30 mL) and the combined organic phases were dried (MgSO4)
and then concentrated. The residue was puriﬁed by column
chromatography (heptane:EtOAc 3:2) affording the product. When
possible the product was recrystallized from EtOAc/heptane.
(2S,6′R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1′-
(6′-methyl-2′-(2-phenylethoxy)-cyclohex-2′-en-4′-one) (22). Yield:
199 mg (86%); Rf (toluene:CH2Cl2:EtOAc 1:1:1): 0.50. 1H NMR
(300 MHz, CDCl3) δ 7.20-7.12 (3H, m), 7.03-6.95 (2H, m), 6.13
(1H, s), 5.49 (1H, s), 4.06 (3H, s), 3.97 (3H, s), 3.95-3.84 (2H,
m), 3.02 (1H, dd, J ) 16.5, 13.5 Hz), 2.89-2.75 (3H, m), 2.40
(1H, dd, J ) 16.5, 4.6 Hz), 0.94 (3H, d, J ) 6.7 Hz). 13C NMR
(75 MHz, CDCl3) 197.0, 192.5, 169.8, 169.5, 164.5, 157.6, 137.2,
128.8 (2C), 128.3 (2C), 126.4, 105.1, 105.0, 97.1, 90.7, 89.4, 69.9,
57.0, 56.3, 39.9, 36.1, 34.7 14.1. HRMS (ESI+) calcd for
[C24H24ClO6] 443.1261, found 443.1264.
(2S,6′R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1′-(6′-
methyl-2′-(4-methylbenzyloxy)-cyclohex-2′-ene-4′-one) (23).Yield: 201
mg (54%) (white crystals); Rf (EtOAc:heptane 5:1): 0.45; mp:
176-178 °C. IR (KBr, cm-1) 1709, 1664. 1H NMR (300 MHz,
CDCl3) δ 7.11-7.04 (4H, m), 6.09 (1H, s), 5.58 (1H, s), 4.87 (1H,
d, J ) 12.2 Hz), 4.76 (1H, d, J ) 12.2 Hz), 4.01 (3H, s), 3.95 (3H,
s), 3.04 (1H, dd, J ) 16.5, 13.4 Hz), 2.85 (1H, ddq, J ) 13.2, 4.5,
6.6 Hz), 2.41 (1H, dd, J ) 16.4, 4.4 Hz), 2.30 (3H, s), 0.97 (3H,
d, J ) 6.6 Hz). 13C NMR (75 MHz, CDCl3) δ 197.1, 192.7, 169.9,
169.8, 164.7, 157.9, 138.2, 131.8, 129.5 (2C), 127.0 (2C), 106.2,
105.8, 97.1, 91.0, 89.7, 71.0, 57.2, 56.6, 40.2, 36.7, 21.4, 14.5.
HRMS (ESI+) calcd for [C24H24ClO6]+ 443.1261, found 443.1273.
(2S,6′R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1′-(2′-
(4-biphenylmethoxy)-6′-methyl-cyclohex-2′-ene-4′-one) (24).Yield: 54
mg (19%); Rf (toluene:CH2Cl2:heptane 2:2:1): 0.32. IR (KBr, cm-1)
1704, 1662. 1H NMR (300 MHz, CDCl3) δ 7.58-7.50 (4H, m),
7.46-7.40 (2H, m), 7.37-7.31 (1H, m), 7.28-7.23 (2H, m), 6.10
(1H, s), 5.63 (1H, s), 4.97 (1H, d, J ) 12.4 Hz), 4.85 (1H, d, J )
12.4 Hz), 4.01 (3H, s), 3.96 (3H, s), 3.07 (1H, dd, J ) 16.5, 13.4
Hz), 2.88 (1H, ddq, J ) 13.4, 4.6, 6.6 Hz), 2.45 (1H, dd, J ) 16.5,
4.6 Hz), 1.00 (3H, d, J ) 6.6 Hz). 13C NMR (50 MHz, CDCl3) δ
197.0, 192.4, 169.5 (2C), 164.5, 157.7, 141.0, 140.4, 133.6, 128.7
(4C), 127.2, 127.0 (4C), 105.9, 105.3, 97.2, 90.7, 89.4, 70.4, 56.9,
56.3, 40.0, 36.3, 14.2. HRMS (ESI+) calcd for [C29H26ClO6]+
505.1418, found 505.1421.
(2S,6′R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1′-
(2′-(1-adamantylmethoxy)-6′-methyl-cyclohex-2′-ene-4′-one) (25).
Yield: 5 mg (2%); Rf (toluene:CH2Cl2:EtOAc 3:3:1): 0.16. 1H NMR
(300 MHz, CDCl3) δ 6.05 (1H, s), 5.37 (1H, s), 3.96 (3H, s), 3.91
(3H, s), 3.26 (1H, d, J ) 9.2 Hz), 3.13 (1H, d, J ) 9.2 Hz), 3.03
(1H, dd, J ) 16.6, 13.6 Hz), 2.87-2.71 (1H, m), 2.36 (1H, dd, J
) 16.6, 4.8 Hz), 1.83-175 (3H, m), 1.63-1.50 (4H, m), 1.45-1.28
(6H, m), 1.20-1.13 (2H, m), 0.95 (3H, d, J ) 6.7 Hz). 13C NMR
(50 MHz, CDCl3) δ 197.1, 192.8, 170.3 (2C), 164.5, 157.7, 104.2
(2C), 97.4, 91.3, 89.3, 78.6, 57.0, 56.4, 40.3, 38.8 (3C), 36.8 (3C),
35.7, 33.5, 27.9 (3C), 14.3. HRMS (ESI+) calcd for [C27H32ClO6]+
487.1887, found 487.1888.
(2S,6′R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1′-
(2′-benzyloxy-6′-methylcyclohex-2′-ene-4′-one-4′-oxime) (29). To a
solution of 20 (0.20 mmol, 1.0 equiv) in EtOH (5 mL, 0.03M) and
DMSO (2.5 mL, 0.03M) was added hydroxylamine hydrochloride
(0.70 mmol, 3.5 equiv) and sodium acetate (0.86 mmol, 4.3 equiv).
The mixture was stirred at 75 °C for 24 h, allowed to reach 20 °C,
and diluted with CH2Cl2 (20 mL). The mixture was washed with
distilled water (2 × 15 mL) and then brine (15 mL). The organic
phase was dried (MgSO4) and concentrated. The crude mixture was
puriﬁed by column chromatography (toluene:CH2Cl2:EtOAc 2:2:
1) to afford the desired product.
Yield: 167 mg (82%) (white needles); Rf (EtOAc:heptane 5:1):
0.39 and 0.36; mp: 139-141 °C. IR (KBr, cm-1) 1706, 1614. 1H
NMR (300 MHz, CDCl3) δ 8.63 (1H, s), 7.30-7.13 (5H, m), 6.36
(0.5H, s), 6.07 (1H, s), 6.68 (0.5H, s), 4.99-4.71 (2H, m), 3.99
(3H, s), 3.93 (3H, s), 3.14 (0.5H, dd, J ) 16.6, 4.7 Hz), 3.04 (0.5H,
dd, J ) 15.0, 13.2 Hz), 2.73 (0.5H, dd, J ) 16.6, 13.0 Hz),
2.69-2.51 (1H, m), 2.42 (0.5H, dd, J ) 15.0, 4.2 Hz), 0.98 (1.5H,
d, J ) 6.6 Hz), 0.97 (1.5H, d, J ) 6.8 Hz). 13C NMR (75 MHz,
CDCl3) δ 194.0 (0.5C), 193.8 (0.5C), 169.5, 164.2, 159.8 (0.5C),
157.4, 157.2 (0.5C), 155.1 (0.5C), 151.8 (0.5C), 135.7 (0.5C), 135.5
(0.5C), 128.3 (2C), 127.7 (0.5C), 127.6 (0.5C), 126.6, 126.5, 105.7,
100.3 (0.5C), 97.0, 93.7 (0.5C), 91.5 (0.5C), 91.4 (0.5C), 89.1, 70.0
(0.5C), 69.7 (0.5C), 56.9, 56.2, 36.4 (0.5C), 35.2 (0.5C), 30.9 (0.5C),
25.5 (0.5C), 14.4 (0.5C), 14.3 (0.5C). HRMS (ESI+) calcd for
[C23H23ClNO6]+ 444.1214, found 444.1204.
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(2S,6′R,E)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-
1′-(2′-methoxy-6′-methyl-cyclohex-2′-ene-4′-one-4′-dimethylhydra-
zine) (30). To a solution of griseofulvin (1.0 g, 2.83 mmol) in
toluene (28.3 mL) was added N,N-dimethylhydrazine (0.9 mL, 11.32
mmol) and 90% aq acetic acid (0.5 mL, 8.66 mmol). The mixture
was heated to 50 °C for 24 h and cooled to 20 °C. The mixture
was diluted with diethyl ether (100 mL), washed with sat. aq
NaHCO3 (50 mL) and brine (50 mL). The combined aqueous phases
were extracted with diethyl ether (50 mL), and the combined organic
phases were dried (Na2SO4) and concentrated. The residue was
puriﬁed by column chromatography (toluene:CH2Cl2:EtOAc 1:1:
2) to yield compound 30. Yield: 208 mg (19%) (orange needles);
Rf (EtOAc:heptane 5:1): 0.22; mp: 118-120 °C. IR (KBr, cm-1)
1708, 1613. 1H NMR (300 MHz, CDCl3) δ 6.11 (1H, s), 5.67 (1H,
s), 4.02 (3H, s), 3.97 (3H, s), 3.56 (3H, s), 3.13 (1H, dd, J ) 16.2,
4.5 Hz), 2.77 (1H, dd, J ) 16.2, 12.9 Hz), 2.60 (1H, ddq, J )
12.8, 4.7, 6.6 Hz), 2.53 (6H, s), 0.94 (3H, d, J ) 6.7 Hz). 13C
NMR (75 MHz, CDCl3) δ 194.4, 169.7, 164.5, 162.7, 160.0, 157.7,
105.8, 103.3, 97.3, 91.9, 89.4, 57.2, 56.5, 56.2, 47.5 (2C), 36.1,
29.4, 14.6. HRMS (ESI+) calcd for [C19H24ClN2O5]+ 395.1374,
found 395.1374.
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Abstract 
Griseofulvin (1) and 53 analogs of this compound have been tested against the pathogenic dermatophytes Trichophyton 
rubrum and T. mentagrophytes as well as against the breast cancer cell line MDA-MB-231. The modifications to 
griseofulvin include the 4, 5, 6, 2’, 3’ and 4’ positions. The SAR of the griseofulvin analogs towards the two fungi followed 
the same trend with the majority being less active than griseofulvin and none had more than twice the potency of the parent 
compound. A comparison of the anti-fungal and the anti-cancer SAR revealed distinct differences, as the majority of 
analogs showed increased activity against the cancer cell line MDA-MB-231, highlighted by 2’-benzyloxy-2’-demethoxy-
griseofulvin, which showed low activity against both fungi, but was among the most potent compounds against MDA-MB-
231 cancer cells. Tubulin has been proposed as the target of griseofulvin in both fungal and mammalian cells, but the 
differences revealed by this SAR study strongly suggest that the mode-of-action of the compound class towards fungi and 
mammalian cancer cells is different. 
 
Introduction 
Griseofulvin (1, see Figure 1) was one of the first anti-
fungal natural products isolated1 from filamentous fungi and 
has been known as an anti-fungal agent for decades.2, 3 The 
compound was until the approval of Lamisil®4 by the US 
Food and Drug Administration5 in 2007, the only drug 
available for treatment of tinea capitis,6 a superficial fungal 
skin infection caused by dermatophytes, which 
predominantly affects children.7 Upon administration to man 
griseofulvin accumulates in the skin (Stratum corneum) 
where it presumably binds to keratin.8 The mode of action is 
still not determined but tubulin binding has been proposed.9, 
10 
 
 
Figure 1. The structure of griseofulvin (1), griseofulvic acid 
(2) and isogriseofulvin (3). The rings A, B and C as well as 
the positions modified in this study in 1 are shown. 
 
More than four hundred griseofulvin analogs have been 
reported since its discovery and the activity of these over 
three hundred of these have been compared with 
griseofulvin (1) against six dermatophytes in a study by 
Crosse et al.11 The curling of hyphae in Botrytis allii were 
also tested, but this phenotype did not correlate with the 
growth inhibitory effect of the analogs.11 Griseofulvin 
analogs with modifications at positions 4, 6, 2’ and 3’ as 
well as isogriseofulvin analogs with modifications at the 4, 
6, 3’ and 4’ positions were tested. No 2’ analogs excelled in 
growth inhibition of the dermatophytes,11 but elongation did 
increase the curling of hyphae with the optimal analogs the 
being 2’-propoxy (46) and 2’-butoxy analogs.12 Most 
griseofulvin analogs tested showed increased potency 
against some dermatophytes, but exhibiting lower activity 
against others. 
Position 5 has been functionalized with nitro (10) and amine 
(9) groups rendering the analogs inactive at relevant 
concentrations against four dermatophytes.13 An 
ethoxycarbonyl group has also been introduced in this 
position and the analog found to be inactive.14 The 4’ 
position has also been examined with the 4’ alcohol analog 
(50) being inactive and the 4’ oxime (36) being seven fold 
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less potent compared to 1, with both analogs tested against 
Microsporum gypseum.15 
Although the initial isolation of 1 was completed in 19391 
both anti-cancer16-19 and anti-viral20 properties of 
griseofulvin have been discovered recently. Three analogs 
tested for the former by Oda et al.21 against chinese hamster 
V79 cells showed increased cytotoxicity with 2’-propoxy-
2’demethoxy-griseofulvin being the most potent (46, IC50 
0.7 μM; 1, 8 μM) and it was proposed that additional 
structural modifications at the 2’ position could enhance 
activity further. This was supported by ourselves in a whole 
cell phenotype-based anti-cancer assay for spindle 
multipolarity induction, where increased activity was seen 
for analogs with modifications in the 2’ position, with the 
2’-benzyloxy-2’-demethoxy-griseofulvin analog (17) being 
the most potent compound tested.22 Multiple papers state 
that griseofulvin arrests several cancer cell lines in G2/M 
phase of the cell cycle.17-19 Several investigators have 
proposed tubulin as the main target for griseofulvin although 
for mammalian cells this proposition is not undisputed.9, 17, 
18, 20, 21, 23, 24 Recently, Panda et al.25 proposed two 
griseofulvin binding sites on tubulin using molecular 
docking studies and similar to Oda21 reported that 
microtubule dynamics were disrupted by 1. Using the 
hepatitis C virus-1b cell culture system Huh7/Rep-Feo, Jin 
et al. reported that G2/M phase arrest in infected cells was 
induced by griseofulvin (1).20 It was speculated that the 
effect was due to interaction with microtubule 
polymerization.20 
Griseofulvin exhibits activity against fungi, mammalian 
cancer cells as well as suppressing RNA replication by the 
hepatitis C virus, with tubulin having been proposed to be 
involved in all three cases. Tubulins are very conserved 
within different eukaryotic cell types,24 and most of the 
variation among different tubulin isoforms is found in the 
amino acids near the C-terminus, which form a ridge on the 
surface of microtubules. Therefore, variations among 
different isoforms are expected to affect primarily the 
association of accessory proteins with the surface of 
microtubules, rather than microtubule polymerization per se. 
In case tubulin is the sole target of griseofulvin in both fungi 
and mammalian cells, the activity profile of an array of 
analogs against these cell types should be similar. To test 
this hypothesis we decided to carry out an SAR study of 
griseofulvin analogs. This is to the best of our knowledge 
the first study of griseofulvin (1) and analogs thereof, which 
compares anti-fungal and anti-cancer SAR from growth 
inhibition assays. 
Griseofulvin (1) and 54 griseofulvin analogs (11 reported 
for the first time here) have been tested in an anti-fungal 
assay against T. mentagrophytes and T. rubrum, two 
dermatophytes causing tinea capitis.7 All compounds were 
also tested in an anti-cancer assay against the human cell 
line MDA-MB-231 (breast adenocarcinoma), which was 
chosen because this cell line represents a common cancer 
type and is known to harbor supernumerary centrosomes 
which are regularly clustered into a bipolar mitotic spindle 
array in a high percentage of cells.26 Analogs with 
alterations at the 4, 5, 6, 2’, 3’ and 4’ positions have all been 
synthesized from commercially available griseofulvin in one 
to five synthetic steps. 
 
Results and Discussion 
Chemistry. The 4-phenol (4) was synthesized from 1 by 
treatment with freshly prepared MgI2, procured by 
sonication of Mg and I2 in Et2O/toluene, affording 4 in 99% 
yield, an improvement on prior methods (Scheme 1).22, 27 
Alkylation of 4 to synthesize 5 and 6 has previously been 
described.22, 27 Position 4 analogs 7 and 8 were prepared 
from 4 with Ag2O and the appropriate alkyl bromide in 
dioxane as solvent.27 The syntheses of 9 and 10 have already 
been described.22, 28 
For the preparation of 11, 12 and 13 see Rønnest et al.29 and 
Arkley et al.27 Compound 12 was alkylated using Ag2O and 
EtBr followed by repeated solvolysis in MeOH with CSA to 
afford 14. The dichloro analogs 16 and 15 were synthesized 
using 2,30 POCl3, LiCl and dioxane, a modification of a 
known method (Scheme 2).31 The compounds 17-33 were 
synthesized by 1,4 addition of the corresponding alcohol to 
16 using either NaH or DBU as base (Scheme 3).31 The 
isogriseofulvin analogs 3 and 35 were synthesized in the 
same manner but from 15. Compound 3 has previously been 
prepared by treating 2 with excess diazomethane yielding 
both 1 and 3.32 Compounds 26 and 38 have been reported in 
a patent,33 which is also the case for 19, 21 and 22.34 The 
dimer 34, which was conveniently synthesized together with 
22 by a second 1,4-addition of 22 to 16, has previously been 
published in a Japanese patent.35  
The analogs with an oxime functionality 36, 37 and 38 were 
synthesized from the corresponding ketones (1, 17 and 26) 
using hydroxylamine hydrochloride in ethanol and 
DMSO.13, 22 Isogriseofulvin (39-44) and griseofulvin analogs 
(45-49 and 17) were synthesized simultaneously in pairs by 
solvolysis with the respective alcohols and catalytic CSA 
and subsequently separated by chromatography (Scheme 4). 
Analogs 50-55 were synthesized according to published 
procedures.22 The fungal secondary metabolite geodin (56) 
was recently isolated from Aspergillus terreus.36 Please see 
the supporting information for 1H and 13C NMR spectra for 
all compounds and experimental for compounds 2, 3, 15, 
39-41 and 44. 
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Scheme 1. (a) MgI2, toluene, Et2O; (b) RBr, Ag2O, dioxane; 
(c) HOAc, 2 M H2SO4; (d) 0.66 M NaOH; (e) MeOH, CSA; 
(f) MeOH, CSA (13) or EtBr, Ag2O, dioxane; then MeOH, 
CSA (14). 
 
 
 
Scheme 2. (a) LiCl, POCl3, dioxane. 
 
 
 
Scheme 3. (a) ROH, DBU, THF or dioxane. (b) 
hydroxylamine, NaOAc, EtOH, DMSO. 
 
 
Scheme 4. (a) ROH, CSA, dioxane (17, 42-44, 48, and 49). 
 
 
 
Figure 2. The analogs 50-55 were prepared according to 
literature procedures.22 Geodin (56) was isolated as 
previously described.36 
Assays. Griseofulvin (1), geodin (56) and 53 griseofulvin 
analogs covering variations on six positions (see Figure 1) 
were tested against two dermatophytes (T. rubrum and T. 
mentagrophytes) and against the breast cancer cell line 
MDA-MB-231 in a cytotoxicity assay. For all the test results 
the following definitions were used: if no activity was 
observed at 50 μM a given compound was deemed inactive; 
if activity was observed but 50% inhibition was not reached 
at 50 μM a given compound is described as having low 
activity and no IC50 value is calculated (see supporting 
information for examples). The IC50 of griseofulvin (1) was 
determined to be 0.38 ± 0.048 μM against the T. rubrum 
isolate and 0.058 ± 0.018 μM against the T. mentagrophytes 
isolate. All IC50 values and 95% confidence intervals are 
given in Table 1. 
Anti-fungal Structure-Activity Relationship for T. 
rubrum and T. mentagrophytes. All compounds in the 
position 4 series of 4- 8 were less active than griseofulvin 
(1) against the two fungi and 8 was completely inactive. For 
T. rubrum 4 and 6 were inactive, 7 had low activity and 5 
was, with an IC50 of 2.0 μM, approximately five times less 
potent than griseofulvin. For T. mentagrophytes analog 4 
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showed low activity and the rest were less potent than 1: 5 
(0.29 μM), 6 (0.25 μM) and 7 (0.17 μM). The activity of 6 
has previously been reported against a number of 
dermatophytes (Epidermophyton  floccosum, Microsporum 
canis, T. interdigitale, T. persicolor, T. mentagrophytes and 
T. rubrum) and found to be less active than 1 against all of 
them.11 
The nitro (9) and amine (10) position 5 analogs were 
inactive against both fungi. Compound 10 has also been 
reported as inactive, but 9 has been reported as weakly 
active with inhibition for both fungi starting at around 25 
μM.13 Other position 5 analogs (ethoxycarbonyl,14 methoxy, 
methyl or chloro37) have been reported to have lower 
activity than 1 against dermatophytes.  
Whereas the position 6 phenols 13 and 11 were inactive 
against both fungi, the 6-ethyl analog (14) had an IC50 of 1.3 
μM against T. rubrum and was as active as griseofulvin (1) 
against T. mentagrophytes with an IC50 of 0.062 μM, which 
is in accordance with the literature.11 
The 2’ series is the most extensively studied due to the 
increased activity observed in the anti-cancer phenotype-
based assay19 by these analogs. For T. rubrum elongation to 
2’-ethyloxy (45, 0.69 μM) and 2’-propyloxy (46, 0.62 μM) 
lowered the activity twofold, confirming the findings of 
Crosse et al.11 The bulkier 2’-isopropyloxy (47, 3.1 μM) was 
ten times less potent. Increasing bulkiness through 2’-
cyclopropylmethoxy (48, 1.5 μM), cyclopentyloxy (49, 2.5 
μM) and benzyloxy (17, 1.1 μM) enol ethers did not reveal a 
trend but all three were less active towards T. rubrum than 1. 
No correlation between the size of the 2’ substituent and the 
activity was seen for T. mentagrophytes with 46 (0.050 μM) 
retaining the activity of 1 and IC50 values of 0.25 μM and 
0.11 μM for 45 and 47, respectively. Both 45 and 46 have 
been reported to retain the activity of 1 against T. 
mentagrophytes by Crosse et al.11 Analog 48 (0.060 μM) 
had the same activity as 1, but 17 (0.26 μM) and 49 (0.24 
μM) were about four times less potent. 
The activities of 17, 45 and 46 have been reported against T. 
mentagrophytes and T. rubrum and all showed lower 
activity when tested against the latter.11 Lower activity than 
1 towards T. mentagrophytes was also reported for 17, but 
45 and 46 had similar potency.11 The three compounds were 
also tested against Epidermophyton floccosum, 
Microsporum canis, T. interdigitale and T. persicolor 
displaying the same trends, with 17 having lower activity 
and 45 and 46 retaining the activity of 1.11 
The rest of the 2’ series includes bulkier analogs (25-27), 
para-substituted variations of 17 (19-22), two sets of ortho-, 
meta- and para-analogs (28-30 and 31-33), modification of 
the linker part (23 and 24) and a vinyl sulfide analog 18. 
Of the bulkier 2’ analogs the naphthalen-1-ylmethoxy 26 
was the only active analog and 25 and 27 were inactive 
against both fungi. With IC50 values of 2.6 μM (T. rubrum) 
and 0.25 μM (T. mentagrophytes) compound 26 is three and 
four times less potent than 1, respectively.  
The three 2’ pyridine analogs (28-30) had low activity 
towards T. rubrum and 30 also showed low activity towards 
T. mentagrophytes. Compounds 29 and 28 had IC50 values 
of 0.35 μM and 1.3 μM, meaning they were approximately 
six and 22 times less potent towards T. rubrum compared to 
1. The series with ortho-, meta- and para-methoxy groups 
revealed 33 as inactive against both fungi, 31 with low 
activity towards T. rubrum and an IC50 of 0.70 μM against 
T. mentagrophytes. The meta-substituted analog 32 (0.96 
μM) was threefold less active against T. rubrum compared 
to 1 and displayed a twofold decrease in activity against T. 
mentagrophytes with an IC50 of 0.14 μM. 
The 2’-phenoxy analog (23) had IC50 values of 6.1 μM 
against T. rubrum and 1.6 μM against T. mentagrophytes, 
while the phenylethoxy analog (24) had low activity against 
T. rubrum and an IC50 of 0.28 μM against T. 
mentagrophytes. Lower activity for 23 has previously been 
reported.11 The vinyl sulfide analog 18 (1.3 μM) was as 
active as 17 against T. rubrum but against T. 
mentagrophytes the IC50 (0.058 μM) was equal to that of 
griseofulvin (1). 
The 3’-dimethyl analog 52 was inactive against both fungi. 
The series of 3’ analogs include three 3’-iodo analogs with 
2’ modifications, 2’-methoxy (53), 2’-ethoxy (54) and 2’-
benzyloxy (55). The 3’-iodo griseofulvin (53) was inactive 
against T. rubrum and had low activity towards T. 
mentagrophytes in accordance with Crosse et al.11 The 2’-
benzyloxy (55) analog was inactive against T. rubrum and 
close to twenty times less potent (1.1 μM) than 1 against T. 
mentagrophytes. Analog 55 was also four times less potent 
than 17, which has no 3’ iodo group. The propoxy (54) 
analog showed activity against both fungi (T. rubrum 1.6 
μM and T. mentagrophytes 0.23 μM) but was less potent 
than both 1 and the analog 46, which does not contain 
iodide. Analog 54 has been reported to be the most potent at 
inducing curling of hyphae, but less active against all 
dermatophytes spare one.11  
The introduction of an oxime functionality on the parent 
compounds 1, 17 and 26 afforded the analogs 36, 37 and 38 
and lowered the activity towards both fungi compared to the 
parent compounds (38 was inactive against both fungi 
altogether). The IC50 values for 36 were 1.3 μM against T. 
rubrum and 0.19 μM against T. mentagrophytes which is in 
accordance with previously published data.13 Analog 36 has 
also been reported active against M. gypseum.15 Compound 
37 had IC50 values of 7.9 μM against T. rubrum and of 0.30 
μM againstT. mentagrophytes, twenty and three times less 
potent than 1, respectively. The 4’ alcohol 50 exhibited low 
activity towards both fungi which was not in agreement with 
prior work as it has been reported that 50 causes 100% 
growth inhibition of T. rubrum and visible inhibition against 
T. mentagrophytes at 28 μM.13 Cmpound 50 has however 
been tested inactive against M. gypseum.15 
The series including isogriseofulvin (3) and isogriseofulvin 
analogs 35 and 39-44 was inactive against T. rubrum and 
showed low activity against T. mentagrophytes. This is in  
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GF# 
T. rubrum 
(µM) 
± STD IC50 
(µM) 
T. menta-
grophytes (µM) 
± STD IC50  
(µM) Cytotox (µM) 
± STD IC50 
(µM) 
1 0.38 0.05 0.058 0.02 18 4 
2 Inactive Inactive Low activity - Inactive Inactive 
3 Inactive Inactive Inactive Inactive Inactive Inactive 
4 Inactive Inactive Low activity - Inactive Inactive 
5 2.0 0.7 0.29 0.1 Inactive Inactive 
6 Inactive Inactive 0.25 0.009 20 4 
7 Low activity - 0.17 0.02 Low activity - 
8 Inactive Inactive Inactive Inactive 17 2 
9 Inactive Inactive Inactive Inactive Inactive Inactive 
10 Inactive Inactive Inactive Inactive Inactive Inactive 
11 Inactive Inactive Inactive Inactive Inactive Inactive 
13 Inactive Inactive Inactive Inactive Low activity - 
14 1.3 0.1 0.062 0.02 36 3 
15 Inactive Inactive Inactive Inactive 1.0 0.1 
16 Low activity - Low activity - 3.2 0.3 
17 1.1 0.2 0.26 0.1 2.1 0.2 
18 1.3 0.4 0.058 0.02 4.7 0.7 
19 0.83 very wide 0.041 0.01 6.5 1 
20 1.0 0.2 0.24 0.1 1.8 0.3 
21 1.5 0.2 0.15 0.1 7.0 0.9 
22 Low activity - 1.7 1 2.8 0.6 
23 6.1 7 1.6 3 7.2 1 
24 Low activity - 0.28 0.2 17 2 
25 Inactive Inactive Inactive Inactive 5.8 1 
26 2.6 0.3 0.25 0.09 13 2 
27 Inactive Inactive Inactive Inactive 4.7 0.5 
28 Low activity - 1.3 3 32 6 
29 Low activity - 0.35 0.2 10 2 
30 Low activity - Low activity - 19 2 
31 Low activity - 0.70 0.6 11 3 
32 0.96 0.4 0.14 0.07 8.1 2 
33 Inactive Inactive Inactive Inactive Low activity - 
34 Inactive Inactive Inactive Inactive 8.5 2 
35 Inactive Inactive Low activity - 25 5 
36 1.3 0.5 0.19 0.1 12 2 
37 7.9 0.9 0.30 0.2 1.4 0.3 
38 Inactive Inactive Inactive Inactive 8.3 0.8 
39 Inactive Inactive Low activity - Low activity - 
40 Inactive Inactive Low activity - 43 6 
41 Inactive Inactive Low activity - 48 10 
42 Inactive Inactive Low activity - 52 10 
43 Inactive Inactive Low activity - 27 4 
44 Inactive Inactive Low activity - Low activity - 
45 0.69 0.2 0.25 0.08 13 3 
46 0.62 0.09 0.050 0.02 16 5 
47 3.1 1 0.11 0.05 11 3 
48 1.5 0.3 0.060 0.02 9.4 2 
49 2.5 0.8 0.24 0.09 3.2 0.5 
50 Low activity - Low activity - Inactive Inactive 
51 Low activity - 3.0 1 Inactive Inactive 
52 Inactive Inactive Inactive Inactive Inactive Inactive 
53 Inactive Inactive Low activity - 22 1 
54 1.6 0.4 0.23 0.08 8.0 1 
55 Inactive Inactive 1.1 0.5 Low activity - 
56 Inactive Inactive Inactive Inactive 9.9 1 
Table 1. All available IC50 values from the screen. If no activity was observed at 50 μM a given compound is deemed inactive. 
If activity was observed, but 50 % inhibition was not reached at 50 μM a given compound is described as having low activity 
and the IC50 value is not calculated.  
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accordance with the literature, where 3 and 39 have been 
reported to be less active than griseofulvin against a number 
of dermatophytes (E. floccosum, M. canis, T. interdigitale, 
T. persicolor, T. mentagrophytes and T. rubrum).11 
Griseofulvic acid (2) was inactive against T. rubrum and had 
low activity against T. mentagrophytes contrary to prior 
work, which reported 2 to be inactive towards T. 
mentagrophytes but having visible growth inhibition at 30 
μM against T. rubrum.13 The griseofulvin dimer 34 was 
inactive against both fungi. The dichloro analog 16 showed 
low activity towards both fungi while 15 was inactive 
against both. The reduced analog 51 had low activity against 
T. rubrum and an IC50 of 3.0 μM against T. mentagrophytes, 
which is 50 times less potent compared to 1. Geodin (56) 
was inactive against both fungi. 
Of the 55 compounds tested, 27 analogs were inactive or 
exhibited low activity for both fungi (see Table 1). Nine of 
the compounds were active against both fungi within the 
same order of magnitude compared to griseofulvin (17, 20, 
21, 23, 26, 32, 36, 49 and 54).  
There were however some compounds that fared differently 
against the two fungi. The compounds 6, 7, 22, 24, 28, 29, 
31, 51 and 55 were all inactive or had low activity towards 
T. rubrum but had IC50 values in the range of 0.25-3.0 μM 
against T. mentagrophytes. For other analogs (14, 18, 19, 37, 
47 and 48) the activity against T. mentagrophytes was 
similar to that of 1 but against T. rubrum it was significantly 
lower. This is in accordance with earlier observations by 
Crosse et al., demonstrating that a given analog was more 
active against some fungi but less active against others.11 
 
Anti-cancer Structure-Activity Relationship. Looking at 
the IC50 values for the 16 analogs (1, 17, 18, 20, 23-25, 27, 
36, 37, 45-49 and 54) tested active in both the multipolarity 
assay19 and the cytotoxicity based assay there was good 
correlation between the data with an R2 of 0.70 (see 
supporting information). 
The IC50 of griseofulvin (1) was determined to be 23 ± 5 μM 
(20 ± 1 μM in the phenotype-based spindle multipolarity 
assay22), while an IC50 of 25 ± 4 μM against HeLa cells was 
found by Panda et al.18 In the position 4 series, 4, 5 and 7 
were all inactive but 6 and 8 harboring aromatic moieties 
had activities similar to griseofulvin (1) with IC50 values of 
20 (6) and 17 μM (8). This indicates a mode of action that 
does not involve induction of multipolar mitosis as 6 was 
inactive in the multipolarity assay. Both the position 5 
analogs 9 and 10 were inactive in the cytotoxicity assay as 
they were in the assay for multipolarity induction. 
The 6-phenol griseofulvic acid analog 11 was inactive and 
the 6-phenol griseofulvin analog (13) showed low activity. 
The 6-ethyl griseofulvin (14) analog was approximately 
50% less active than griseofulvin. The two dichloro analogs 
15 and 16 were some of the most cytotoxic among the tested 
analogs with IC50 values of 1.0 and 3.2 μM, respectively.  
When elongating the 2’ position from the parent methoxy 
(1) to ethoxy (45) and propoxy (46) and then further 
increasing the bulkiness with isopropoxy (47), cyclopentoxy 
(49) and benzyloxy (17) the activity increased through the 
series (see Figure 3), plateauing with 17 and 49 at 2.1 and 
3.2 μM, respectively. The same trend was seen when these 
compounds were tested in the phenotype-based 
multipolarity assay. Moving from the benzyloxy derived 
analogs to even bulkier groups like the naphthalen-1-
ylmethoxy (26, 13 μM), biphenylmethoxy (25, 5.8 μM) and 
1-adamantylmethoxy (27, 4.7 μM) analogs, the activity did 
not increase further. The three compounds were still more 
potent than griseofulvin though, which was also observed 
for 25 and 27 in the phenotype-based assay. 
 
Figure 3. The activity increases with the number of carbon 
atoms at the 2’ position from griseofulvin itself to the 2’ 
ethoxy (45), propoxy (46), isopropoxy (47) and cy-
propylmethoxy (48) before leveling out with the 
cyclopentoxy (49) and benzyloxy (17) analogs. The bulkier 
analogs 25, 27 and 26 were less active than the benzyloxy 
analog (17). 
A number of variations of 17 have been tested (18-24, 28-30 
and 31-33) and although all except 33 (low activity), 28 (32 
μM) and (24, 17 μM; 30, 19 μM) were more active than 1, 
only 20 was as active as 17 with an IC50 of 1.8 μM. The 
difference in activity between the phenoxy (23, 7.2 μM) and 
phenylethoxy (24, 17 μM) analogs was less pronounced in 
the cytotoxicity assay than in the multipolarity assay with 
two and a half orders of magnitude compared to the 
approximately seven-fold difference in the phenotype-based 
assay. The dimer (34) was about twice as active as 1 with an 
IC50 value of 8.5 μM. 
The introduction of an oxime functionality at the 4’ position 
(36) increased potency twofold to 12 μM, an increase in 
activity that was also seen in the phenotype-based assay. 
Introducing the oxime to analogs 17 and 26 affording 37 and 
38 improved the activity further for both compounds. Apart 
from 15, 37 is the most active analog in the cytotoxicity 
assay with an IC50 of 1.4 μM. The stability of the oximes in 
PBS buffer (pH 7.4) was tested and less than 5% hydrolysis 
to the parent ketones could be detected after 48 hours (data 
not shown).  
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The isogriseofulvin analogs tested in the multipolarity assay 
(3 and 39-44) were all inactive. In the cytotoxicity assay 35 
retained the activity of 1, while the rest were either inactive 
(3), showed low activity (39, 44) or were less potent (40, 43 
μM; 41, 48 μM; 42, 52 μM and 43, 27 μM). 
Geodin (56) did not induce multipolar mitoses and was in 
that respect deemed inactive.36 Geodin (56) is however twice 
as cytotoxic as griseofulvin when tested against the MDA-
MB-231 cell line, with an IC50 of 9.9 μM opposed to 18 μM 
for 1. 
The reduced analogs 50 and 51 as well as the 3’-dimethyl 
analog 52 were inactive in both anti-cancer assays. In the 3’ 
iodo series, 53 (22 μM) retained activity, the 2’ propoxy 
analog (54, 8.0 μM) had increased activity and 55 exhibited 
low activity. 53 and 55 were inactive in the phenotype-based 
assay but 54 was more potent than 1. 
 
Anti-cancer SAR versus anti-fungal SAR. The difference 
between the anti-fungal and anti-cancer data is illustrated in 
Figure 4 demonstrating that most of the analogs had 
increased potency against the cancer cell line but against the 
two fungal strains the activity was lower than for 
griseofulvin (1). Looking at the 4 position there were 
inconsistencies throughout all three cell types. The ethyl 
analog 5 was active against both fungi but inactive towards 
the cancer cells, while the bulkier naphtyl analog 8 was 
inactive against both fungi but more potent than griseofulvin 
against the MDA-MB-231 cells. Analogs 6 and 7 were more 
potent than 5 against T. mentagrophytes, but both 
compounds were inactive or showed low activity towards T. 
rubrum. The most potent analog towards the cancer cells 
(15) was inactive against both fungi and the isomer (16), 
which was amongst the most active compounds, only had 
low activity towards the two fungi. The two bulky analogs 
25 and 27 as well as the dimer (34) inactive in the anti-
fungal assays but were all more potent than griseofulvin 
against the cancer cell line. It is also worth noticing that 
geodin (56) was inactive against both fungi but twice as 
potent as 1 against the cancer cell line. 
 
 
Figure 4. The IC50 values for each cell line have been normalized defining the activity of griseofulvin as having a value of 1. It is 
seen that of the 53 analogs the majority was less active against the two fungi opposed to the anti-cancer activity where most 
analogs were more active than griseofulvin. 
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The introduction of an oxime at the 4’ position (36, 37 and 
38) decreased the potency compared to the parent 
compounds (1, 17 and 26) against both fungi. The opposite 
effect was seen for the cancer cell line, where the 
introduction of this moiety increased the activity in all three 
compounds (36, 37 and 38). 
There were however some similar trends for all three cell 
types as well. A number of analogs were inactive or had low 
activity towards both fungi and cancer cells. Amongst these 
were the position 5 analogs (9, 10), isogriseofulvin (3) and 
the series of isogriseofulvin analogs (39-44) with 35 as the 
sole exception. The two 6 phenols (11, 13) were virtually 
inactive against all cell types, which was the same for 50-52. 
 
Conclusion 
The first comparison of anti-fungal and anti-cancer SAR for 
griseofulvin analogs is presented in this work covering 53 
analogs of griseofulvin as well as the natural product geodin 
(56). All compounds have been tested against T. rubrum, T. 
mentagrophytes and in a cytotoxicity assay against MDA-
MB-231 breast cancer cells. 
Even though there were similarities between the SAR of the 
two fungi, with some compounds showing no activity 
against both fungi and some active against both, there were 
also some differences. Analogs 46 and 48 retain the activity 
of griseofulvin against T. mentagrophytes but were two and 
four fold less active against T. rubrum than 1, respectively. 
This is in accordance with reported observations by Crosse 
et al. that analogs differ in activity against different 
dermatophytes.11 
We show that there is a good correlation between the IC50 
values from analogs that were active in both the phenotype-
based assay for spindle multipolarity22 and the cytotoxicity 
assay used in this work with an R2 of 0.70. Comparing the 
two fungal SAR’s with the anti-cancer cytotoxicity SAR 
afforded distinct differences. The analogs 8, 25, 27 and 38 
were inactive or had low potency against both fungi, but 
either retained the activity (8) or were at least twofold more 
active against the cancer cells compared to 1. The 2’-
benzyloxy analog (17) was less active against both fungi in 
this study and against six dermatophytes in the study by 
Crosse et al.11 This analog is however nine times more 
potent than 1 against the cancer cell line MDA-MB-231. It 
is noteworthy that the two dichloro compounds 15 and 16 
were inactive against both fungi, but featured as some of the 
most cytotoxic agents against the cancer cell line. 
The differences in activity observed for the two fungi and 
the MDA-MB-231 cell line could rise from a number of 
factors, such as transport over the cell membrane, efflux 
pumps or different modes of action. We find it unlikely that 
transport or efflux pumps could explain that the majority of 
analogs were more active against MDA-MB-231 cells and 
less active against both fungi. Our conclusion therefore is 
that the mode-of-action of griseofulvin(s) towards fungal 
and mammalian cells is different, making it unlikely that 
tubulin itself constitutes the main cellular target in both 
fungi and mammalian cells. Since it has been shown that 
griseofulvin leads to mitotic arrest in both fungal and 
mammalian cells, an alternative explanation is that 
griseofulvin disrupts microtubule dynamics without directly 
interacting with tubulin, e.g. through interaction with 
microtubule-associated proteins (MAPs). 
 
Experimental Section 
The fungal micro broth dilution assay was performed in 
sterile flat bottomed microplates (cat.# 655101) and lids 
(cat.# 656161) from Greiner Bio-One GmbH 
(Frickenhausen, Germany). Each microplate accommodated 
five dilution series starting at 50 μM of a given analog. Each 
plate was also fitted with four negative and four positive 
control wells. The fungi T. rubrum (IBT29284) and T. 
mentagrophytes (IBT2724) are kept in the IBT fungal 
collection at department of Systems Biology at the 
Technical University of Denmark. The correct identity of 
the fungal cultures were verified by microscopy after the last 
test round in the antifungal assay. For testing against T. 
rubrum a fourfold dilution series was used, resulting in ten 
concentrations with the lowest at 0.2 μM. For T. 
mentagrophytes an eightfold dilution series was used 
resulting in 10 concentrations with the last one at 0.4 pM.  
Inoculum preparation was performed in accordance with the 
document M38-A238 from the “Committee for Clinical 
Laboratory Standards”. Inoculum was adjusted to 0.90-1.5 
OD at 530 nM on a Genesys 10uv from Thermo Electron 
Corporation (Waltham, MA, US). The inoculums were 
diluted fiftyfold with RPMI media (with L-glutamine, 
without NaHCO3, cat.# R6504 in MOPS buffer (cat.# 
69947)) both from Sigma-Aldrich (St Louis, MO, US). The 
pH was adjusted to 7.00 with 1 M NaOH and the volume 
with MilliQ water from a Milli-Q gradient fitted with a 
Millipore 0.22 μm filter (cat.# MPGL04001) both from 
Millipore (Billerica, MA, US). 
Each well contained 99μL RPMI media with inoculum, 
99μL MilliQ water and 2 μL DMSO. Microplates were 
incubated for 7 days at 37 °C in a WTB binder incubator 
from VWR (Radnor, PA, US) at which point the OD of the 
wells were measured at 530 μM on a BioTek® Synergy 2 
(Brøndby, Denmark) using Gen5TM 1.10.8 software. The 
half maximal inhibitory concentration (IC50) values were 
obtained with GraphPad Prism5 (ver. 5.04) from GraphPad 
Software (La Jolla, CA, US) using the “nonlinear regression, 
sigmoidal dose-response (variable slope)” function. The 
fitting method used was “automatic outlier elimination”,39 
which eliminated less than 1.1% data points. 
1H NMR spectra were recorded using either a Varian Unity 
Inova 500 MHz spectrometer or a Varian Mercury 300 MHz 
spectrometer both from Agilent (Santa Clara, CA, US). 13C 
NMR spectra were recorded using either a Varian Mercury 
300 MHz or a Bruker AC 200 MHz from Bruker Optics 
(Ettlingen, Germany). Chemical shifts were measured in 
ppm and coupling constants in Hz. When CDCl3 was used 
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as solvent the residual peak was used as internal reference at 
δ 7.27 for 1H NMR and δ 77.00 for 13C NMR spectra.  
IR spectra were recorded using a Bruker Alpha ATR and 
measured in cm-1. All melting points are uncorrected. TLC 
was performed on aluminium sheets precoated with silica 
gel 60 F254 (Merck 1.05554.0001). 
High-resolution LC-DAD-MS was performed on an Agilent 
1100 system equipped with a photodiode array detector 
(DAD) and coupled to a LCT orthogonal time-of-flight mass 
spectrometer (Waters-Micromass, Manchester, UK) with a 
Z-spray electrospray ionisation (ESI) source and a 
LockSpray probe (M+H 556.2771) and controlled by 
MassLynx 4.0 software. LC-MS calibration from m/z 100-
900 was done with a PEG mixture. Standard separation 
involved a LUNA 2 column with an acetonitrile (50 ppm 
TFA) in water gradient starting from 15% to 100% over 25 
minutes with a flow rate of 0.3 mL/min. 
Compounds were visualized by charring after dipping in a 
solution of 1% KMnO4, 6.7% K2CO3 and 0.08% NaOH in 
water. UV visualization was done using a Model UVGL-25 
Mineralight Lamp.  
Microanalyses were obtained from H. Kolbe 
Mikroanalytisches Laboratorium in Mülheim an der Ruhr, 
Germany. 
General Procedure for the Synthesis of position 4 ethers 
(7 and 8) 
The appropriate alkyl bromide (1.2 mmol, 3 equiv.) was 
added to a solution of 4 (0.4 mmol, 1 equiv), Ag2O (1.2 
mmol, 3 equiv), and 1,4-dioxane (5 mL). The mixture was 
stirred at 50 °C for 18 h and then cooled to 20 °C. EtOAc 
(10 mL) was added to the solution and the mixture was 
washed with brine (15 mL). The aqueous phase was 
extracted with EtOAc (2 × 10 mL), the combined org. 
phases were dried (MgSO4), and concentrated. The residue 
was purified by column chromatography (EtOAc:heptane 
1:3) to afford the desired product. 
(2S,6’R)-(7-Chloro-6-methoxy-4-pentoxy-benzofuran-3-
one)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-ene-
4’-one) 7 
Yield: 80 mg (44 %) (yellow oil); Rf-value (EtOAc/heptane, 
2:1): 0.39; IR (neat, cm-1): 1709, 1664, 1612, 1586; 1H NMR 
(CDCl3, 500 MHz): δ 6.11 (1H, s), 5.52 (1H, s), 4.13-4.05 
(2H, m), 4.00 (3H, s), 3.61 (3H, s), 3.04 (1H, dd, J = 16.7, 
13.5 Hz), 2.82 (1H, d, J = 4.7, 6.7, 13.5 Hz), 2.41 (1H, dd, J 
= 16.7, 4.7 Hz), 1.92-1.85 (2H, m), 1.50-1.42 (2H, m), 1.42-
1.34 (2H, m), 0.95 (3H, d, J = 6.7 Hz), 0.92 (3H, t, J = 7.2 
Hz); 13C NMR (CDCl3, 50 MHz):  196.9, 192.0, 170.9, 
169.4, 164.4, 157.4, 105.2, 104.7, 96.9, 90.6, 90.3, 69.6, 
56.9, 56.6, 40.0, 36.5, 28.4, 27.9, 22.3 14.2, 13.9; [α]20D = 
+270° (c = 0.3 in CHCl3); HRMS (ESI+) calcd for [M+H]+ 
[C21H26ClO6]+ 409.1418, found 409.1419. 
(2S,6’R)-(7-Chloro-6-methoxy-4-(naphthalen-1-
ylmethoxy)-benzofuran-3-one)-2-spiro-1’-(2’-methoxy-
6’-methyl-cyclohex-2’-ene-4’-one) 8 
Yield: 25 mg (12 %) (yellow oil); Rf-value (EtOAc/heptane, 
2:1): 0.35; IR (neat, cm-1): 1704, 1662, 1612, 1588; 1H NMR 
(CDCl3, 500 MHz): δ 7.94-7.82 (4H, m), 7.57 (1H, dd, J = 
8.5, 0.9 Hz), 7.52-7.48 (2H, m), 6.23 (1H, s), 5.56 (1H, s), 
5.44 (2H, s), 3.92 (3H, s), 3.63 (3H, s), 3.07 (1H, dd, J = 
16.7, 13.5 Hz), 2.86 (1H, ddq, J = 13.5, 6.7, 4.7 Hz), 2.45 
(1H, dd, J = 16.7, 4.7 Hz), 0.99 (3H, d, J = 6.7 Hz); 13C 
NMR (CDCl3, 50 MHz):  197.0, 192.2, 170.8, 169.5, 
164.3, 156.7, 133.2, 132.9, 128.8, 128.0, 127.8, 126.5, 126.4 
(2C), 126.1, 124.5, 105.7, 104.9, 97.6, 91.8, 90.7, 71.5, 56.9, 
56.7, 40.1, 36.5, 14.3; [α]20D = +123° (c = 0.6 in CHCl3); 
HRMS (ESI+) calcd for [M+H]+ [C27H24ClO6]+ 479.1261, 
found 479.1266. 
(2S,6’R)-(7-Chloro-6-ethoxy-4-methoxy-benzofuran-3-
one)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-ene-
4’-one) 14 
Ethyl bromide (0.9 mmol, 3 equiv) was added to a solution 
of 12 (0.3 mmol, 1 equiv), Ag2O (0.9 mmol, 3 equiv), and 
1,4-dioxane (3 mL). The mixture was stirred at 50 °C for 18 
h and then cooled to 20 °C. EtOAc (10 mL) was added to 
the solution and the mixture was washed with brine (15 
mL). The aqueous phase was extracted with EtOAc (2 × 10 
mL), the combined org. phases were dried (MgSO4), and 
concentrated. The following process was repeated three 
times: The residue was dissolved in MeOH (10 mL) and 
CSA (0.1 mmol) was added, the mixture was heated to 65 
°C for 18 h.  EtOAc (10 mL) was added to the solution and 
the mixture was washed with sat. aq. NaHCO3 (15 mL). The 
aqueous phase was extracted with EtOAc (2 × 10 mL), the 
combined org. phases were dried (MgSO4), and 
concentrated. The residue was purified by column 
chromatography (EtOAc:heptane 1:3) to afford the desired 
product 14. 
Yield: 5 mg (5 %) (yellow oil); Rf-value (EtOAc/heptane, 
5:1): 0.43; IR (neat, cm-1): 1709, 1666, 1613, 1587 (Litt.40); 
1H NMR (CDCl3, 300 MHz): δ 6.13 (1H, s), 5.56 (1H, s), 
4.25 (2H, q, J = 7.0 Hz), 3.98 (3H, s), 3.63 (3H, s), 3.05 
(1H, dd, J = 16.7, 13.4 Hz), 2.86 (1H, ), 2.45 (1H, dd, J = 
16.7, 4.7 Hz), 1.56 (3H, t, J = 7.0 Hz), 0.98 (3H, d, J = 6.7 
Hz); 13C NMR (CDCl3, 50 MHz):  197.0, 192.4, 170.8, 
169.6, 164.1, 157.7, 104.9 (2C), 93.4, 90.7, 90.2, 65.8, 56.6, 
56.3, 40.1, 36.4, 14.6, 14.2; [α]20D =  +252° (c = 0.5 in CCl3) 
(Litt.27); HRMS (ESI+) calcd for [M+H]+ [C18H20ClNO6]+ 
367.0948, found 367.0949. 
General Procedure for the synthesis of 2’ enol ethers (19, 
21, 22, 26, 28-33) 
To a solution of 16 (0.65 mmol, 1 equiv) in 1,4-dioxane (3 
mL, 0.2 M) was added the desired alcohol (1.30 mmol, 2 
equiv) and DBU (1.63 mmol, 2.5 equiv). The mixture was 
heated to 100 °C and stirred for 12 h. The mixture was then 
cooled to 20 °C, and excess reagent was quenched with sat. 
aq. NH4Cl (30 mL). The aqueous phase was extracted with 
EtOAc (3 × 30 mL) and the combined organic phases were 
dried (MgSO4) and concentrated. The residue was purified 
by column chromatography (EtOAc:heptane: 1:3) affording 
the product. When possible the product was recrystallized 
from EtOAc/heptane. 
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(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2’-4-fluorobenzyloxy-6’-methyl-cyclohex-2’-
ene-4’-one) 19 
Yield: 116 mg (46 %) (white crystals); Rf-value 
(EtOAc/heptane, 5:1): 0.46; m.p. 103-105 C; IR (neat, cm-
1): 1704, 1661, 1610, 1587; 1H NMR (CDCl3, 300 MHz): δ 
7.19-7.11 (2H, m), 7.02-6.93 (2H, m), 6.10 (1H, s), 5.58 
(1H, s), 4.87 (1H, d, J = 12.1 Hz), 4.76 (1H, d, J = 12.1 Hz), 
4.02 (3H, s), 3.96 (3H, s), 3.05 (1H, dd, J = 16.5, 13.4 Hz), 
2.93-2.79 (1H, m), 2.43 (1H, dd, J = 16.5, 4.5 Hz), 0.98 
(3H, d, J = 6.7 Hz); 19F NMR (CDC13) δ -114.29 (m); 13C 
NMR (CDCl3, 50 MHz):  196.7, 192.2, 169.3, 164.8, 
164.5, 159.9, 157.6, 130.3, 128.6, 128.4, 115.6, 115.2, 
105.8, 105.0, 97.0, 90.6, 89.5, 69.9, 56.9, 56.3, 39.9, 36.3, 
14.1; [α]20D = +118° (c = 1 in CHCl3); HRMS (ESI+) calcd 
for [M+H]+ [C23H21ClFO6]+ 447.1011, found 447.1009. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2’-4-trifluoromethylbenzyloxy-6’-methyl-
cyclohex-2’-ene-4’-one) 21 
Yield: 128 mg (46 %) (white crystals); Rf-value 
(EtOAc/heptane, 5:1): 0.58; m.p. 103-105 C; IR (neat, cm-
1): 1705, 1664, 1612, 1589; 1H NMR (CDCl3, 300 MHz): δ 
7.56 (2H, d, J = 8.2 Hz), 7.29 (2H, d, J = 8.2 Hz), 6.12 (1H, 
s), 5.58 (1H, s), 4.97 (1H, d, J = 12.9 Hz), 4.85 (1H, d, J = 
12.9 Hz), 4.04 (3H, s), 3.97 (3H, s), 3.07 (1H, dd, J = 16.5, 
13.4 Hz), 2.97-2.77 (1H, m), 2.45 (1H, dd, J = 16.5, 4.5 
Hz), 1.00 (3H, d, J = 6.6 Hz); 19F NMR (CDC13) δ -63.30 
(s); 13C NMR (CDCl3, 50 MHz):  196.7, 192.2, 169.5, 
169.1 (2C), 164.7, 157.8, 138.6, 130.3 (q, J = 32.4 Hz) 
126.6 (2C), 125.5, 106.1, 105.1, 97.2, 90.7, 89.6, 69.6, 57.0, 
56.4, 40.0, 36.4, 14.2; [α]20D = +81° (c = 1 in CHCl3); 
HRMS (ESI+) calcd for [M+H]+ [C24H21ClF3O6]+ 497.0979, 
found 497.0974. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2’-((4-(hydroxymethyl)- benzyl)oxy)-6’-methyl-
cyclohex-2’-ene-4’-one) 22 
Yield: 120 mg (47 %) (white crystals); Rf-value 
(CH2Cl2/MeOH/HOAc, 89:10:1): 0.48; m.p. 160-163 C; IR 
(neat, cm-1): 1704, 1661, 1613, 1589; 1H NMR (CDCl3, 500 
MHz): δ 7.30 (2H, d, J = 8.0 Hz), 7.17 (2H, d, J = 8.0 Hz), 
6.11 (1H, s), 5.59 (1H, s), 4.91 (1H, d, J = 12.3 Hz), 4.81 
(1H, d, J = 12.3 Hz), 4.67 (2H, s), 4.02 (3H, s), 3.96 (3H, s), 
3.05 (1H, dd, J = 16.7, 13.4 Hz), 2.86 (1H, ddq, J = 13.4, 
6.7, 4.7 Hz), 2.43 (1H, dd, J = 16.7, 4.7 Hz), 0.99 (3H, d, J 
= 6.7 Hz); 13C NMR (CDCl3, 50 MHz):  197.1, 192.4, 
169.5 (2C), 164.5, 157.7, 140.9, 133.9, 127.1 (2C), 126.9 
(2C), 105.9, 105.1, 97.1, 90.7, 89.5, 70.5, 64.9, 57.0, 56.3, 
40.0, 36.4, 14.3; [α]20D = +148° (c = 0.6 in CHCl3); HRMS 
(ESI+) calcd for [M+H]+ [C24H24ClO7]+ 459.1211, found 
459.1212. 
(1'S,6'R)-7-Chloro-4,6-dimethoxy-6'-methyl-2'-
(naphthalen-1-ylmethoxy)-spiro[benzofuran-2,1'-
cyclohex[2]ene]-3,4'-dione 26 
Yield: 354 mg (53 %) (white crystals); Rf-value 
(EtOAc/heptane, 5:1): 0.46; m.p. 180-182 C; IR (neat, cm-
1): 1706, 1662, 1613, 1589; 1H NMR (500 MHz, CDCl3):  
7.84-7.76 (3H, m), 7.51-7.44 (2H, m), 7.39-7.33 (2H, m), 
6.00 (1H, s), 5.77 (1H, s), 5.31 (1H, d, J = 19.6 Hz), 5.28 
(1H, d, J = 19.6 Hz), 3.96 (3H, s), 3.93 (3H, s), 3.08 (1H, 
dd, J = 16.7, 13.5 Hz), 2.88 (1H, ddq, J = 13.5, 6.7, 4.6 Hz), 
2.45 (1H, dd, J = 16.7, 4.6 Hz), 0.98 (3H, d, J = 6.7 Hz); 
13C-NMR (75 MHz, CDCl3):  197.0, 192.4, 169.6, 169.4, 
164.4, 157.6, 133.4, 131.0, 129.7, 129.3, 128.5, 126.6, 
126.3, 125.8, 124.9, 123.2, 105.9, 105.0, 97.0, 90.7, 89.3, 
70.0, 56.8, 56.2, 40.0, 36.2, 14.2; [α]20D = +112 (c 1.0, 
CHCl3); HRMS (ESI+) calcd for [M+H]+ [C27H24ClO6]+ 
479.1261, found 479.1258. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2’-(pyridin-2-ylmethoxy)-6’-methyl-cyclohex-
2’-ene-4’-one) 28 
Yield: 118 mg (49 %) (white crystals); Rf-value 
(MeOH/CH2Cl2, 1:9): 0.70; m.p. 222-224 C; IR (neat, cm-
1): 1697, 1661, 1612, 1586; 1H NMR (CDCl3, 300 MHz): δ 
8.50 (1H, ddd, J = 4.8, 1.7, 1.0 Hz), 7.63 (1H, ddd, J = 7.9, 
7.7, 1.7 Hz), 7.18 (1H, ddd, J = 7.7, 4.8, 1.0 Hz), 7.14 (1H, 
ddd, J = 7.9, 1.0, 1.0 Hz), 6.14 (1H, s), 5.60 (1H, s), 5.05 
(1H, d, J = 13.9 Hz), 4.94 (1H, d, J = 13.9 Hz), 4.04 (3H, s), 
3.98 (3H, s), 3.06 (1H, dd, J = 16.4, 13.4 Hz), 2.97-2.78 
(1H, m), 2.44 (1H, dd, J = 16.4, 4.5 Hz), 1.00 (3H, d, J = 
6.6 Hz); 13C NMR (CDCl3, 50 MHz):  196.7, 192.1, 169.5, 
169.0, 164.6, 157.8, 154.8, 149.0, 136.9, 122.8, 120.3, 
106.2, 105.1, 97.1, 90.7, 89.6, 70.9, 57.0, 56.3, 40.0, 36.3, 
14.2; [α]20D = +163° (c = 1 in CHCl3); HRMS (ESI+) calcd 
for [M+H]+ [C22H21ClNO6]+ 430.1057, found 430.1059. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2’-(pyridin-3-ylmethoxy)-6’-methyl-cyclohex-
2’-ene-4’-one) 29 
Yield: 76 mg (32 %) (yellow oil); Rf-value (MeOH/CH2Cl2, 
1:9): 0.65; IR (neat, cm-1): 1705, 1663, 1613, 1589; 1H NMR 
(CDCl3, 300 MHz): δ 8.55 (1H, dd, J = 4.8, 1.1 Hz), 8.45 
(1H, d, J = 1.1 Hz), 7.54 (1H, d, J = 7.8 Hz), 7.27 (1H, dd, J 
= 7.8, 4.8 Hz), 6.13 (1H, s), 5.64 (1H, s), 4.95 (1H, d, J = 
12.32 Hz), 4.85 (1H, d, J = 12.31 Hz), 4.04 (3H, s), 3.99 
(3H, s), 3.09 (1H, dd, J = 16.4, 13.5 Hz), 2.90 (1H,  ddq, J = 
13.5, 6.6, 4.4 Hz), 2.47 (1H, dd, J = 16.4, 4.4 Hz), 1.01 (3H, 
d, J = 6.6 Hz); 13C NMR (CDCl3, 75 MHz):  196.8, 192.2, 
169.4, 169.2, 164.6, 157.7, 149.7, 148.2, 134.6, 130.2, 
123.5, 106.0, 105.0, 97.1, 90.6, 89.5, 68.3, 57.0, 56.3, 40.0, 
36.4, 14.2; [α]20D = +181° (c = 0.3 in CCl3); HRMS (ESI+) 
calcd for [M+H]+ [C22H21ClNO6]+ 430.1057, found 
430.1054. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2’-(pyridin-4-ylmethoxy)-6’-methyl-cyclohex-
2’-ene-4’-one) 30 
Yield: 70 mg (29 %) (yellow oil); Rf-value (MeOH/CH2Cl2, 
1:9): 0.60; IR (neat, cm-1): 1706, 1664, 1615, 1590; 1H NMR 
(CDCl3, 300 MHz): δ 8.53 (2H, d, J = 4.8, Hz), 7.08 (2H, d, 
J = 4.8 Hz), 6.13 (1H, s), 5.55 (1H, s), 4.92 (1H, d, J = 13.5 
Hz), 4.79 (1H, d, J = 13.5 Hz), 4.04 (3H, s), 3.97 (3H, s), 
3.07 (1H, dd, J = 16.4, 13.5 Hz), 2.89 (1H, ddq, J = 13.5, 
4.2, 6.6 Hz), 2.46 (1H, dd, J = 16.4, 4.2 Hz), 1.01 (3H, d, J = 
6.6 Hz); 13C NMR (CDCl3, 50 MHz):  196.6, 192.1, 169.5, 
68
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168.9, 164.7, 157.8, 150.0 (2C), 143.6, 120.7 (2C), 106.1, 
105.1, 97.1, 90.6, 89.6, 68.5, 57.0, 56.4, 40.0, 36.3, 14.2; 
[α]20D = +148° (c = 0.3 in CCl3); HRMS (ESI+) calcd for 
[M+H]+ [C22H21ClNO6]+ 430.1057, found 430.1053. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2’-2-methoxybenzyloxy-6’-methyl-cyclohex-2’-
ene-4’-one) 31 
Yield: 82 mg (43 %) (white crystals); Rf-value 
(EtOAc/heptane, 5:1): 0.43; m.p. 92-95 C; IR (neat, cm-1): 
1705, 1660, 1610, 1588; 1H NMR (CDCl3, 500 MHz): δ 
7.23 (1H, m), 7.09 (1H, m), 6.86 (1H, m), 6.81 (1H, m), 
6.11 (1H, s), 5.64 (1H, s), 4.95 (1H, d, J = 13.2 Hz), 4.88 
(1H, d, J = 13.2 Hz), 4.03 (3H, s), 3.96 (3H, s), 3.78 (3H, s), 
3.06 (1H, dd, J = 16.7, 13.5 Hz), 2.87 (1H, ddq, J = 13.5, 
4.7, 6.6 Hz), 2.43 (1H, dd, J = 16.7, 4.7 Hz), 0.99 (3H, d, J 
= 6.6 Hz); 13C NMR (CDCl3, 50 MHz):  197.0, 192.3, 
169.6, 169.5, 164.4, 157.6, 156.3, 129.0, 127.3, 122.9, 
120.4, 110.0, 105.6, 105.1, 97.1, 90.7, 89.4, 66.2, 56.9, 56.2, 
55.2, 39.9, 36.2, 14.2; [α]20D = +124° (c = 1 in CHCl3); 
HRMS (ESI+) calcd for [M+H]+ [C24H24ClO7]+ 459.1211, 
found 459.1216. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2’-3-methoxybenzyloxy-6’-methyl-cyclohex-2’-
ene-4’-one) 32 
Yield: 101 mg (52 %) (white crystals); Rf-value 
(EtOAc/heptane, 5:1): 0.56; m.p. 166-167 C; IR (neat, cm-
1): 1707, 1662, 1613, 1589 ; 1H NMR (CDCl3, 300 MHz): δ 
7.23-7.15 (1H, m), 6.82-6.68 (3H, m), 6.11 (1H, s), 5.59 
(1H, s), 4.91 (1H, d, J = 12.5 Hz), 4.79 (1H, d, J = 12.5 Hz), 
4.02 (3H, s), 3.96 (3H, s), 3.73 (3H, s), 3.06 (1H, dd, J = 
16.4, 13.4 Hz), 2.96-2.77 (1H, m), 2.44 (1H, dd, J = 16.4, 
4.5 Hz), 0.99 (3H, d, J = 6.6 Hz); 13C NMR (CDCl3, 50 
MHz):  196.9, 192.4, 169.6, 169.4, 164.5, 159.8, 157.7, 
136.1, 129.6, 118.6, 114.6, 110.8, 106.0, 105.2, 97.1, 90.8, 
89.5, 70.4, 57.0, 56.3, 55.1 40.0, 36.3, 14.3; [α]20D = +151° 
(c = 1 in CHCl3); HRMS (ESI+) calcd for [M+H]+ 
[C24H24ClO7]+ 459.1211, found 459.1217. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2’-4-methoxybenzyloxy-6’-methyl-cyclohex-2’-
ene-4’-one) 33 
Yield: 62 mg (51 %) (white crystals); Rf-value 
(EtOAc/heptane, 5:1): 0.46; m.p. 148-150 C; IR (neat, cm-
1): 1705, 1660, 1611, 1588; 1H NMR (CDCl3, 300 MHz): δ 
7.12 (2H, d, J = 8.7 Hz), 6.82 (2H, d, J = 8.7 Hz), 6.09 (1H, 
s), 5.60 (1H, s), 4.85 (1H, d, J = 11.8 Hz), 4.74 (1H, d, J = 
11.8 Hz), 4.02 (3H, s), 3.96 (3H, s), 3.78 (3H, s), 3.05 (1H, 
dd, J = 16.5, 13.3 Hz), 2.94-2.76 (1H, m), 2.43 (1H, dd, J = 
16.5, 4.5 Hz), 0.98 (3H, d, J = 6.6 Hz); 13C NMR (CDCl3, 
50 MHz):  197.0, 192.4, 169.6 (2C), 164.5, 159.5, 157.7, 
128.5 (2C), 126.6, 113.9 (2C), 105.9, 105.2, 97.2, 90.8, 
89.5, 70.7, 56.9, 56.3, 55.2, 40.0, 36.4, 14.2; [α]20D = +103° 
(c = 1 in CHCl3); HRMS (ESI+) calcd for [M+H]+ 
[C24H24ClO7]+ 459.1211, found 459.1214. 
Griseofulvin dimer 34 
Yield: 20 mg (5 %) (yellow oil); Rf-value 
(CH2Cl2:MeOH:HOAc, 89:10:1): 0.63; IR (neat, cm-1): 
1705, 1662, 1613, 1588; 1H NMR (CDCl3, 300 MHz): δ 
7.10 (4H, s), 6.11 (2H, s), 5.56 (2H, s), 4.88 (2H, d, J = 12.4 
Hz), 4.76 (2H, d, J = 12.4 Hz), 4.03 (6H, s), 3.96 (6H, s), 
3.04 (2H, dd, J = 16.7, 13.4 Hz), 2.85 (2H, ddq, J = 13.4, 
4.7, 6.7 Hz), 2.43 (2H, dd, J = 16.7, 4.7 Hz), 0.99 (6H, d, J = 
6.7 Hz); 13C NMR (CDCl3, 50 MHz):  196.9 (2C), 192.4 
(2C), 169.5 (4C), 164.6 (2C), 157.7 (2C), 134.7 (2C), 126.7 
(4C), 105.9 (2C), 105.2 (2C), 97.2 (2C), 90.8 (2C), 89.6 
(2C), 70.2 (2C), 57.0 (2C), 56.4 (2C), 40.0 (2C), 36.4 (2C), 
14.3 (2C); [α]20D = +167° (c = 0.3 in CHCl3); HRMS (ESI+) 
calcd for [M+H]+ [C40H37Cl2O12]+ 779.1662, found 
779.1658. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2'-(naphthalen-1-ylmethoxy)-6’-
methylcyclohex-2’-ene-4’-one-4’-oxime) 38 
To a solution of 26 (0.08 mmol, 1.0 equiv.) in EtOH (2 mL) 
and DMSO (1 mL) was added hydroxylamine hydrochloride 
(0.30 mmol, 3.5 equiv.) and sodium acetate (0.37 mmol, 4.3 
equiv.). The mixture was stirred at 75 °C for 18 hours, 
allowed to reach 20 °C and diluted with EtOAc (5 mL). The 
mixture was washed with brine (3×4 mL). The organic 
phase was dried (MgSO4) and concentrated. The crude 
mixture was purified by column chromatography 
(EtOAc:heptane 1:1) to afford 38 (40 mg, 96 %) as a yellow 
oil. Rf-values (EtOAc/heptane, 5:1): 0.60 and 0.51; IR (neat, 
cm-1): 1704, 1613, 1590; 1H NMR (500 MHz, CDCl3):  
7.82-7.73 (3H, m), 7.50-7.42 (2H, m), 7.37-7.32 (2H, m), 
6.54 (0.4H, s), 5.99 (0.6H, s), 5.96 (0.4H, s), 5.84 (0.6H, s), 
5.31 (0.4H, d, J = 12.0 Hz), 5.29 (0.6H, d, J = 12.0 Hz), 5.26 
(0.4H, d, J = 11.9 Hz), 5.23 (0.6H, d, J = 11.9 Hz), 3.95 
(1.8H, s), 3.93 (1.2H, s), 3.91 (1.8H, s), 3.90 (1.2H, s), 3.15 
(0.6 H, dd, J = 16.8, 4.9 Hz), 3.06 (0.4 H, dd, J = 15.0, 13.3 
Hz), 2.75 (0.6 H, dd, J = 16.8, 13.1 Hz), 2.70-2.57 (1 H, m), 
2.44 (0.4 H, dd, J = 15.0, 4.1 Hz), 0.98 (1.8H, d, J = 6.7 Hz), 
0.98 (1.2H, d, 6.8 Hz); 13C NMR (75 MHz, CDCl3):  194.0 
(0.5C, s), 193.9 (0.5C, s), 169.3 (0.5C, s), 164.0 (0.5C, s), 
160.0 (0.5C, s), 157.3 (0.5C, s), 157.3 (0.5C, s), 157.3 
(0.5C, s), 155.0 (0.5C, s), 151.8 (0.5C, s), 133.3 (0.5C, s), 
131.2 (0.5C, s), 131.1 (0.5C, s), 130.8 (0.5C, s), 130.6 
(0.5C, s), 128.9 (0.5C, s), 128.9 (0.5C, s), 128.8 (0.5C, s), 
128.3 (0.5C, s), 128.2 (0.5C, s), 128.1 (0.5C, s), 126.3 
(0.5C, s), 126.3 (0.5C, s), 126.2 (0.5C, s), 126.0 (0.5C, s), 
125.7 (0.5C, s), 125.6 (0.5C, s), 125.2 (0.5C, s), 125.0 
(0.5C, s), 124.9 (0.5C, s), 123.6 (0.5C, s), 123.5 (0.5C, s), 
105.6 (0.5C, s), 105.5 (0.5C, s), 100.5 (0.5C, s), 96.9 (0.5C, 
s), 96.8 (0.5C, s), 93.9 (0.5C, s), 91.5 (0.5C, s), 91.4 (0.5C, 
s), 89.0 (0.5C, s), 89.0 (0.5C, s), 69.4 (0.5C, s), 69.0 (0.5C, 
s), 56.7 (1 C, s), 56.1 (0.5C, s), 56.1 (0.5C, s), 36.4 (0.5C, s), 
35.2 (0.5C, s), 30.9 (0.5C, s), 25.5 (0.5C, s), 14.4 (0.5 C, s), 
14.3 (0.5 C, s); [α]20D = +112° (c = 1.0 in CDCl3); HRMS 
(ESI+) calcd for M+H [C27H25ClNO6]+ 494.1370, found 
494.1371. 
The analog 35 was synthesized according to the general 
procedure for 2’ enol ethers with the starting material being 
15 instead of 16. 
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(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-
spiro-1’-(4’-(3-methoxybenzyl)oxy-6’-methyl-cyclohex-
3’-en-2’-one] 35 
Yield: 83 mg (32 %) (white crystals); Rf-value 
(EtOAc/heptane, 5:1): 0.65; m.p. 173-175 C; IR (neat, cm-
1): 1691, 1653, 1605, 1584; 1H NMR (CDCl3, 300 MHz): δ 
7.37-7.27 (1H, m), 7.02-6.84 (3H, m), 6.09 (1H, s), 5.54 
(1H, d, J = 1.0 Hz), 5.01-4.85 (2H, m), 4.01 (3H, s), 3.93 
(3H, s), 3.84 (3H, s), 3.26 (1H, ddd, J = 17.5, 11.9, 1.0 Hz), 
2.96-2.80 (1H, m), 2.54 (1H, dd, J = 17.5, 5.6 Hz), 1.03 
(3H, d, J = 6.6 Hz); 13C NMR (CDCl3, 50 MHz):  191.7, 
188.8, 177.7, 169.7, 164.5, 159.9, 157.7, 136.0, 129.7, 
120.0, 114.2, 113.2, 105.1, 100.7, 97.3, 95.1, 89.5, 71.0, 
57.0, 56.2, 55.3, 35.2, 33.2 14.5; [α]20D =  +179° (c = 0.6 in 
CCl3); HRMS (ESI+) calcd for [M+H]+ [C24H24ClO7]+ 
459,1211, found 459,1216. 
General procedure for the synthesis of enol ethers by 
solvolysis (42 and 43). 
CSA (0.1 mmol, 0.1 equiv.) was added to a solution of 
griseofulvic acid (0.6 mmol, 1 equiv.) in the appropriate 
alcohol (6 mL, 0.1 M). The mixture was stirred at 100 °C for 
6 hours, and then cooled to 20 °C. EtOAc (20 mL) was 
added to the solution and the mixture was washed with sat. 
aq. NaH2PO4 (20 mL) and water (20 mL). The combined 
aqueous phases were extracted with EtOAc (3×20 mL), the 
combined org. phases were dried (MgSO4) and 
concentrated. The residue was purified by column 
chromatography (toluene:CH2Cl2:EtOAc 7:7:1) to afford the 
desired products. When possible the products were re-
crystallized from EtOAc/Heptane. 
(2S,6’R)-(7-chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(4’-cyclopropylmethoxy-6’-methyl-cyclohex-3’-en-
2’-one) 42 
Yield: 520 mg (21 %) (white crystals); Rf-value 
(EtOAc/heptane, 5:1): 0.61; m.p. 160-162 C; IR (neat, cm-
1): 1703, 1658, 1610, 1592; 1H NMR (CDCl3, 500 MHz): δ 
6.06 (1H, s), 5.36 (1H, d, J = 1.2 Hz), 3.99 (3H, s), 3.89 
(3H, s), 3.73 (2H, dq, J = 10.4, 7.2 Hz), 3.20 (1H, dd, J = 
17.5, 12.2 Hz), 2.88-2.79 (1H, m), 2.49 (1H, dd, J = 17.5, 
5.9 Hz), 1.27-1.17 (1H, m), 1.01 (3H, d, J = 6.6 Hz), 0.67-
0.60 (2H, m), 0.35-0.29 (2H, m); 13C NMR (CDCl3, 50 
MHz):  191.7, 188.7, 178.1, 169.6, 164.4, 157.6, 105.1, 
99.9, 97.2, 95.0, 89.4, 74.0, 56.9, 56.2, 35.1, 33.2, 14.4, 9.3, 
3.2 (2C); [α]20D = +180 (c = 0.4 in CHCl3); HRMS (ESI+) 
calcd for [M+H]+ [C20H22ClO6]+ 393.1105, found 393.1114. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(4’-cyclopentoxy-6’-methyl-cyclohex-3’-en-2’-one) 
43 
Yield: 448 mg (36 %) (white crystals); Rf-value 
(EtOAc/heptane, 5:1): 0.61; m.p. 200-202 C; IR (neat, cm-
1): 1696, 1648, 1614, 1585; 1H NMR (CDCl3, 300 MHz): δ 
6.03 (1H, s), 5.35 (1H, s), 4.62-4.67 (1H, m), 3.96 (3H, s), 
3.82 (3H, s), 3.08 (1H, dd, J = 17.6, 12.1 Hz), 2.82-2.73 
(1H, m), 2.37 (1H, dd, J = 17.6, 5.7 Hz), 1.89-1.52 (8H, m), 
0.96 (3H, d, J = 6.7 Hz); 13C NMR (CDCl3, 50 MHz):  
191.6, 188.7, 177.3, 169.5, 164.3, 157.6, 104.9, 100.7, 97.0, 
94.9, 89.3, 81.4, 56.9, 56.1, 34.9, 33.3, 32.5, 32.4, 23.9 (2C) 
14.3; [α]20D = +188° (c = 0.5 in CHCl3); HRMS (ESI+) calcd 
for [M+H]+ [C21H24ClO6]+ 407.1261, found 407.1259. Anal. 
Calcd for C21H23ClO6: C, 61.99; H, 5.70, found: C, 62.02; H, 
5.73. 
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Chapter 5
Synthesis and Single Crystal X-ray Analysis of
two Griseofulvin metabolites
Reprinted from Tetrahedron Letters, 51, Mads H. Rønnest, Pernille Harris, Char-
lotte H. Gotfredsen, Thomas O. Larsen, Mads H. Clausen, Synthesis and single
crystal X-ray analysis of two griseofulvin metabolites, 5881-5882. Copyright 2010,
with permission from Elsevier.
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a b s t r a c t
The two phenols, 6-O-desmethyl griseofulvin and 4-O-desmethyl griseofulvin are metabolites of the anti-
fungal drug griseofulvin. Herein, we present an improved synthesis of the 6-phenol derivative, and an
unequivocal proof of both structures by single-crystal X-ray analysis.
 2010 Elsevier Ltd. All rights reserved.
The natural product griseofulvin (1) (see Fig. 1) was ﬁrst iso-
lated by Oxford et al. in 19391 and later shown to possess anti-
fungal properties.2 This antifungal agent is still in clinical use
today3 and is the only orally administered drug approved by the
Food and Drug Administration for the treatment of tinea capitis
(ringworm of the scalp).4 Recently, griseofulvin has received re-
newed attention due to reports of both antiproliferative effects in
cancer cells5–7 as well as suppression of hepatitis C replication.8
As a result of its notoriously low water solubility, griseofulvin is
furthermore, often used as a benchmark compound in formulation
studies and in the development of drug delivery systems.9
The metabolism of griseofulvin has been studied both in vitro10
and in vivo and reported in several publications. In addition to
studies in fungi,11 the in vivo metabolism of griseofulvin has been
investigated in rats,12 mice,13 rabbits,14 dogs,15 and man.16,17
Known important metabolites of griseofulvin include 6-O-desm-
ethylgriseofulvin (2) and 4-O-desmethylgriseofulvin (3), but their
structures have never been proven unambiguously. In the litera-
ture, it is commonly merely stated that the metabolites were com-
pared with authentic samples.11–13,15,17 Others10,14 have used
spectroscopic properties and melting points to identify the struc-
tures by comparing these data with earlier work.18–21 We present
herein, the synthesis and crystal structures of both 6-O-desmethyl-
griseofulvin (2) and 4-O-desmethylgriseofulvin (3), which provide
ﬁnal veriﬁcation of the structural assignments.
6-O-Desmethylgriseofulvin (2) was ﬁrst synthesized by Arkley
et al. in six steps with an overall yield of 14% (Scheme 1).22 To con-
ﬁrm the outcome of these transformations, the synthetic route was
reproduced and we were actually able to isolate a small amount of
2 at step three (Scheme 1). The lengthy synthesis and poor yield of
this route prompted us to search for a more convenient method to
access 2. Thus, we were pleased to obtain the desired phenol in 29%
yield after the treatment of griseofulvin (1) with LiI in pyridine at
115 C (Scheme 2).22 The synthesis of 4-O-desmethylgriseofulvin
0040-4039/$ - see front matter  2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetlet.2010.08.095
⇑ Corresponding author. Tel.: +45 45252131; fax: +45 45933968.
E-mail address: mhc@kemi.dtu.dk (M.H. Clausen).
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Figure 1. The structures of griseofulvin (1), 6-O-desmethylgriseofulvin (2) and 4-O-
desmethylgriseofulvin (3).
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(3) was performed by treatment of 1 with MgI2 in a mixture of
diethyl ether and toluene (Scheme 2), a slight modiﬁcation of the
procedure originally published by Arkley et al.23
The structures of 2 and 3 were conﬁrmed unequivocally by the
use of single-crystal X-ray analysis (Figs. 2 and 3).24 It is not possi-
ble to distinguish between the 4 and 6 methoxy groups of 1 by
gHMBC as no 4J correlation is observed. The 1H NMR spectrum of
2 (see Supplementary data) does not exhibit a signal for the pheno-
lic hydroxy group, due to rapid proton exchange, and thus no het-
eronuclear correlations can be used to aid in the assignment of the
spectrum. For 3, the phenolic proton is observed (see Supplemen-
tary data) and the gHMBC contains a single 3JHC correlation to C-3a,
conﬁrming the position of the phenol. The UV and ﬂuorescence
spectra of 2 and 3 were all but identical, and despite small differ-
ences in the MS–MS spectra (see Supplementary data), the reten-
tion time25 is still the most reliable and sensitive analytical
method for distinguishing the two phenols.
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Figure 2. ORTEP view of 6-O-desmethylgriseofulvin (2).
Figure 3. ORTEP view of 4-O-desmethylgriseofulvin (3).
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Chapter 6
A Technique for Selective ipso-Substitution of
ortho-, meta- or para-Aryl Trimethylsilyl
Groups with Radioactive Iodide in Quantitative
Yields
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A technique for selective ipso-substitution of ortho-, meta- or para-aryl trimethylsilyl groups 
with radioactive iodide in quantitative yields. 
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A novel technique for the radiolabeling of either ortho-, meta- or para-aryl trimethylsilyl-substituted small molecules 
was developed. The method takes advantage of the ipso-directing and activating properties of a trimethylsilyl 
substituent on the arene. Treatment of a trimethylsilyl precursor with Tl(OOCF3)3 followed by sodium 125I or 131I 
consistently affords radioactive yields over 95% for all three regioisomers. 
Introduction 
The natural product griseofulvin (1, see Figure 1) was 
isolated by Oxford et al.1 in 1939 and besides its long 
known anti-fungal properties2, 3 it has recently been shown 
to possess anti-cancer4-6 as well as anti-viral properties.7 
The 2’-benzyloxy-2’-demethoxy-griseofulvin analog (2), 
was previously found8 to be 25 times more active than 1, 
in a phenotypical whole cell assay9 against the cancer cell 
line SCC114 (an oral squamous cell carcinoma cell line). 
The analog (2) was found to be the most potent amongst 
the 34 griseofulvin analogs tested.8 
  
Figure 1: Griseofulvin (1) and 2’-benzyloxy-2’-
demethoxy-griseofulvin (2) 
The griseofulvin analog 2 warranted further investigation 
including 125I/131I scintigraphic in vivo imaging to assess 
bio-distribution and half-life.10 McKillop et al.11 have 
developed a popular method for the introduction of 
radioactive iodide by direct electrophilic thallation of 
aromatic systems with Tl(OOCCF3)3, followed by 
addition of potassium 125I-iodide or 131I-iodide. The 
substitution of the aryl thallium(III) bistrifluoroacetate 
with iodide affords solely the ipso substituted product.12 
However, the initial thallation can yield mixtures of the 
ortho-, meta- or para-thallium(III) bistrifluoroacetate 
products, and thus the equivalent iodo products, 
depending on the substrate and conditions.11, 13 Using a 
mixture of radiolabeled compounds is not satisfactory and 
the separation of such iodo isomers can be laborious.14 
Bell et al. published a study concerning the transformation 
of aryl trimethylsilanes  to aryl thallium(III) bistrifluoro-
acetates.15 It was noted that this method proceeds solely 
with ipso substitution of the TMS group. The reaction is 
also efficient for deactivated aromatic substrates, while 
direct thallation of such compounds proceeds slowly.11  
When looking for an efficient route to a radiolabeled 
analog of 2, we were faced with two challenges: the 
instability of 2 in neat TFA, where hydrolysis to 
griseofulvic acid took place within minutes, and 
controlling the regioselectivity of the thallation. We 
hypothesized that combining the work of McKillop et al.11 
and Bell et al.15 would afford a simple route from aryl-
TMS compounds to aryl iodides, via aryl thallium(III) 
bistrifluoroacetates, in a regioselective manner, effectively 
substituting the TMS group for an iodide, while taking 
advantage of the activating property of the silane to use 
milder conditions for the thallation. The activities of 10, 
11 and 12 in the phenotypic assay for multipolarity are 
markedly different (data not shown) and we found it 
prudent to develop a method that would afford a single 
product, while also enabling us to acces either the ortho- 
(10), meta- (11) or para-iodo (12) isomer. Here we 
describe the initial results using the thallation/iodation 
reaction in the preparation of radiolabeled small 
molecules. 
Chemistry 
The ortho-, meta- and para- (trimethylsilyl)-benzyl 
alcohols 3, 4 and 5 were synthesized following a known 
procedure16 as was compound 6.8 The 1,4 conjugate 
addition of the alcohols to 6 was achieved with 
diaza(1,3)bicyclo-[5.4.0]undecane (DBU) in dioxane as 
previously described to yield 7, 8 and 9.8 The “cold” iodo 
compounds (10, 11 and 12) were prepared by the same 
method from the corresponding ortho, meta and para 
(iodo)-benzyl alcohols (commercially available).  
The synthesis of the three “cold” iodo compounds were 
also completed by treating the appropriate TMS analog for 
30 min. with 2 equiv. of thallium(III)trifluoroacetate in 
MeCN/TFA (7:3) followed by addition of excess NaI. 
Experiments were performed with 10, 15 and 20% TFA in 
MeCN, still using 2 equiv. of Tl(OOCCF3)3 and excess 
NaI. At 10% TFA the iodo product was only observed in 
trace amounts but at 15 and 20% the conversion to the 
iodo product was 6 and 14%, respectively. It was also 
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investigated how 0.9 equiv of Tl(OOCCF3)3 in 
MeCN/TFA (7:3) affected the reaction and under these 
conditions the conversion from 7, 8 and 9 to the iodo 
products was trace amounts, 7 and 24%, respectively. 
The “hot” thallation/iodation was performed by treating a 
substrate with 50 mol% of Tl(OOCCF3)3 for 2 min. 
followed by addition of sodium 125I-iodide or 131I- iodide 
and after 30 sec. the mixture was purified by HPLC to 
afford the radiolabeled compounds. 
 
 
Scheme 1 (a) DBU, dioxane; (b) Tl(OOCCF3)3, NaI, 
MeCN/TFA (7:3). 
Results and Discussion 
The “cold” synthesis of the iodo compounds 10, 11 and 12 
from the corresponding TMS precursors by 
thallation/iodation were completed on a 10 mg scale. The 
identity of these iodo products were confirmed by 
comparison (NMR, MS and retention time) with 10, 11 
and 12 prepared by the known method.  
The subsequent thallation experiments were performed on 
a 1 mg scale and analyzed by HPLC-DAD-MS using the 
starting materials and verified iodo products as standards. 
The ratio of starting material to product is based on the 
absorption of each peak. All experiments were performed 
with a 2 min. reaction time for the thallation step and 1 
min. for the introduction of iodine, which was added in 
excess. 
Treatment of 1 with Tl(OOCCF3)3/NaI in TFA hydrolyses 
the 2’-enol ether completely and is thus not a viable 
method for introduction of radioactive iodide for this 
compound class. Using a mixture of MeCN/TFA (7:3), in 
which 1 is stable, with the same conditions resulted in no 
conversion. However, treating the para-TMS compound 
(9) with 2 equiv. of Tl(OOCCF3)3/NaI in MeCN/TFA 
(7:3) afforded 60% conversion to the para iodo compound 
(12) with starting material as the only other peak. Using 
the same conditions for 7 and 8 afforded the iodo products 
in 30% and 50% yields, respectively. The reaction does 
not proceed without Tl(OOCCF3)3. 
As “hot” labeling is performed with sub molar amounts of 
sodium 125-iodide/131-iodide, these levels of conversions 
are satisfactory as the starting material and thallium(III) 
bistrifluoroacetate intermediates are easily separated from 
the desired radiolabeled compound. The experiments with 
“hot” iodide consistently afforded radioactive yields of 
over 95%.  
Conclusion 
A novel technique for the introduction of radioactive 
iodide has been described using thallation/iodation in 30% 
TFA in MeCN of aryl TMS precursors. This was achieved 
at both the ortho-, meta- and para-position of the 
griseofulvin analog, affording the products in over 95% 
radioactive yields.  
 
Experimental 
1H NMR spectra were recorded using a Varian Mercury 
300 MHz spectrometer from Agilent (Santa Clara, CA, 
US). 13C NMR spectra were recorded using either a 
Varian Mercury 300 MHz or a Bruker AC 200 MHz from 
Bruker Optics (Ettlingen, Germany). Chemical shifts were 
measured in ppm and coupling constants in Hz. The 
residual peak of the solvent CDCl3 was used as internal 
reference at δ 7.27 for 1H NMR and δ 77.00 for 13C NMR 
spectra. IR spectra were recorded using a Bruker Alpha 
ATR and measured in cm-1. All melting points are 
uncorrected. TLC was performed on aluminium sheets 
precoated with silica gel 60 F254 (Merck 1.05554.0001). 
High-resolution LC-DAD-MS was performed on an 
Agilent 1100 system equipped with a photodiode array 
detector (DAD) and coupled to a LCT orthogonal time-of-
flight mass spectrometer (Waters-Micromass, Manchester, 
UK) with a Z-spray electrospray ionisation (ESI) source 
and a LockSpray probe (M+H 556.2771) and controlled 
by MassLynx 4.0 software. LC-MS calibration from m/z 
100-900 was done with a PEG mixture. Standard 
separation involved a LUNA 2 column with an 
acetonitrile (50 ppm TFA) in water gradient starting from 
15% to 100% over 25 minutes with a flow rate of 0.3 
mL/min. 
Compounds were visualized by charring after dipping in a 
solution of 1% KMnO4, 6.7% K2CO3 and 0.08% NaOH in 
water. UV visualization was done using a Model UVGL-
25 Mineralight Lamp.  
All reagents and solvents were purchased from 
commercial suppliers and were used without further 
purification. Analysis of the products was performed by 
reversed-phase high-performance liquid chromatography 
(RP-HPLC) at 60 °C on a Zorbax Stable Bond C18 1.8 
μm, 4.6 × 150 mm column (Agilent) with a gradient of 5-
60% B over 120 min (flow rate 250 μl/min; solvent A: 
0.1% TFA in water, solvent B: 0.1% TFA in acetonitrile). 
Analysis of the radio iodinated compounds were 
performed by RP-HPLC (Chromolith® Performance RP-
18e column, 100 × 4.6 mm) fitted with a Raytest GABI 
gamma detector (Raytest GmbH, Straubenhardt, 
Germany) using a gradient of 0-100% B over 5 min (200 
μl/min; solvent A: 0.1% TFA in water, solvent B: 0.1% 
TFA in acetonitrile UV-absorption = 214 nm, γ-
detection).  
 
General procedure A – Compounds 3, 4 and 5. 2-
Bromobenzyl alcohol (200 mg, 1.06 mmol) was mixed 
with anhydrous Et2O (2 mL) and cooled to 0 °C. BuLi 
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(1.87 mL, 2.25 mmol) was added drop-wise and the 
mixture stirred at 0 °C for 30 min. TMSCl (0.68 mL, 5.35 
mmol) was added drop-wise and the solution was allowed 
to reach room temperature. After 20 h the reaction mixture 
was quenched with sat. aq. NH4Cl (2 mL), extracted with 
EtOAc (3×3 mL), and the combined organic phases were 
dried (MgSO4) and concentrated. MeOH (20 mL) and a 
drop of HOAc was added and the mixture stirred for 1 h 
before re-concentration. The residue was purified by 
column chromatography (EtOAc:heptane 1:12.5) 
affording the product 3. 
2-(Trimethylsilyl)benzyl alcohol (3). Yield: 100 mg (52 
%) (yellow oil); Rf-value (EtOAc/heptane, 1:3): 0.32; 1H 
NMR (CDCl3, 300 MHz): δ 7.56 (1H, dd, J = 7.3, 1.4 
Hz), 7.49 (1H, dd, J = 7.6, 1.4 Hz), 7.41 (1H, ddd, J = 
7.6, 7.3, 1.4 Hz), 7.31 (1H, dt, J =  1.4, 7.3 Hz), 4.77 (2H, 
s), 2.06 (1H, s), 0.37 (9H, s) (Litt.17); 13C NMR (CDCl3, 
50 MHz):  146.1, 138.0, 134.6, 129.4, 127.6, 126.9, 65.2, 
0.3 (3C) (Litt.17). 
3-(Trimethylsilyl)benzyl alcohol (4). Yield: 74 mg (39 
%) (yellow oil) Rf-value (EtOAc/heptane, 1:3): 0.30; 1H 
NMR (CDCl3, 300 MHz): δ 7.50 (1H, s), 7.48-7.43 (1H, 
m), 7.36-7.31 (2H, m), 4.65 (2H, s), 2.11 (1H, s), 0.27 
(9H, s) (Litt.17); 13C NMR (CDCl3, 50 MHz):  140.8, 
139.9, 132.6, 131.9, 127.9, 127.6, 65.4, -1.2 (3C) (Litt.17). 
4-(Trimethylsilyl)benzyl alcohol (5). Yield: 97 mg (50 
%) (yellow oil); Rf-value (EtOAc/heptane, 1:3): 0.33; 1H 
NMR (CDCl3, 300 MHz): δ 7.54 (2H, d, J = 7.9 Hz), 7.37 
(2H, d, J = 7.9 Hz), 4.69 (2H, s), 1.66 (1H, s), 0.27 (9H, s) 
(Litt.17); 13C NMR (CDCl3, 50 MHz):  141.3, 139.8, 
133.5 (2C), 126.3 (2C), 65.2, -1.2 (3C) (Litt.17). 
General procedure B – Compounds 7, 8, 9, 10, 11 and 
12.  
To a solution of 6 (0.65 mmol, 1 equiv) in 1,4-dioxane (3 
mL, 0.2 M) was added the desired alcohol (1.30 mmol, 2 
equiv) and DBU (1.63 mmol, 2.5 equiv). The mixture was 
heated to 100 °C and stirred for 18 h. The mixture was 
then cooled to 20 °C, and excess reagent was quenched 
with sat. aq. NH4Cl (30 mL). The aqueous phase was 
extracted with EtOAc (3×30 mL) and the combined 
organic phases were dried (MgSO4) and concentrated. The 
residue was purified by column chromatography 
(heptane:EtOAc 3:2) affording the product. When 
possible the product was recrystallized from 
EtOAc/heptane. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-
2-spiro-1’-(2’-(2-trimethylsilyl)-benzyl-oxy-6’-methyl-
cyclohex-2’-ene-4’-one) (7). Yield: 53 mg (20 %) (yellow 
oil); Rf-value (toluene:CH2Cl2,EtOAc, 3:3:1): 0.30; 
IR(neat): 1708, 1663, 1612, 1589; 1H NMR (CDCl3, 300 
MHz): δ 7.49-7.44 (2H, m), 7.32-7.14 (2H, m), 6.09 (1H, 
s), 5.61 (1H, s), 4.96 (1H, d, J = 12.1 Hz), 4.88 (1H, d, J = 
12.1 Hz), 4.00 (3H, s), 3.95 (3H, s), 3.08 (1H, dd, J = 
16.5, 13.4 Hz), 2.89 (1H, ddq, J = 13.4, 4.5, 6.6 Hz), 2.45 
(1H, dd, J = 16.5, 4.5 Hz), 0.99 (3H, d, J = 6.6 Hz), 0.26 
(9H, s); 13C NMR (CDCl3, 50 MHz):  197.0, 192.2, 
169.7, 169.5, 164.5, 157.7, 139.5, 137.8, 134.5, 129.4, 
127.4, 127.2, 105.8, 105.2, 97.2, 90.7, 89.5, 71.0, 56.9, 
56.3, 40.0, 36.5, 14.2, 0.0 (3C); [α] +162° (c = 1.0 in 
CHCl3); HRMS (ESI+) calcd for [M+H]+ [C26H30ClO6Si]+ 
501.1500, found 501.1509. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-
2-spiro-1’-(2’-(3-trimethylsilyl)-benzyl-oxy-6’-methyl-
cyclohex-2’-ene-4’-one) (8). Yield: 58 mg (32 %) (yellow 
oil); Rf-value (toluene:CH2Cl2,EtOAc, 3:3:1): 0.31; 
IR(neat): 1710, 1664, 1613, 1590; 1H NMR (CDCl3, 300 
MHz): δ 7.43-7.38 (1H, m), 7.30-7.12 (3H, m), 6.10 (1H, 
s), 5.62 (1H, s), 4.93 (1H, d, J = 12.2 Hz), 4.81 (1H, d, J = 
12.2 Hz), 4.01 (3H, s), 3.96 (3H, s), 3.06 (1H, dd, J = 
16.4, 13.4 Hz), 2.87 (1H, ddq, J = 13.4, 4.4, 6.6 Hz), 2.44 
(1H, dd, J = 16.4, 4.4 Hz), 0.98 (3H, d, J = 6.6 Hz), 0.20 
(9H, s); 13C NMR (CDCl3, 50 MHz):  196.9, 192.4, 
169.6 (2C), 164.5, 157.7, 140.9, 133.7, 133.0, 131.2, 
127.8, 127.0, 105.9, 105.1, 97.2, 90.7, 89.5, 70.8, 56.9, 
56.3, 40.0, 36.4, 14.2, -1.3 (3C); [α] +187° (c = 1.0 in 
CHCl3); HRMS (ESI+) calcd for [M+H]+ [C26H30ClO6Si]+ 
501.1500, found 501.1494. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-
2-spiro-1’-(2’-(4-trimethylsilyl)-benzyl-oxy-6’-methyl-
cyclohex-2’-ene-4’-one) (9). Yield: 86 mg (31 %) (white 
crystals); Rf-value (EtOAc/heptane, 5:1): 0.59; m.p. 166-
168 C; IR: 1708, 1664, 1613, 1590, 1351, 1220; 1H NMR 
(CDCl3, 300 MHz): 7.45 (2H, d, J = 7.7 Hz), 7.16 (2H, d, 
J = 7.7 Hz), 6.11 (1H, s), 5.58 (1H, s), 4.92 (1H, d, J = 
12.6 Hz), 4.82 (1H, d, J = 12.6 Hz), 4.03 (3H, s), 3.97 
(3H, s), 3.05 (1H, dd, J = 16.3, 13.5 Hz), 2.87 (1H, ddq, J 
= 13.5, 4.3, 6.5 Hz), 2.43 (1H, dd, J = 16.4, 4.3 Hz), 0.98 
(3H, d, J = 6.5 Hz), 0.24 (9H, s); 13C NMR (CDCl3, 50 
MHz):  196.9, 192.3, 169.5 (2C), 164.5, 157.7, 140.4, 
135.1, 133.5 (2C), 125.7 (2C), 105.9, 105.1, 97.1, 90.7, 
89.5, 70.6, 56.9, 56.3, 39.9, 36.4, 14.2, -1.3 (3C); [α] 
+151° (c = 1.0 in CHCl3); HRMS (ESI+) calcd for [M+H]+ 
[C26H30ClO6Si]+ 501.1500, found 501.1494. 
General procedure C – Compounds 10, 11 and 12. 
Compound 9 (9.8 mg, 0.02 mmol) was dissolved in 30% 
TFA in MeCN (340 μL) and Tl(OOCCF3)3 was added (21 
mg, 0.04 mmol, in 210 μL 30% TFA/MeCN). After 30 
min. NaI (11.7 mg, 0.08 mmol) was added and after 
another 2 min. the reaction mixture was quenched with 
sat. aq. Na2CO3 (2 mL). The mixture was extracted with 
EtOAc (3×3 mL), and the combined organic phases were 
dried (MgSO4) and concentrated. The residue was purified 
by column chromatography (heptane:EtOAc 2:1) to afford 
the product 12 (8.7 mg, 80% yield).  
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-
2-spiro-1’-(2’-(2-iodobenzyloxy)-6’-methyl-cyclohex-
2’-ene-4’-one) (10). Yield: 5.4 mg (44 %) (white 
crystals); Rf-value (EtOAc/heptane, 5:1): 0.48; m.p. 167-
169 C; IR (neat, cm-1): 1705, 1661, 1610, 1588; 1H-NMR 
(CDCl3):  7.77 (1H, d, J = 7.8 Hz), 7.27 (1H, m), 7.12 
(1H, d, J = 7.4 Hz), 6.97 (1H, m), 6.12 (1H, s), 5.63 (1H, 
s), 4.85 (1H, d, J = 13.3 Hz), 4.78 (1H, d, J = 13.3 Hz), 
4.03 (3H, s), 3.97 (3H, s), 3.09 (1H, dd, J = 16.5, 13.4 
Hz), 2.97-2.80 (1H, ddq, J = 13.4, 4.4, 6.6 Hz), 2.46 (1H, 
dd, J = 16.5, 4.4 Hz), 1.00 (3H, d, J = 6.6 Hz); 13C-NMR 
(CDCl3):  196.9, 192.2, 169.5, 169.1, 164.6, 158.8, 
139.2, 136.7, 129.7, 129.3, 127.8, 106.1, 105.3, 97.2, 96.2, 
90.7, 89.5, 74.4, 57.0, 56.4, 40.0, 36.4, 14.2. [α] +134° (c 
= 1.0 in CHCl3); HRMS (ESI+) calcd for [M+H]+ 
[C23H21ClIO6]+ 555.0071, found 555.0087. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-
2-spiro-1’-(2’-(3-iodobenzyloxy)-6’-methyl-cyclohex-
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2’-ene-4’-one) (11). Yield: 1.1 mg (8 %) (white crystals); 
Rf-value (EtOAc/heptane, 5:1): 0.45; m.p. 171-174 C; IR 
(neat, cm-1): 1703, 1661, 1609, 1586; 1H-NMR (CDCl3):  
7.59 (1H, d, J = 7.8 Hz), 7.44 (1H, s), 7.13 (1H, d, J = 7.8 
Hz), 7.03 (1H, t, J = 7.8 Hz), 6.13 (1H, s), 5.57 (1H, s), 
4.85 (1H, d, J = 12.5 Hz), 4.73 (1H, d, J = 12.5 Hz), 4.03 
(3H, s), 3.98 (3H, s), 3.08 (1H, dd, J = 16.5, 13.5 Hz), 
2.88 (1H, ddq, J = 13.5, 4.5, 6.6 Hz), 2.45 (1H, dd, J = 
16.5, 4.5 Hz), 1.01 (1H, d, J = 6.6 Hz); 13C-NMR 
(CDCl3):  196.7, 192.2, 169.4, 169.1, 164.6, 157.7, 
137.1, 136.8, 135.2, 130.1, 125.5, 105.7, 105.0, 97.1, 94.2, 
90.6, 89.6, 69.2, 56.9, 56.3, 40.0, 36.1, 14.2; Anal. Calcd 
for C23H20ClIO6: C, 49.80; H, 3.63. Found: C, 49.69; H, 
3.68. [α] +96° (c = 1.0 in CHCl3); HRMS (ESI+) calcd for 
[M+H]+ [C23H21ClIO6]+ 555.0071, found 555.0063. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-
2-spiro-1’-(2’-(4-iodo)benzyloxy-6’-methyl-cyclohex-
2’-ene-4’-one) (12). Yield: 8.7 mg (80 %) (white 
crystals); Rf-value (EtOAc/heptane, 5:1): 0.48; m.p. 166-
168 C; IR (neat, cm-1): 1705, 1662, 1612, 1589; 1H NMR 
(CDCl3, 300 MHz):  7.60 (2H, d, J = 8.2 Hz), 6.90 (2H, 
d, J = 8.2 Hz), 6.10 (1H, s), 5.54 (1H, s), 4.83 (1H, d, J = 
12.4 Hz), 4.71 (1H, d, J = 12.4 Hz),  4.01 (3H, s), 3.95 
(3H, s), 3.03 (1H, dd, J = 16.5, 13.4 Hz), 2.85 (1H, ddq, J 
= 13.4, 4.5, 6.6 Hz), 2.42 (1H, dd, J = 16.5, 4.5 Hz), 0.96 
(3H, d, J = 6.6 Hz); 13C NMR (CDCl3, 75 MHz):  197.3, 
192.6, 169.6, 164.9, 169.7, 153.0, 137.9 (2C), 134.5, 
128.7 (2C), 106.2, 105.3, 97.4, 94.1, 90.9, 89.8, 70.2, 
56.6, 57.3, 40.2, 36.6, 14.1; Anal. Calcd for C23H20ClIO6: 
C, 49.80; H, 3.63. Found: C, 49.89; H, 3.74. [α] +116° (c 
= 1.0 in CHCl3); HRMS (ESI+) calcd for [M+H]+ 
[C23H21ClIO6]+ 555.0071, found 555.0070. 
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The fungal metabolite (+)-geodin [systematic name: (2R)-
methyl 5,7-dichloro-4-hydroxy-60-methoxy-6-methyl-3,40-dioxo-
spiro[benzofuran-2,10-cyclohexa-20,50-diene]-20-carboxylate],
C17H12Cl2O7, was isolated fromAspergillus terreus. The crystal
structure contains two independent molecules in the asym-
metric unit. Molecules denoted 1 interact through O—H  O
hydrogen bonds creating chains of molecules parallel to the
crystallographic 21 screw axis. Molecules denoted 2 interact
through an O  Cl halogen bond, also creating chains of
molecules parallel to the crystallographic 21 screw axis.
Molecules 1 and 2 interact through another O  Cl halogen
bond. The two molecules are similar but molecules 2 have a
slightly more planar cyclohexadiene ring than molecules 1.
The absolute structure of (+)-geodin has been unequivocally
assigned with the spiro centre having the R conﬁguration in
both molecules. The structurally related (+)-griseofulvin has
an S conﬁguration at the spiro centre, a difference of potential
biological and biosynthetic relevance.
Comment
(+)-Geodin, (I), was originally isolated from Aspergillus
terreus (Raistrick & Smith, 1936) and elucidation of its
structure was initiated (Clutterbuck et al., 1937; Calam et al.,
1939, 1947), eventually resulting in the correct relative struc-
ture (Barton & Scott, 1958). A number of biological activities
have been reported for (I), including antiviral (Takatsuki,
Suzuki et al., 1969; Takatsuki, Yamaguchi et al., 1969), anti-
microbial (Rinderknecht et al., 1947), enhancement of ﬁbri-
nolytic activity (Shinohara et al., 2000) and stimulation of
glucose uptake for rat adipocytes (Sato et al., 2005). Further-
more, (I) is a subunit of the compound Sch 202596, an
antagonist of the galanin receptor subtype GALR1 (Chu et al.,
1997). In an effort to synthesize Sch 202596, the total synthesis
of racemic geodin was completed (Katoh et al., 2002; Katoh &
Ohmori, 2000). Geodin, (I), shares the same grisan backbone
as (+)-griseofulvin, (II), consisting of ring systems A, B and C,
as shown for (II) in the Scheme below (Grove et al., 1952).
Additionally, both compounds (I) and (II) are dextrorotatory
and this general similarity prompted our interest in (I) since
(II) has anticancer properties (Ho et al., 2001; Panda et al.,
2005). (I) was isolated from A. terreus and tested in our
cellular anticancer assay (Rebacz et al., 2007) but did not
exhibit any activity (data not shown).
(I) crystallizes with two independent molecules in the
asymmetric unit (Fig. 1). Although the two molecules are quite
similar, there are small differences in their geometries.
Cyclohexadienone ring C in (I) is almost planar, with an r.m.s.
deviation of the least-square planes of 0.045 and 0.016 A˚ for
molecules 1 and 2, respectively. The largest deviation from this
plane is 0.070 (2)/0.024 (2) A˚ found for atoms C12/C22. The
distances O15  O13/O25  O23 are 4.999 (3)/5.245 (4) A˚,
reﬂecting the fact that the C ring in (I) for molecule 2 is
slightly more planar than that of molecule 1. In comparison,
cyclohexenone ring C in griseofulvin, (II) (Puttaraja et al.,
1982), has a half-chair conformation, with atoms C2 and C60
on the opposite sides of the plane. This means that the
distance O5  O3 is only 4.06 A˚, i.e. much shorter than the
equivalents O15  O13 and O25  O23 in (I). The ester
groups in the two molecules in the asymmetric unit of (I) are
rotated 21.4 (5)/16.9 (4) with respect to the planes of the
respective cyclohexadienone rings so that atoms O17/O27 are
located more or less above the centre of the respective ﬁve-
membered ring with short interatomic O17  O11/O27  O21
distances of 2.916 (4)/2.954 (3) A˚. The ﬁve-membered B rings
in the two molecules in (I) are rotated 89.89 (9)/88.13 (10)
with respect to the C rings. They are almost planar, with an
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Figure 1
A perspective view of the two independent molecules of geodin, (I),
showing the atom-numbering scheme and with displacement ellipsoids
drawn at the 50% probability level.
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r.m.s. deviation of the ﬁve atoms of 0.028/0.034 A˚ for both
molecules. However, atoms O11(O21) and C13(C23) are
below the plane and C12(C22) above the plane. In both
molecules, there is an intramolecular hydrogen bond from
atom O12/O22 to O13/O23 (see Table 2).
The crystal packing down the a axis is shown in Figs. 2 and 3,
with the view showing the different packing of molecules 1
(Fig. 3a) and 2 (Fig. 3b) down the c axis. Molecules 1 are
hydrogen bonded with a hydrogen bond from atom O12 to
atom O15 in a neighbouring molecule (see Table 2, and Figs. 2
and 3a). This creates a chain of molecules along the crystal-
lographic 21 screw axis. A similar hydrogen bond is not found
in molecules 2. They are tilted slightly and the distance
between atoms O22 and O25(x + 2, y + 12, z + 2) is
4.521 (4) A˚. There are, however, halogen bonds between
atoms O23 and Cl21 from neighbouring molecules (see
Table 1, and Figs. 2 and 3b) creating chains of molecules along
the crystallographic 21 screw axis. Furthermore, molecules of
type 2 are oriented so that the AB ring system stacks with the
C ring from the next molecule in the helix. Molecules 1 and 2
interact via halogen bonds between atoms O27 and Cl12 (see
Table 1).
To increase knowledge of the structure–activity relationship
of these related compounds (Rønnest et al., 2009) the absolute
structure of (I) presented here was determined using anom-
alous signal from all reﬂections (Flack, 1983). This showed an
R conﬁguration at the spiro centre of both crystallographically
independent molecules. In contrast, for (II) the absolute
conﬁguration was determined based on alcoholytic reactions
(MacMillan, 1959) and later veriﬁed by Brown & Sim (1963)
by crystal structure determination of a brominated derivative
using ﬁlm data to be S at the spiro centre and R at atom C60.
This structural difference between (I) and (II) could poten-
tially contribute to the observed absence of anticancer activity
(Rebacz et al., 2007) for (I).
Based on enzymatic studies of the biosynthesis of geodin,
(I) (Fujii et al., 1983), the spirocyclization reaction joining the
organic compounds
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Figure 2
The molecular packing of (I), showing the hydrogen- and halogen-bond
architecture; the view direction is down [100]. Hydrogen and halogen
bonds are drawn as dashed lines. [Symmetry codes: (i)x + 1, y + 12,z + 2;
(ii) x, y  12, z + 1.]
Figure 3
Helical chains in (I), viewed in the [001] direction, showing (a) molecules
of type 1 and (b) molecules of type 2. [Symmetry codes: (i) x + 1, y + 12,z + 2; (ii) x, y  12, z + 1.]
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B and C rings is believed to be catalysed by an enzyme of the
multicopper protein class. The same reaction in the griseo-
fulvin, (II), biosynthesis, on the other hand, is presumed to be
mediated by a cytochrome P450 enzyme. The latter assump-
tion is founded on the identiﬁcation of the griseofulvin, (II),
biosynthesis gene cluster (Chooi et al., 2010). These observa-
tions could explain the different conﬁguration of the spiro
centres of (I) and (II) since it is reasonable that enzymes of
different classes lead to a disparate outcome in a similar
reaction with comparable substrates.
Experimental
A. terreus [IBT 28226, culture collection at Department of Systems
Biology, Technical University of Denmark (Lyngby, Denmark)] was
cultured on 50 plates of yeast extract sucrose agar at 298 K for 7 d,
extracted with ethyl acetate (2 l) and then concentrated to afford
1.2 g of raw extract. The raw extract was dissolved in 10% H2O in
MeOH (50 ml) and the aqueous phase was extracted with heptane
(50 ml). The water content was increased to 50% by adding H2O
(40 ml) and the resulting mixture was shaken with CH2Cl2 (90 ml).
The CH2Cl2 phase was concentrated (0.86 g) and further puriﬁcation
was performed on a Phenomenex Luna(2) HPLC column (250 
10 mm, 5 mm, C-18) using 5 ml min1 H2O/CH3CN (isocratic run at
50/50 for 15 min) as the mobile phase to yield (I) (11.6 mg as a yellow
oil). Geodin, (I), was crystallized using sitting-drop vapour diffusion,
the drop consisting of EtOAc–heptane (4:1 v/v) and the reservoir
containing heptane, to afford yellow crystals.
Crystal data
C17H12Cl2O7
Mr = 399.17
Monoclinic, P21
a = 8.9276 (3) A˚
b = 11.3625 (4) A˚
c = 16.5006 (6) A˚
 = 94.456 (1)
V = 1668.76 (10) A˚3
Z = 4
Mo K radiation
 = 0.43 mm1
T = 120 K
0.25  0.15  0.08 mm
Data collection
Bruker SMART platform CCD
diffractometer
Absorption correction: multi-scan
(SADABS; Bruker, 2000)
Tmin = 0.82, Tmax = 0.97
22828 measured reﬂections
8165 independent reﬂections
7496 reﬂections with I > 2(I)
Rint = 0.029
Reﬁnement
R[F 2 > 2(F 2)] = 0.053
wR(F 2) = 0.145
S = 1.06
8165 reﬂections
480 parameters
1 restraint
H-atom parameters constrained
max = 0.81 e A˚
3
min = 0.36 e A˚3
Absolute structure: Flack (1983),
3819 Friedel pairs
Flack parameter: 0.04 (6)
H atoms were observed in a difference synthesis and subsequently
placed in idealized positions. They were reﬁned using a riding model,
with aryl C—H = 0.95 A˚ and Uiso(H) = 1.2Ueq(C), methyl C—H =
0.98 A˚ and Uiso(H) = 1.5Ueq(C), and hydroxy O—H = 0.84 A˚ and
Uiso(H) = 1.2Ueq(O).
Data collection: SMART and SAINT (Bruker, 1998); cell reﬁne-
ment: SMART and SAINT; data reduction: SMART and SAINT;
program(s) used to solve structure: SHELXS97 (Sheldrick, 2008);
program(s) used to reﬁne structure: SHELXL97 (Sheldrick, 2008);
molecular graphics: ORTEP-3 (Farrugia, 1997) andMercury (Macrae
et al., 2006); software used to prepare material for publication:
enCIFer (Allen et al., 2004).
We thank the Danish Instrument Center for NMR Spec-
troscopy of Biological Macromolecules for NMR time. We
thank the Danish Research Council (reference No. 274-07-
0561) for ﬁnancial support (MHR) and the Faculty of Life
Sciences, University of Copenhagen, for scholarship ﬁnancing
for MTN.
Supplementary data for this paper are available from the IUCr electronic
archives (Reference: LG3050). Services for accessing these data are
described at the back of the journal.
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Chapter 8
Aurantiamine from Penicillium cavernicola
Prior to my external stay at DKFZ I worked with the active strain Penicillium
cavernicola (IBT 3235, CYA) and although the known diketopiperazine auranti-
amine was quickly identiﬁed as a possible candidate for the activity, the isolation
of aurantiamine was initiated.
This was done for a number of reasons, the inhibition of centrosomal clustering
had not earlier been associated with aurantiamine, no other active compound
was close to being isolated and the reason for the external stay at DKFZ was to
learn about the assay and the experiments used for the initial paper by Blanka
Rebacz.1 As those experiments had already been performed with griseofulvin,
repeating them again would be unproductive. On those grounds it was decided
to isolate aurantiamine and bring it to DKFZ. In the following section experiments
have been performed by me under the guidance of Blanka Rebacz except for the
centrin staining (in Figure 8.2) and the work on the HeLa, U2OS, MDA-MB-231
and RPE cells which was performed by Simon Anderhub.
Penicillium cavernicola - aurantiamine
The alkaloid aurantiamine (1) was ﬁrst isolated from Penicillium aurantiogri-
seum 2 and HPLC coupled to diode array analysis suggested that it is also pro-
duced by P. cavernicola.3 This has been conﬁrmed by the isolation and identiﬁ-
cation of aurantiamine as a free base (1) in an extract from P. cavernicola (IBT
3235, CYA).
Aurantiamine (1) is a diketopiperazine derived from histidine and valine. Dike-
topiperazines have been isolated from numerous natural sources such as marine
derived fungi,4 sponges5 and bacteria.6 They display a broad range of biologi-
cal activities, including anti-fungal,7 anti-viral,8 anti-bacterial9 and anti-cancer
activity.10
Aurantiamine is structurally similar to phenylahistin11 (2, Figure 1), which
was initially isolated from Aspergillus ustus. Phenylahistin has shown anti-tumor
activity with IC50 values in the low micromolar range against several cancer
cell lines.11,12,13,14 Using 2 as a lead compound, an anti-cancer drug candidate
(NPI-2358) has been developed and is currently in phase II clinical trials.15,16,17
The cytotoxic potency of 1 and 2 against P388 murine leukemia cells has been
examined and phenylahistin (2) was reported to be forty times more active than
aurantiamine (1).18
The IC50 of 1, for induction of multipolar mitoses, was determined to be 40 ± 4
μM in SCC114 squamous cell carcinoma cells. Cell cycle analysis was performed
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Figure 8.1: The structures of aurantiamine (1) and phenylahistin (2)
Table 8.1: Flow cytometry of SCC114 cells treated with 46 μM aurantiamine
Mock 24 h Mock 48 h Auran. 24 h Auran. 48 h
M-phase 5.3 ± 0.9 4.2 ± 1.2 42.1 ± 8.0 9.4 ± 1.4
Sub G1 2.0 ± 0.3 3.8 ± 1.3 9.4 ± 1.4 32.2 ± 7.4
to evaluate the eﬀect of aurantiamine (1) on SCC114 cells and BJ ﬁbroblasts.
Treated cells were analyzed by ﬂow cytometry following staining with propidium
iodide and an antibody to phospho-histone H3 as a mitosis marker (Figure 8.2A,
B). Treatment of SCC114 cells with 46 μM aurantiamine for 24 hours led to
an increase of cells in M phase of the cell cycle to 42.1 ± 8.0% compared to
only 5.3 ± 0.9% of mock-treated cells (see Table 8.1). In contrast, treatment of
BJ ﬁbroblasts with the same concentration of 1 for 24 hours led to only 7.2 ±
1.9% of cells in M phase with mock treated ﬁbroblasts having 2.7 ± 1.2% of the
population in M phase (see Table 8.2). After 48 hours the percentage of SCC114
cells arrested in mitosis had decreased to 9.4 ± 1.4% compared to 4.2 ± 1.2% for
the control, but simultaneously, the percentage of sub-G1 cells had risen to 32.2
± 7.4%, an eﬀect most likely caused by apoptosis. This phenomenon was further
investigated by analyzing cells treated with 1 with an apoptosis marker: whole
cell lysates of SCC114 cells treated with 46 μM aurantiamine were evaluated
by Western blotting for the presence of the p85 fragment of poly (ADP-ribose)
polymerase (PARP), a downstream target of activated caspase 319 (Figure 8.2E).
PARP cleavage was already detected after a 24 hour treatment of SCC114 cells
with a further increase seen after 48 hours, strongly suggesting that these cells
undergo apoptosis. For the mock treated cells no p85 fragment of PARP was
seen after either 24 or 48 hours (Figure 8.2D).
The possibility of aurantiamine acting through another mechanism that inhi-
bition of centrosomal clustering was examined by Alwin Kra¨mer and Simon An-
Table 8.2: Flow cytometry of BJ ﬁbroblasts cells treated with 46 μM auranti-
amine
Mock 24 h Mock 48 h Auran. 24 h Auran. 48 h
M-phase 2.7 ± 1.2 0.7 ± 0.6 7.2 ± 1.9 4.1 ± 1.4
Sub G1 4.5 ± 1.0 4.6 ± 0.9 5.1 ± 1.3 8.6 ± 2.8
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derhub. Aurantiamine was tested against HeLa (human cervical cancer), U2OS
(human osteosarcoma) and MDA-MB-231 (human breast cancer), showing induc-
tion of multipolar mitosis in all three cell lines. However, when tested against an-
other, faster proliferating, non cancerous control cell line called Retinal Pigment
Endothelial (RPE) multipolar mitosis was also induced. This was further investi-
gated by staining MDA-MB-231, SCC114 and RPE cells with centrin antibodies
(to label single centrosomes/centrioles) and γ-tubulin (to label spindlepoles). It
was then checked whether each pole in the multipolar cells (after incubation with
aurantiamine (1)) also had a centrin signal, which would support the mode of
action being centrosomal declustering. This was not the case, instead it was
observed that the majority of cells which divide by multipolar mitosis have at
least one pole without a centrin signal. So the multipolar mitoses induced by
aurantiamine (1) is not a speciﬁc inhibition of centrosomal clustering although it
is possible that it also includes inhibition of centrosomal clustering.
It was conﬁrmed by isolation and NMR analysis that P. cavernicola pro-
duces aurantiamine (1). The IC50 value for induction of spindle multipolarity
in SCC114 cells for aurantiamine (1) has been determined to be 40 ± 4 μM. Cell
cycle analyses were performed and showed that following exposure to 1, SCC114
cells are arrested in M phase followed by apoptosis, while BJ ﬁbroblasts were af-
fected to a much smaller extent by aurantiamine (1). However RPE cells treated
with 1 followed by staining against centrin and γ-tubulin showed poles with no
centrosomes and thus aurantiamine (1) is not a speciﬁc inhibitor of centrosomal
clustering.
8.1 Experimental
Solvents were purchased from Sigma-Aldrich Chemical Co. and used without fur-
ther puriﬁcation. 1D and 2D NMR spectra were recorded using a Varian Unity
Inova 500 MHz spectrometer. Chemical shifts were measured in ppm and cou-
pling constants in Hz. The residual peak for CDCl3 was used as internal reference
at σ 7.27 for 1H NMR and σ 77.00 for 13C NMR spectra. High-resolution LC-
DAD-MS was performed on an Agilent 1100 system equipped with a photodiode
array detector (DAD) coupled to a LCT orthogonal time-of-ﬂight mass spectrom-
eter (Waters-Micromass) with a Z-spray electrospray ionisation (ESI) source, a
LockSpray probe (M+H 556.2771) and controlled by MassLynx 4.0 software.
SSC114 cells were used for determining IC50 value, cell cycle analysis and
Western blotting. Despite the presence of supernumerary centrosomes in 64.5%
of SCC114 cells, only 3.6% of the cells in mitosis form multipolar spindles. The
remainder of the cell population clusters its centrosomes and undergoes bipolar
mitoses, making this cell line an ideal model system.
Flow cytometry to assay cell cycle distribution: trypsinized cells were ﬁxed in
70% aq. ethanol and stained with an antibody to phosphorylated histone H3
(Upstate Biotechnologies, 1:500) for 2 hours at room temperature, followed by a
30 min incubation with secondary antibody Alexa Fluor R© 488 (Molecular Probes,
1:1000). Cells were then counterstained with propidium iodide and analyzed on
a FACScan ﬂow cytometer (BD Biosciences) using Cellquest software.
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Figure 8.2: (A) FACS histograms of BJ ﬁbroblasts treated with aurantiamine
(1), where a slight increase of cells in mitosis can be seen. (B) SCC114 squamous
cell carcinoma cells treated with 1. After 24 hours the population in mitosis has
increased signiﬁcantly, while after 48 hours the sub-G1 population has increased.
(C) Mock-treated SCC114 cancer cells and same cells treated with 1. Cells were
stained with an anti-centrin mouse monoclonal antibody and an anti-γ-tubulin
rabbit polyclonal antibody using goat anti-mouse Cy3 and goat anti-rabbit Alexa
488 as secondary antibodies. Bipolar and multipolar mitosis can be seen, respec-
tively. (D) Dose-response curve for SCC114 cells treated with 1. (E) Western
blot (PARP) using whole cell lysates stained with an antibody to full-length and
cleaved PARP. Actin provides the loading control.
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Western blot (PARP): whole cell protein extracts were prepared by lysis of
cells in an appropriate volume of RIPA buﬀer (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1% Nonidet P40 (Genaxxon), 0.5% sodium deoxycholate, 0.1% SDS)
supplemented with one Complete Protease Inhibitor Cocktail Tablet (Roche Diag-
nostics) per 50 ml of buﬀer, followed by mechanical homogenization and collection
of the supernatant after centrifugation for 10 min at 20,000 x g. Immunoblotting
was performed according to standard protocols. For detection, an antibody to
full-length and cleaved PARP (Clone 9532, Cell Signaling) was used following
incubation with a HRP-conjugated secondary antibody in BSA.
P. cavernicola (IBT 3235) was cultured on 200 plates of Czapek yeast au-
tolysate agar at 25 ◦C for 7 days and extracted with 1% formic acid in ethyl
acetate. 1.0 g of the extract (2.6 g total) was fractionated on an IsoleraTM (Bio-
tage) using a gradient from 30 to 100% acetonitrile in water over 30 minutes and
a 50 gram SNAP cartridge. The fraction collected from 6.1 to 9.4 minutes was
puriﬁed on a Luna HPLC column (250 × 10 mm, 5 μm, C-18) using 4 mL/min
H2O/CH3CN (Starting at 70/30, increasing to 40/60 over 14 minutes) as the
mobile phase to yield 1 (6.2 mg as an yellow oil).
Aurantiamine 1: 1H NMR (500 MHz, CDCl3): σ 11.99 (1H, s), 9.01 (1H, br
s), 7.55 (1H, s), 6.94 (1H, s), 6.13 (1H, s), 6.04 (1H, dd, J = 17.3, 10.5 Hz), 5.22
(1H, d, J = 10.5 Hz), 5.18 (1H, d, J = 17.3 Hz), 4.06 (1H, t, J = 2.7 Hz), 2.48
(1H, dhept, J = 2.7, 7.0 Hz), 1.52 (6 H, s), 1.06 (3H, d, J = 7.0), 0.96 (3H, d, J
= 7.0) (in agreement with litt.18); 13C NMR (from gHSQC, gHMBC, 500 MHz,
CDCl3): σ 164.7, 160.6, 144.3, 136.4, 132.1 (2C), 123.6, 113.2, 105.1, 61.0, 37.4,
32.8, 27.8 (2C), 18.5, 15.8 (in agreement with litt.18); HRMS (ESI+) calcd for
[M+H] [C16H23N4O2]
+ 303.1821, found 303.1814. [α]21D -116 (c 0.10, MeOH) (in
agreement with litt.18).
Aurantiamine was tested in triplicate at 8 diﬀerent concentrations (80, 60,
40, 20, 10, 5, 2.5, 1 μM). Cells were then ﬁxed and examined by ﬂuorescence
microscopy. Two hundred mitotic cells per well were analyzed with the percentage
of mitotic cells with multipolar spindles being the read-out. The relationship
between readout and the dose was described by a logistic model (see equation
8.1)
p =
1
(1 + exp(−α− βx)) (8.1)
where p is the percentage of mitotic cells with multipolar spindles and x is the
dose scaled according to x=ln(dose+1). The dose axis was scaled to spread out
the low concentration data. The IC50 values and the corresponding 95% con-
ﬁdence intervals were estimated based on the ﬁtted dose-response curves. The
calculations were performed in Matlab 7.0.4.365 (The Mathworks, Natick, Mas-
sachusetts, USA) using the glmﬁt and glmval functions.
8.2 2’-Benzyloxy-2’-demethoxy-griseofulvin and inhi-
bition of centrosomal clustering
The most potent compound from the initial phenotypical assay, 2’-benzyloxy-2’-
demethoxy-griseofulvin (3, see Figure 8.3) was examined further based on the
109
94 BIBLIOGRAPHY
ﬁndings with 1. It was attempted to verify if the multipolarity was indeed inhi-
bition of centrosomal clustering or unspeciﬁc induction of multipolarity (For the
full manuscript see Appendix A). At lower concentrations 3 showed inhibition of
centrosomal clustering, while at higher concentrations unspeciﬁc multipolar mi-
toses were observed. 2’-Benzyloxy-2’-demethoxy-griseofulvin (3) is therefore not
100% speciﬁc towards cancer cells, but the diﬀerence in activity between cancer
cells and healthy cells provide a therapeutic window.
Figure 8.3: 2’-Benzyloxy-2’-demethoxy-griseofulvin 3
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Chapter 9
Conclusion
A possible way to speciﬁc anti-cancer agents is to explore the diﬀerences between
healthy cells and cancer cells. One speciﬁc diﬀerence is the supernumerary cen-
trosomes discovered in cancer cells. This aﬀords the possibility of multipolar
mitosis producing unviable progeny. To circomvent this, the cancer cells utilize
a mechanism called centrosomal clustering, in order to ensure bipolar mitosis.
As healthy cells contain only two centrosomes during mitosis, this mechanism is
not used by healthy cells. A small molecule that inhibits centrosomal clustering
and forces cancer cells to undergo multipolar mitosis, could therefore be an anti-
cancer agent with speciﬁcity for cancer. Prior to this project, griseofulvin (1, see
Figure 9.1) was identiﬁed as a small molecule that induces multipolar mitosis in
cancer cells.
The chemistry of griseofulvin (1) was reviewed in Chapter 2, covering the areas
of total synthesis, biosynthesis, microbial transformation, spectroscopic studies,
and analog synthesis. More than 400 analogs have been synthesized since the
discovery of griseofulvin (1) covering most positions of griseofulvin. The review
will be of help to other researchers working in the ﬁeld of griseofulvin, with its
overview of more than 120 published papers concerning griseofulvin (1).
In Chapter 3 the structure-activity relationship study of griseofulvin analogs
tested in a phenotypical assay was described. A total of 34 (nine novel) griseoful-
vin analogs were described with a further ten isogriseofulvin analogs tested and
found inactive. The analogs covered ﬁve positions of griseofulvin (1), namely the
4, 5, 2’, 3’, and 4’ positions. Elongation of the 2’ position increased activity and
introducing bulkier groups further improved potency with the 2’-benzyloxy (2)
analog the most potent with an IC50 value of 0.9 μM. Introduction of an oxime
to 1 at the 4’ position increased activity slightly but did not show a cumula-
tive eﬀect with the 2’-benzyloxy group (3). Alterations at the 4 and 5 positions
rendered the analogs inactive and isogriseofulvin analogs were all inactive. This
work has contributed to griseofulvin’s structure-activity relationship study, an
area otherwise poorly examined.
In Chapter 4 55 analogs (11 novel) were tested against two dermatophytes (Tri-
chophyton rubrum and T. mentagrophytes) as well as the cancer cell line MDA231
(human breast adenocarcinoma) in growth inhibition assays. The IC50 values
from the phenotypical assay was found to correlate well with the values from
the cytotoxicity assay (R2 = 0.70). Tubulin has been proposed as the target for
griseofulvin in both fungal cells and mammalian cancer cells. Tubulin is highly
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Figure 9.1: The structures of griseofulvin (1), 2’-benzyloxy-2’-demethoxy-
griseofulvin (2), the 4’-oxime (3) of the latter and aurantiamine (4)
conserved in eucaryotic cells and if tubulin indeed is the target both for fungi
and cancer cells, it was anticipated that the structure-activtiy relationship study
would show the same trend, however this was not the case. The vast major-
ity of analogs showed lower potency against the two fungi and higher potency
against the cancer cell line. The 2’-benzyloxy-2’-demethoxy-griseofulvin analog
(2) was less active against both fungi tested in this work and also less active
against six dermatophytes previosuly tested by Crosse et al (1964). By contrast
compound 2 was nine times more potent than griseofulvin (1) in the cytotoxcity
assay, highlighting the diﬀerent SAR and thus indicates diﬀerent targets in fungi
and mammalian cancer cells.
The accepted standards (Clinical and Laboratory Standards Institute and the
European Committee on Antimicrobial Susceptibility Testing) for testing com-
pounds against various fungi uses concentrations in mg/L, also for comparing
compounds with a variety of molar masses. Visual inspection is used as a mean of
evaluating minimum inhibition concentrations. The assay used for testing against
fungi in this work used molar concentrations to be able to compare analogs more
accurately. The minimum inhibition concentrations were based on spectroscopic
measurements, which were processed to IC50 values by ﬁtting to a sigmoidal model
with the software GraphPad Prism. Using a spectrophotometer as opposed to
visual inspection is a more objective way of evaluating raw data. The work pre-
sented here is thus a valuable input to the science of antimicrobial susceptibility
testing.
In Chapter 5 syntheses of the two phenols of griseofulvin were described. The
4-phenol was obtained in quantitative yields by treatment with MgI2 with a yield
of 29% for the 6-phenol by treatment with LiI in pyridine. The position of each
phenol was determind by single crystal X-ray analysis and this proved the posi-
tion of the 4-methoxy group in 1H NMR to resonate upﬁeld from the 6-methoxy
group. This diﬀerentiation of the two methoxy groups will be of help to future
synthetic work at ring A of griseofulvin.
The absolute structure of (+)-geodin, isolated from Aspergillus terreus, was de-
termined in Chapter 7 by single crystal X-ray analysis. The spirocenter was
found to have the R conﬁguration, by using the Flack parameter. The compound
shares the grisan A, B, and C rings of 1 but was tested inactive in the phenotyp-
ical assay. However, (+)-geodin was twice as potent when tested in the toxicity
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assay against MDA-MB-231 cancer cells in Chapter 4. The determination of the
absolute structure will be of interest to research of the biosynthesis of (+)-geodin.
The isolation of aurantiamine (4) from Penicillium cavernicola was described
in Chapter 8. The compound was tested in a phenotypical assay for multipolar-
ity inducing eﬀects in SCC114 cancer cells (squamous cell carcinoma cells). The
compound had an IC50 of 40 ± 4 μM and by ﬂuorescence-activated cell sorting
(FACS) analysis it was observed that aurantiamine (4) induces M phase arrest
in the SCC114 cells. It was also observed that the G0 population increased upon
treatment with aurantiamine, which was conﬁrmed using Western blot analysis
for the p85 fragment of poly (ADP-ribose) polymerase (PARP), a downstream
target of activated caspase 3. The eﬀect on BJ ﬁbroblasts treated with auranti-
amine (4) was minor, but RPE cells (Retinal Pigment Endothelial) were aﬀected
and multipolar spindles were observed. Aurantiamine (4) was therefore found
not to be speciﬁc for cancer cells. It was investigated if 2 inhibited centrosomal
clustering or like 4 induced unspeciﬁc multipolarity in both healthy cells and can-
cer cells. It was found that 2 at lower concentrations in fact inhibits centrosomal
clustering in cancer cells, while at higher concentrations unspeciﬁc induction of
multipolarity was observed. The analog aﬀected healhty control cells to a lesser
extent, providing an overall selectivity index of 10 to 30 fold. Though not truly
speciﬁc 2 still provides a theraputic window and at lower concentrations it does
inhibit centrosomal clustering.
A novel method for the introduction of radioactive iodide to aromatic rings was
described in Chapter 6. This method was used in scintigraphic in vivo imaging
to assess bio-distribution and half-life of a radioactive griseofulvin analog. The
treatment of an aryl trimethylsilyl with thallium(III)triﬂuoroacetate in 30% TFA
in MeCN followed by potassium 125I-iodide or 131I-iodide aﬀords the radiolabeled
compound in over 95% radiochemical yield for all three regioisomers (ortho-,
meta- or para-aryl). Since direct thallation/iodation of aryl compounds can yield
all three regioismers, this method oﬀers a more selective approach. The ortho-,
meta- or para-iodo-aryl of a given compound can be synthesized and tested to
assess potency. The most suitable analog can then be chosen and the equvilant
TMS compound synthesized. In this way the propterties of the radiolabeled ana-
log can be evaluated prior to labeling and only the desired iodo analog is produced.
Regarding future eﬀorts to identify selective inhibitors of centrosomal cluster-
ing, the current setup with MDA-MB-231 cells as the cancer cell line screened
against, and the RPE cells as controls, holds the foundation of a successful screen-
ing strategy. However, the assay is still operated fully manually and thus very
time consuming. For the setup to be more successful the assay must be high
throughput, making it possible to test a greater number of fungal raw extracts
and e.g. synthetic libraries. The fractionation of raw extracts prior to testing
should also be attempted. The use of explorative solid phase extraction could be
used for initially active compounds to minimize the risk of isolating known anti-
cancer compounds, although making this method and the assay compatible would
take some work. Using a phenotypical assay, which can identify small molecules
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that induces multipolar spindles in cancer cells, is still a rational screening ap-
proach, as ﬁnding a cancer speciﬁc compound is more likely than screening with
a simple cytotoxicity assay.
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GF-15, a Novel Inhibitor of Centrosomal
Clustering, Suppresses Multiple Myeloma
Growth in vitro and in vivo
This manuscript has been submitted to Blood.
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Abstract 
 
In contrast to normal cells, malignant plasma cells are highly aneuploid and 
frequently contain multiple centrosomes. To allow for bipolar mitotic division, 
supernumerary centrosomes are clustered into two functional spindle poles in many 
cancer cells. Recently, we have shown that griseofulvin forces tumor cells with 
supernumerary centrosomes to undergo multipolar mitoses resulting in apoptotic cell 
death. Here, we describe the characterization of the novel small molecule GF-15, a 
derivative of griseofulvin, as inhibitor of centrosomal clustering in myeloma cells. In a 
wide array of myeloma cell lines, the mean inhibitory concentrations (IC50) for 
proliferation and survival were found to be in the range of 1-5 M, associated with 
activation of caspases 8, 9, and 3. GF-15 overcomes the growth advantage conferred 
by bone marrow stromal and endothelial cell-myeloma co-culture. In addition, 
treatment with GF-15 was associated with inhibition of VEGF- and IGF1-triggered 
myeloma cell migration. Importantly, treatment of mouse xenograft models of human 
myeloma with GF-15 resulted in tumor growth inhibition and significantly prolonged 
survival. These results demonstrate the in vitro and in vivo anti-tumor efficacy of a 
prototype small molecule inhibitor of centrosomal clustering and strongly support the 
further evaluation of this new class of molecules. 
104 Manuscript
120
3 
 
Introduction 
 
Although recent advances in the therapeutic management of multiple myeloma (MM) 
have improved its prognosis, no curative therapy currently exists for this disorder, 
which is the second most commonly diagnosed hematologic malignancy in the 
Western world1. MM is a plasma cell malignancy characterized almost universally by 
aneuploidy and chromosomal instability. In hyperdiploid MM, which accounts for 
approximately 50% of cases, multiple trisomies and monosomies are observed in 
clonal cells. Even though the mechanisms leading to chromosomal instability in MM 
are only beginning to be unraveled, accumulating evidence suggests that 
centrosome amplification might contribute to the acquisition of aneuploidy in MM2-4. 
Centrosomes are small cytoplasmic organelles which consist of a pair of 
centrioles embedded in pericentriolar material and act as microtubule organizing 
centers. During mitosis, centrosomes function as spindle poles, directing the 
formation of bipolar spindles, a process essential for accurate chromosome 
segregation5,6. Centrosomes duplicate precisely once per cell cycle to assure spindle 
bipolarity, with each daughter cell receiving one centrosome upon cytokinesis. 
Centrosome amplification is frequent in both solid tumors and hematologic 
malignancies, and is linked to tumorigenesis and aneuploidy2-4,7-11. The extent of 
centrosomal aberrations correlates with the degree of chromosomal instability and 
malignant behaviour in tumor cell lines, mouse tumor models, and human 
tumors7,10,11-13. 
 In mitosis, supernumerary centrosomes can lead to the formation of multipolar 
spindles, which is a hallmark of many tumor types9. Multipolar spindles, however, are 
antagonistic to cell viability14,15. Most progeny derived from a multipolar mitosis will 
undergo apoptosis. To circumvent this problem, many cancer cells appear to have 
mechanisms that suppress spindle multipolarity, the best studied being clustering of 
supernumerary centrosomes into two spindle poles enabling bipolar division9,14-20. 
Bipolar spindle formation via centrosomal clustering is associated with an increased 
frequency of lagging chromosomes during anaphase, thereby explaining the link 
between supernumerary centrosomes and chromosomal instability15. 
The mechanisms of centrosomal clustering in tumor cells are incompletely 
understood. Recent genome-wide RNAi screens in cells containing supernumerary 
centrosomes suggest the involvement of the spindle assembly checkpoint, spindle 
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tension as controlled by cortical actin cytoskeleton and cell adhesion molecules as 
well as centrosome and kinetochore components in this process19-21. 
 Supernumerary centrosomes are almost exclusively found in a wide variety of 
neoplastic disorders but not in non-transformed cells. Therefore, inhibition of 
centrosomal clustering with consequential induction of multipolar spindles and 
subsequent cell death would specifically target tumor cells with no effect on normal 
cells with regular centrosome content9,17. Using a phenotype-based screening 
strategy, we have recently identified griseofulvin as chemical inhibitor of centrosomal 
clustering in human cancer cells14. This compound induced multipolar spindles by 
inhibition of centrosome coalescence, mitotic arrest, and subsequent cell death in 
multiple tumor cell lines but not in diploid fibroblasts and keratinocytes with normal 
centrosome content. Chemical optimization of griseofulvin led to the development of 
compounds with significantly increased activity and mean inhibitory concentrations 
(IC50) of proliferation and survival in the lower micromolar range when applied to the 
human squamous cell carcinoma cell line SCC114, which had been used for the 
initial screening22. 
Here, we describe that the griseofulvin derivative GF-15 potently inhibits 
centrosomal clustering followed by apoptosis induction in MM both in vitro and in 
vivo. 
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Materials and methods 
 
Materials 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-benzyloxy-6’-
methylcyclohex-2’-en-4’-one) (2'-benzyloxy-2'-demethoxygriseofulvin; GF-15) was 
synthesized following the procedures described recently22. Other reagents were 
obtained as follows: VEGF165 and IGF-1 from R&D Systems (Minneapolis, MN); 
Caspase 8 and PARP antibodies from Santa Cruz Biotechnology (Santa Cruz, CA). 
 
Cell culture 
All human MM cell lines (RPMI-8226, OPM-2, NCI-H929, OPM-1, KMS-12BM, KMS-
12PE, KMS-11, KMS-18, U-266, MM1.S, LR5, Dox40, MM1.R, PAT1) and primary 
patient MM cells were cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Harlan, Indianapolis, IN), 100 U/mL penicillin, 10 
g/mL streptomycin, and 2 mM L-glutamine (Cellgro, Herndon, VA). Leukemia lines 
used were HEL, MOLM14, and Ku812 and cultured as described above. Solid tumor 
cell lines comprised HeLa (cervical carcinoma), HT29, HCT116, SW480 (colorectal 
carcinoma), PANC1, PACA1 (pancreatic carcinoma), and LN229 (glioblastoma). 
HS4, KM105, KM104 (bone marrow stromal cells), THLE3 (liver cells), peripheral 
blood mononuclear cells (PBMC), and primary bone marrow stromal cells (BMSC) 
served as non-malignant controls. All solid tumor cell lines and non-malignant 
controls were grown in DMEM medium supplemented with 10% heat-inactivated FBS 
(Harlan, Indianapolis, IN), 100 U/mL penicillin, 10 g/mL streptomycin, and 2 mM L-
glutamine (Cellgro, Herndon, VA). 
 
Isolation of patient tumor cells 
After patients provided informed consent in accordance with the Declaration of 
Helsinki and approval by the Institutional Review Board of the University of 
Heidelberg, MM patient cells (96% CD38+ CD45RA-) were obtained as described23. 
 
Cell lysis and immunoblotting 
Cell lysis and Western blot analysis were performed as described previously23. 
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Evaluation of cell viability 
Cell viability was examined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT; Sigma Chemical, St Louis, MO) colorimetric 
assay, as previously described24. Briefly, cells were plated in 96-well microtitre plates 
at a density of 2-3 x 104 cells per well, and each plate was incubated for 24 and/or 48 
h, with MTT added to each well for at least 4 h. The absorbance of each well was 
measured at 570/630 nm using a spectrophotometer (Molecular Devices, Sunnyvale, 
CA). Each condition was analyzed in at least three replicates, and the results are 
presented as the mean ± standard deviation of replicates of a representative 
experiment that was repeated at least three times. 
 
DNA synthesis and cell proliferation assay 
Cell proliferation was assessed by measuring [3H]-thymidine uptake, as described in 
prior studies23. 
 
Measurement of caspase 3/7 activation 
Caspase 3/7 activation was analyzed using the Apoptosis Detection Kit from 
Promega according to the recommendations of the manufacturer. 
 
Flow cytometry 
Cell cycle analysis by flow cytometry including the quantification of cells in mitosis by 
phospho-S10-histone H3 staining was done as previously described14. 
 
Transwell migration assay 
Cell migration was assayed using a modified Boyden chamber assay, as described 
previously23. 
 
Immunofluorescence 
Immunofluorescence staining was done as described25. The following fluorochrome-
conjugated secondary antibodies were used: anti-rabbit Alexa 488 (Molecular 
Probes) and anti-mouse Cy3 (Jackson ImmunoResearch Laboratories). 
Immunostained cells were examined using a Zeiss Axiovert 200 M fluorescence 
microscope. Images were processed with Photoshop software (Adobe). 
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MM xenograft mouse model 
To determine the in vivo anti-MM activity of GF-15, beige-nude Xid mice were 
inoculated s.c. in the right flank with 3 x 106 OPM2 cells in 100 mL RPMI 1640 
medium, together with 100 mL matrigel (Becton Dickinson Biosciences, Bedford, 
MA). When a tumor was measurable, mice were assigned to a GF-15 treatment 
group or the control group. GF-15 was dissolved in 100% DMSO and given daily five 
times a week by i.p. injection for indicated periods. The control group received the 
carrier alone at the same schedule and route of administration. Tumor burden was 
measured every alternate day using a calliper (calculated volume = 4π/3 x (width/2)2 
x (length/2)). Animals were sacrificed when their tumor reached 2 cm or when the 
mice became moribund. Survival was evaluated from the first day of treatment until 
death. All animal studies were approved by the Dana-Farber Animal Care and Use 
Committee. 
 
Preparation of the radiolabeled GF-15 analogue 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-(4-(125/131-
iodo)benzyloxy)-6’-methyl-cyclohex-2’-ene-4’-one) was prepared by thallation-
iodination with 125I-iodide or 131I-iodide (Perkin Elmer, Dreieich, Germany) of (2S,6’R)-
(7-chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(6’-methyl-2’-(4-trimethylsilyl-
benzyloxy)-cyclohex-2’-ene-4’-one), which was in turn synthesized from p-
trimethylsilylbenzyl alcohol26 using a known method22. The radiolabeled analogue 
was compared to a sample of (2S,6’R)-(7-chloro-4,6-dimethoxy-benzofuran-3-one)-2-
spiro-1’-(2’-(4-iodobenzyloxy)-6’-methyl-cyclohex-2’-ene-4’-one) prepared from p-
iodobenzyl alcohol22 and found to be identical by HPLC-DAD-MS .  
 
125I scintigraphic in vivo imaging 
For imaging studies, 200 µL of a solution of the 125I-labeled GF-15 analogue  
(5 MBq/mice) was injected into the tail vein of six week old female NMRI mice. 
Scintigraphic images were taken using a gamma camera (Biospace, France). The 
accumulation of the radioactive tracer was monitored by static planar images at 5 
min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h and 24 h after injection. 
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Biodistribution studies 
131I-labeled GF-15 analogue (1 MBq/mice) was injected via the tail vein of six week 
old female NMRI mice. At the time points specified, the animals were sacrificed, 
weighed and dissected. Organs or tissues were blotted dry and weighed. The 
radioactivity was measured in a -counter along with a sample of the injection 
solution to calculate the percentage of injected dose per gram of tissue (%ID/g). 
 
Stability experiments 
The serum stability was determined by incubation of the 125I-labeled GF-15 analogue 
in human serum at 37 °C. Aliquots were taken at several points in time, and the 
degradation was stopped by precipitation of the serum proteins with acetonitrile. After 
30 min at 0 °C and a further centrifugation step the clear supernatant was analyzed 
by reverse-phase HPLC on a Chromolith Performance RP-18e 100  4.6 mm column 
using water and acetonitrile containing 0.1% trifluoroacetic acid as the eluent. 
 
Statistical analysis 
Statistical significance of differences observed in GF-15-treated versus control cell 
cultures and mice was determined using an unpaired Student’s t test. Overall survival 
in animal studies was measured using the Kaplan-Meier method. (* P>0.01; ** 
P>0.001) 
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Results 
 
GF-15 leads to multipolar mitosis induction in the upper nanomolar range 
Recently, we have shown that especially 2’-modified derivatives of griseofulvin have 
an enhanced capacity for multipolar mitosis induction as compared to griseofulvin 
itself22. Initial testing for the ability to inhibit centrosomal clustering was performed in 
SCC114 cells, an oral squamous cell carcinoma line showing pronounced 
centrosome amplification14,18. GF-15 (2'-benzyloxy-2'-demethoxygriseofulvin,) is 
significantly more potent with regard to the induction of spindle multipolarity than 
griseofulvin (Figure 1A). The EC50 value of multipolar spindle induction for GF-15 was 
900 nM, corresponding to a 27-fold increased activity compared to griseofulvin. 
Importantly, SCC114 cells that became resistant to GF-15 after long-term culture with 
increasing doses (0.2 – 1 M) of the compound over a period of ten weeks, showed 
significantly less centrosome amplification and formed fewer multipolar spindles upon 
treatment with therapeutic doses (5 M) of the drug (Figure 1B, Figure S1). 
To test for the contribution of centrosome declustering to total multipolar mitosis 
induction after treatment with GF-15, the PC-3 prostate carcinoma cell line, which 
harbors supernumerary centrosomes in 28 ± 4% of the cells, was treated with 
increasing concentrations of the drug for 24 h (Figure 1C). Intriguingly, at the highest 
analyzable concentration (1.5 M), GF-15 induced centrosome declustering – as 
determined by the detection of two centrioles at each spindle pole (Figure 1D) – in 27 
± 4% of the cells, thereby closely matching the total percentage of cells with 
supernumerary centrosomes. At the lowest concentration tested (0.375 M), 
multipolarity induction was mostly due to inhibition of centrosomal clustering. With 
increasing doses of GF-15, the contribution of multipolarity induction by other means 
in cells without supernumerary centrosomes gradually increased. From these results, 
it may be concluded that mechanisms responsible for holding supernumerary 
centrosomes together might be similar to the forces that bundle microtubules into a 
bipolar spindle array in cells with a regular centrosome content. However, different 
sensitivities of both mechanisms provide a window of opportunity to preferentially 
target centrosome clustering at certain dose levels. 
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GF-15 is particularly active against MM cells 
Next, we examined the effect of GF-15 on the growth of several different cancer cell 
lines. GF-15 exhibits potent cytotoxicity in a concentration-dependent manner against 
a broad spectrum of tumor cell types including colon, cervix, glioblastoma, pancreas, 
leukemia, and myeloma-derived cell lines (Figure 2A). As compared to solid tumor 
cell lines, MM cell lines were particularly susceptible to the cytotoxic and anti-
proliferative effect of GF-15 with IC50 values ranging from 1 - 2.5 M, including MM 
cell lines resistant to doxorubicin (Dox40), melphalan (LR5), and dexamethasone 
(MM1.R) (Figure 2 A, B). Moreover, primary MM cells freshly isolated from the bone 
marrow of three patients with relapsed myeloma showed marked cytotoxic effects 
upon treatment with GF-15. This was in stark contrast to their corresponding BMSCs, 
which displayed virtually no cytotoxicity when exposed to GF-15 (Figure 2C). 
Similarly, GF-15 did not induce significant cytotoxicity in PBMCs from healthy 
volunteers even after stimulation with phytohemagglutinin (PHA), providing an overall 
selectivity index of 10- to 30-fold when compared to IC50 values of cancer cell lines 
(Figure 2D). These data suggest that GF-15 exhibits both potent and selective 
cytotoxicity against malignant cells. 
 
Induction of spindle multipolarity, mitotic arrest and apoptosis by GF-15 
GF-15 induced multipolar mitoses in MM cell lines NCI H929, OPM2, and RPMI 8226 
(Figure 3A). After 24 h of treatment with 3 M GF-15, no significant induction of 
spindle multipolarity could be detected in primary BMSCs, whereas >80% of mitoses 
were multipolar in NCI H929, OPM2, and RPMI 8226 cells (Figure 3B). To examine 
the effect of multipolar mitosis induction on cell cycle progression, starvation-
synchronized OPM2 cells were exposed to GF-15, stained with propidium iodide, and 
subsequently analyzed by flow cytometry. GF-15 induced a pronounced G2/M cell 
cycle arrest within 12 h of treatment followed by an increase of the sub-G1 population 
compared to mock-treated cells (Figure 3C, upper panel). Indicating induction of 
apoptosis, the increase of the sub-G1 population was concentration-dependent 
(Figure 3C, lower panel), analogous to the effect of griseofulvin in SCC114 cells14. To 
further verify apoptotic cell death triggered by GF-15, protein profiling in GF-15 
treated MM cells showed dose-dependent cleavage of caspase 8, caspase 9, 
caspase 3, and PARP (Figure 3D). Cleavage fragments of these proteins became 
detectable at 0.5 M and strongly increased at 3 M of GF-15. Importantly, exposure 
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of primary BMSCs to 3 M of GF-15 for 24 h did not induce activation of effector 
caspases 3 and 7 compared to OPM2 cells (Figure 3E). 
 
Evaluation of combinations of GF-15 with other anti-myeloma agents 
Clinical experience in the therapeutic management of MM patients supports the 
notion that drug combinations can induce higher response rates when compared with 
single-agent treatment1,24. We therefore evaluated the effects of combinations of GF-
15 with other established anti-MM drugs on the viability of MM cells. Specifically, GF-
15 was combined with conventional agents (melphalan, dexamethasone) as well as 
with more recently developed compounds such as bortezomib. While GF-15 together 
with dexamethasone or bortezomib, respectively, resulted in at least additive effects 
(data not shown), the combination with melphalan led to a marked abrogation of GF-
15 induced cytotoxicity (Figure 3F). This is consistent with an S-phase arrest induced 
by the DNA-damaging drug melphalan, thereby preventing entry into mitosis of 
melphalan-exposed cells. This underlines the specificity of GF-15 for cells in G2/M-
phase and provides important information for its possible use in clinical application. 
 
GF-15 inhibits myeloma cell growth triggered by bone marrow stromal cells 
In addition to the autocrine/paracrine effects mediated by growth factors and 
cytokines within the MM bone marrow microenvironment, direct MM-BMSC contact 
also triggers tumor cell growth. We therefore evaluated the effect of GF-15 on MM 
cell proliferation induced by the stimulatory effect of BMSCs (Figure 4A, B). Binding 
of OPM2 or RPMI-8226 cells to primary BMSCs triggered increased MM cell 
proliferation, which was completely abrogated by GF-15. Importantly, as also shown 
in Figure 2C, GF-15 did not affect the viability of BMSC lines, as determined by MTT 
assays. 
 
GF-15 inhibits cytokine-induced myeloma cell migration 
Migration activity is required for homing of tumor cells to the bone marrow, expansion 
within the bone marrow microenvironment, and tumor cell egress into the peripheral 
blood23,27. Since centrosomes and microtubules as targets of GF-15 are not only 
important for mitotic spindle formation but also for interphase cell shape and 
migration28, we next investigated whether vascular endothelial growth factor (VEGF)- 
and insulin-like growth factor-I (IGF-I)-induced migration of MM cells can be 
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abrogated by pre-treatment with GF-15. Our data show that GF-15 completely 
abrogates both VEGF/FN- (fibronectin) and IGF-I-triggered MM-cell migration (Figure 
4C). 
 
GF-15 is rapidly eliminated in vivo 
Derived from its parental molecule griseofulvin, GF-15 has been modified at the 2’-
position (Figure 1A). We therefore sought to analyze in vivo stability and 
pharmacokinetics of this new compound. By introducing a p-iodobenzyl group in the 
2'-position of the griseofulvin molecule we generated a 125I-labeled GF-15-analogue. 
HPLC analysis showed only minimal degradation of this molecule in human serum 
with a half-life of 48 h at 37 °C. The cleavage products resulting from degradation are 
presumably 4-iodobenzyl alcohol and griseofulvic acid, consistent with the analogue 
undergoing hydrolysis (data not shown). After i.v.-application of trace amounts of this 
analogue, rapid renal clearance was observed within the first 6 h after injection 
(Figure 5). In light of the clearance data and the poor solubility of GF-15 at higher 
concentrations, we went on to investigate its in vivo efficacy after intraperitoneal (i.p.) 
application. 
 
GF-15 exhibits in vivo anti-MM activity in a myeloma xenograft mouse model 
In view of the potent and selective in vitro activity of GF-15 against MM cell lines and 
freshly isolated primary MM patient cells, we next examined the in vivo effect of GF-
15 on human MM growth in immunodeficient mice. A cohort of 30 immunodeficient 
beige-nude-Xid (BNX) mice was inoculated with 3 x 106 OPM2 cells s.c. in the right 
flank. Treatment with a daily dose of 20 mg/kg (ten mice) or 100 mg/kg (ten mice) i.p. 
five days per week for two weeks was started when tumors became palpable. Ten 
mice served as a control cohort and received i.p. injections of the vehicle alone. GF-
15 treatment decreased tumor growth in both cohorts of treated mice with a greater 
effect in the group that received 100 mg/kg i.p. (Figure 6A). Kaplan-Meier and log-
rank analysis revealed a significant prolongation of survival for the GF-15 treated 
groups compared with the vehicle-treated controls (log-rank P<0.001; Figure 6B). 
The toxicity profile of GF-15 seems to be quite favourable as body weight was not 
affected by treatment with GF-15 compared with untreated controls (Figure 6C). 
Importantly, examination of histological tumor sections revealed a dose-dependent, 
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significant increase of aberrant and multipolar mitoses in the GF-15-treated mice 
compared with controls (P<0.01 for 20mg/kg, P<0.001 for 100mg/kg; Figure 6D, E). 
 
 
Discussion 
 
Here, we have shown that treatment of MM cells with GF-15, a derivative of 
griseofulvin, leads to multipolar spindle formation, centrosomal declustering, mitotic 
cell cycle arrest, and apoptosis both in tissue culture and in a myeloma xenograft 
mouse model. 
MM, presently an incurable plasma cell malignancy, accounts for approximately 20% 
of deaths from hematologic malignancies and nearly 2% of deaths from cancer1,29. In 
virtually all cases, it is preceded by a premalignant tumor called monoclonal 
gammopathy of undetermined significance (MGUS), which occurs in about 3% of 
individuals over the age of 5030. Virtually all MGUS and MM tumor cells have numeric 
and/or structural chromosome abnormalities and are characterized by gross 
chromosomal instability1,31. Using gene expression profiling, we and others have 
shown that genes relevant for cell cycle progression and chromosomal instability are 
overexpressed in high-risk MM patients32,33. 
Centrosome amplification is common in MM and already present in MGUS2-4. 
Moreover, its magnitude constitutes an independent prognostic factor in both newly 
diagnosed and relapsed MM2,3. Mutation or misregulation of a variety of tumor 
suppressors or oncogenes has been shown to disrupt the normal function and 
numeral integrity of centrosomes, among them aurora-A, a protein often 
overexpressed in high-risk MM33-35. 
Recent genome-wide RNAi screens in cells containing supernumerary centrosomes 
suggest that only an intact spindle assembly checkpoint allows for sufficient time in 
order for centrosomal clustering to occur and that spindle tension is necessary for 
clustering of supernumerary centrosomes into a bipolar mitotic spindle array19,20. In 
this regard, it is interesting to note that gene expression profiling identified 
overexpression of key regulators that normally maintain faithful segregation of 
chromosomes, including MAD2, BUBR1, ZWINT, PRC1, survivin, and aurora-B, both 
as part of a high-risk 15-gene signature in MM and a 70-gene signature of 
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chromosomal instability associated with poor clinical outcome in multiple cancer 
types32,36. 
Microtubule-interacting drugs are effective in the treatment of both newly diagnosed 
and relapsed/refractory MM, with clinical activity having been demonstrated for both 
microtubule-depolymerizing (vincristine) and microtubule-stabilizing agents 
(paclitaxel, epothilone B)37-39. Also, inhibition of the mitotic kinesin Eg5 effectively kills 
myeloma cells in vitro40. The limited success of paclitaxel in the treatment of MM 
seems to primarily reflect the fact that it serves as a substrate for the MDR1/Pgp drug 
efflux pump. The mechanisms by which microtubule-interacting drugs induce cell 
death are still not completely clear41. Importantly, aside from the formation of stable 
microtubule bundles associated with G2/M cell cycle arrest and increased microtubule 
polymer mass at high concentrations, taxanes have been described to affect 
centrosome organization with subsequent mitotic catastrophe at low nanomolar 
concentrations42. 
Griseofulvin has been used for many years for the treatment of dermatophyte 
infections43. Mechanistically, it inhibits mitosis in sensitive fungi44 and mammalian 
cells45,46 but whether mitotic arrest is a consequence of microtubule depolymerization 
or some other action on microtubules in both fungi and human cells is still 
unclear47,48. Although griseofulvin has been reported to bind to mammalian brain 
tubulin and to inhibit microtubule polymerization in vitro, it does so only at 
concentrations significantly higher than those needed for spindle multipolarity 
induction in cancer cells with extra centrosomes48. Also, whether griseofulvin binds to 
tubulin directly or to microtubule associated proteins remains conflicting48-51. Already 
more than 30 years ago it was reported that griseofulvin treatment induces spindle 
multipolarity with each mitotic center containing two centrioles in HeLa cells45. While 
at lower concentrations the drug leads to multipolar spindles with centrosomes at 
each pole in cells with extra centrosomes, at higher concentrations spindle 
multipolarity with acentrosomal spindle pole formation is additionally induced. This is 
consistent with the concept that clustering extra centrosomes in cancer cells might be 
similar to focusing microtubules into a bipolar spindle array in normal cells. For 
detailed mechanistic understanding, it will be important to clearly determine the 
sequence of events: does the drug at low concentrations indeed cause declustering 
of supernumerary centrosomes with subsequent multipolar spindle formation or does 
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spindle multipolarity occur first with successive distribution of centrosomes to each 
pole? 
For GF-15, the EC50 value for multipolar spindle induction was 900 nM in SCC114 
cells, corresponding to a 27-fold increased activity compared to griseofulvin itself. 
Also, whereas griseofulvin inhibits cell proliferation only weakly with half-maximal 
inhibition occurring at 25 M48, GF-15 led to inhibition of MM cell growth in vitro at 
IC50 values of 1 to 3 M. 
GF-15 was well tolerated and effective in a murine MM model, as evidenced by 
significant inhibition of MM tumor growth in mice treated with either 20 or 100 mg/kg 
GF-15 i.p. daily for seven days a week. Since GF-15 is only poorly soluble in water 
and its biological half-life is short with little drug left 1 h after administration, it is 
expected that medicinal chemical optimization will lead to a further improvement in 
the drugs potency and in this novel therapeutic strategy in general. Indeed, 
preliminary data suggest that another, slightly modified analogue (GF-61) with 
improved water solubility exerts anti-myeloma activity in our xenograft mouse model 
even when administered orally (our unpublished data). 
In summary, we have shown that single-agent GF-15 potently inhibits MM cell growth 
in vitro and in vivo, overcoming both cell-intrinsic as well as cell-interaction mediated 
mechanisms of drug resistance. These observations, coupled with GF-15’s lack of 
major toxicity in a preclinical mouse model and the lack of significant toxicity of 
griseofulvin in humans, provide the framework for further clinical development of GF-
15 in particular and centrosomal cluster inhibitors in general, directed at improving 
patient outcome in MM. 
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Figures 
 
Figure 1. GF-15 is a potent and specific inducer of spindle multipolarity. (A) 
Chemical structures of griseofulvin and GF-15. SCC114 cells stably expressing -
tubulin were treated with increasing concentrations of griseofulvin or GF-15 for 24 h, 
EC50 of spindle multipolarity was assessed by immunofluorescence microscopy. (B) 
SCC114 cells resistant to GF-15 after long-term culture under increasing 
concentrations of GF-15 display significantly fewer cells with supernumery 
centrosomes than wild type SCC114. Centrosomes were counted in interphase by -
tubulin staining. (C) In PC-3 prostate cancer cells, GF-15 induces centrosomal 
declustering (declustered) in cells with amplified centrosomes, and spindle 
multipolarity by other means (aberrant) in cells with regular centrosome content in a 
concentration-dependent manner. The dashed line depicts the overall percentage of 
PC-3 cells with centrosome amplification. (D) Spindle phenotypes of PC-3 cells upon 
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treatment with vehicle only (D’, D’’) or GF-15 (D’’’, D’’’’) according to their centrosome 
content. Cells were treated with GF-15 or vehicle only for 24 h, spindle poles were 
counted by -tubulin staining, centrioles by centrin staining. 
 
Figure 2. GF-15 selectively inhibits proliferation and survival of tumor cells. (A) 
IC50 values of cell lines of indicated origins. (B) Dose-related effects of GF-15 on cell 
survival (upper panel, 48 h) and proliferation (lower panel, 24 h) on indicated MM cell 
lines. Cell proliferation was assessed by uptake of [3H]-thymidine during the last 8 hrs 
of 24 h cultures. (C) GF-15 differentially inhibits cell survival of primary cells from MM 
patients compared to bone marrow stroma cells (BMSCs). (D) Peripheral 
mononuclear cells (PBMCs) of three healthy donors activated by PHA do not show 
significant toxicity upon treatment with indicated concentrations of GF-15. Viable cells 
are expressed as x-fold of respective control. Cell survival: Unless otherwise 
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indicated, viable cells were measured by MTT cleavage during the last 4 hrs of 48 h 
cultures. Data shown are the mean +/- SD of experiments performed in triplicates. 
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Figure 3. GF-15 specifically induces spindle multipolarity, cell cycle arrest, and 
apoptosis in MM cells. (A) MM cell lines display multipolar spindles upon treatment 
with GF-15. NCI H929 (A’), OPM2 (A’’), and RPMI 8226 (A’’’) cells were exposed to 
GF-15 (3 M; 24 h) and stained for Eg5 (red), -tubulin (green), and DAPI (blue). (B) 
GF-15 selectively induces multipolar mitotic spindles in MM cells (NCI H929, OPM2, 
RPMI 8226; left to right) compared to three primary BMSCs. At least 200 mitotic cells 
were counted for spindle polarity after staining for -tubulin, Eg5, and DAPI. (C) 
Synchronized OPM2 cells arrest in G2/M phase upon treatment with GF-15 followed 
by increase of sub-G1 population (upper panel). Increase of sub-G1 cells is dose-
dependent (lower panel). OPM2 cells were cultured for indicated times to indicated 
concentrations of GF-15 and stained with propidium iodine after ethanol fixation. (D) 
GF-15 triggers apoptotic cell death in MM cells. OPM2 cells were exposed to 
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indicated concentrations of GF-15 for 24 h, followed either by immunoblot analysis of 
lysates with indicated antibodies or (E) ELISA-based assessment of activation of 
effector caspases 3 and 7. Identical treatment of BMSCs showed no significant 
induction of caspase 3/7 activation compared to OPM2 cells. Results are expressed 
as x-fold of control. (F) Co-treatment of MM cells with melphalan partially abrogates 
the growth inhibitory effects of GF-15. OPM2 cells were treated with indicated 
concentrations of GF-15 with or without 5 M melphalan for 48 h. MTT cleavage was 
measured during the last 4 hrs of 48 h cultures. 
Data shown are the mean +/- SD of experiments performed in triplicates. 
 
Figure 4. GF-15 abrogates the  growth advantage conferred by adhesion to 
BMSCs, and inhibits cytokine-triggered cell migration. (A-B) Indicated MM cell 
lines were cultured with or without BMSCs. GF-15 was added at indicated 
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concentrations and proliferation was measured by [3H]-thymidine uptake during the 
last 8 hrs of 24 h cultures. (C) GF-15 abrogates VEGF/FN- and IGF-1 – triggered 
MM-cell migration. Growth factor-deprived GF-15 treated (1, 3, 5 M) or untreated 
OPM2 cells were plated on either a fibronectin-coated or non-coated membrane (8 
m pore size) in a Boyden modified chamber and stimulated with the indicated 
cytokines. Cells in lower chamber were counted with Coulter counter ZBII after 6 hrs 
of treatment. Data shown are the mean +/- SD of experiments performed in 
triplicates, representative of three independent experiments. 
 
Figure 5. GF-15 is rapidly eliminated after intravenous injection. (A) Whole-body 
scintigraphic images of beige-nude-Xid mice at indicated times after intravenous 
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injection of the 125I-labeled GF-15 analogue. (B) Biodistribution of a 131I-labeled GF-
15 analogue at different times after intravenous administration to beige-nude Xid 
mice (n = 12). Data are expressed as mean %ID/g +/- SD of each time point.  
 
Figure 6. GF-15 induces mitotic aberrations, decreases tumor growth, and 
prolongs survival in a xenograft mouse model. Beige-nude Xid mice were 
subcutaneously inoculated in the right flank with 3 x 106 OPM2 cells. Treatment by 
intraperitoneal injection (vehicle alone or indicated concentrations) was started when 
tumors were measurable. Arrows indicates treatment stop. (A) Tumor burden was 
measured every alternating day using an electronic caliper. Tumor volume is 
presented as means +/- SE. (B) Survival was evaluated using Kaplan-Meier curves 
and log-rank analysis. (C) Body weight was evaluated three times per week. (D) In 
HE-stained tumor sections (n = 3 per cohort) at least 200 mitotic cells were counted 
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for mitotic aberrations. (E) Dose-dependent effects of GF-15 on mitotic figures. 
Paraffin-embedded sections of tumor tissue, explanted 24 hrs after last treatment, 
were HE-stained and analyzed by light microscopy. Representative microscopic 
images are shown. 
 
Suppl. figure 1. GF-15 does not induce spindle multipolarity in resistant cells 
SCC114 cells resistant to EC50 concentrations of GF15 after long-term culture under 
increasing concentrations of GF-15 do not display spindle multipolarity upon 
treatment with 5µM GF-15 for 24h. Centrosomes were counted in interphase by -
tubulin staining.  
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 S1 
Synthesis and Structure-Activity Relationship of Griseofulvin Analogues as Inhibitors 
of Centrosomal Clustering in Cancer Cells 
 
Mads H. Rønnest, Blanka Rebacz, Lene Markworth, Anette H. Terp, Alwin Krämer, Thomas O. Larsen, 
Mads H. Clausen 
Supporting Information 
 
 
S2  Combustion analysis (Table S1). 
S3-9 Experimental 
S10-S42 NMR spectra of 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 
26, 27, 28, 29, 30, 31, 32, 33, 34, 35. 
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Table S1. Combustion analysisbb. 
 
Compound Formula Anal. Calc’d Anal. found 
2 C16H15ClO6 C 56.73, H 4.46 56.75, 4.49 
7 C17H16ClNO8 C 51.33, H 4.05 51.20, 3.98 
10 C18H19ClO6 C 58.94, H 5.22 58.78, 5.20 
11 C19H21ClO6 C 59.92, H 5.56 59.86, 5.47 
12 C19H21ClO6 C 59.92, H 5.56 59.75, 5.60 
13 C20H23ClO6 C 60.84, H 5.87 60.71, 5.83 
14 C21H25ClO6 C 61.69, H 6.16 61.73, 5.99 
15 C22H27ClO6 C 62.48, H 6.44 62.39, 6.37 
16 C20H21ClO6 C 61.15, H 5.39 60.95, 5.45 
18 C16H14Cl2O5 C 53.80, H 3.95 53.69, 3.88 
21 C23H21ClO5S C 62.09, H 4.76 62.15, 4.78 
27 C19H21ClO6 C 57.23, H 5.93 57.27, 5.90 
28 C17H18ClNO6 C 55.52, H 4.93 55.60, 4.96 
35 C23H20ClIO6 C 49.80, H 3.63 49.73, 3.67 
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(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(6’-methyl-cyclohex-2’,4’-dione) 2. 
To a solution of griseofulvin (7.0 g, 19.8 mmol) in HOAc (50 mL) was added 2 M H2SO4 (13 mL). The 
mixture was stirred at 80 C for 45 min. where crystals of the product started to separate. The mixture was 
cooled to 20 °C, the product collected and then washed successively with cold EtOAc. The crystals were 
dried to afford griseofulvic acid 2. Yield: 6.2 g (93%) (white crystals); Rf (MeOH:DCM 1:9): 0.31; m.p.: 
262-263 °C (Litt.1); IR(KBr, cm1): 3244, 1657, 1606 (Litt.2); 1H NMR(500 MHz, DMSO-d6):  11.90 (1H, 
s), 6.46 (1H, s), 5.31 (1H, s), 4.03 (3H, s), 3.91 (3H, s), 2.89-2.70 (2H, m), 2.52-2.43 (1H, m), 0.85 (3H, d, J 
= 6.2 Hz) (Litt.3,17); 13C NMR(50 MHz, DMSO-d6):  191.1, 187.7, 179.3, 170.0, 164.1, 157.4, 104.3, 
101.4, 95.2, 94.3, 90.9, 57.5, 56.5, 34.4, 33.0, 14.2; Anal. [C16H15ClO6]: C, H. 
 
(2S,6’R)-(7-Chloro-6-methoxy-4-hydroxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-
en-4’-one) 4. 
A solution of 2 M MgI2 was prepared by adding magnesium turnings (0.88 g, 36.0 mmol) and iodine (4.49 
g, 17.7 mmol) to anhydrous Et2O (6 mL) and toluene (12 mL). This solution was refluxed at 80 °C for 2 h, 
ltered and added to a solution of griseofulvin (3.03 g, 8.5 mmol) in anhydrous toluene (20 mL) at 80 °C. 
The solution was cooled to 20 °C after 3 h. The mixture was diluted with EtOAc (50 mL) and washed with 
sat. aq. NH4Cl (40 mL) and then 10% aq. Na2S2O3 (40 mL). The combined aqueous phases were extracted 
with EtOAc (3×60 mL) and the organic layer was dried (MgSO4) and concentrated. The crude mixture was 
puried by reverse phase chromatography (C-18, MeOH and water gradient) yielding 4. Yield: 521 mg 
(18%) (yellow crystals); Rf (MeOH:CH2Cl2 1:9, 1% HOAc): 0.45; IR(KBr, cm): 1627, 1559; 1H NMR(500 
MHz, DMSO-d6):  7.68 (1H, s), 6.49 (1H, s), 5.58 (1H, s), 3.89 (3H, s), 3.62 (3H, s), 2.77 (1H, ddq, J = 
12.6, 6.5, 4.8 Hz), 2.67 (1H, dd, J = 16.3, 13.4 Hz), 2.33 (1H, dd, J = 16.3, 4.5 Hz), 0.80 (3H, d, J = 6.5 Hz) 
13C NMR(50 MHz, DMSO-d6):  195.9, 193.8, 171.1, 170.9, 166.5, 165.8, 106.6, 104.5, 97.3, 89.8 (2C), 
56.9, 56.5, 39.4, 35.9, 13.8; HRMS (ESI+) calcd for [C16H16ClO6]+ 339.0635, found 339.0633. 
 
General procedure for the synthesis of ring A ethers 5 and 6. 
To a solution of 4 (0.7 mmol, 1 equiv.) in DMF (3 mL, 0.2 M) was added NaH (0.7 mmol, 1 equiv.) and 
tetrabutylammonium iodide (0.1 mmol, 0.1 equiv.). The mixture was stirred at 100 °C and after 20 min. The 
alkyl bromide (1.1 mmol, 1.5 equiv.) was added. After 24 h the solution was diluted with EtOAc (20 mL) 
and washed with sat. aq. NH4Cl (20 mL). The aqueous phase was extracted with EtOAc (3×30 mL), the 
combined organic phases were dried (MgSO4) and concentrated. The residue was puried by column 
chromatography (EtOAc:heptane 1:2) affording the desired product, which was re-crystallized from 
CH2Cl2/heptane. 
 
(2S,6’R)-(7-Chloro-4-ethoxy-6-methoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-
en-4’-one) 5. 
Yield: 39 mg (15%) (white crystals); Rf (EtOAc:heptane 5:1): 0.55; m.p.: 205-206 °C (Litt.1); 1H NMR(500 
MHz, CDCl3):  6.12 (1H, s), 5.53 (1H, s), 4.25-4.15 (2H, m), 4.00 (3H, s), 3.61 (3H, s), 3.04 (1H, dd, J = 
16.8, 13.5 Hz), 2.84 (1H, ddq, J = 13.5, 4.7, 6.7 Hz), 2.42 (1H, dd, J = 16.8, 4.7 Hz), 1.52 (3H, t, J = 7.0 
Hz), 0.96 (3H, d, J = 6.7 Hz) (Litt.4); 13C NMR(50 MHz, CDCl3):  196.9, 192.2, 170.8, 169.5, 164.4, 
157.2, 105.6, 104.7, 97.0, 90.6, 90.3, 65.1, 56.9, 56.6, 40.0, 36.4, 14.3, 14.2; HRMS (ESI+) calcd for 
[C18H20ClO6]+ 367.0948, found 367.0944. 
 
(2S,6’R)-(7-Chloro-4-benzyloxy-6-methoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-
2’-en-4’-one) 6. 
Yield: 40 mg (14%) (white crystals); Rf (EtOAc:heptane 4:1): 0.69; m.p.: 237-239 °C (Litt.1); 1H NMR(500 
MHz, CDCl3):  7.49-7.46 (2H, m), 7.42-7.38 (2H, m), 7.36-7.31 (1H, m), 6.17 (1H, s), 5.55 (1H, s), 5.27 
(2H, s), 3.94 (3H, s), 3.63 (3H, s), 3.05 (1H, dd, J = 16.6, 13.6 Hz), 2.85 (1H, m), 2.44 (1H, dd, J = 16.6, 4.6 
Hz), 0.98 (3H, d, J = 6.7 Hz); 13C NMR(50 MHz, CDCl3):  196.9, 192.1, 170.8, 169.4, 164.3, 156.6, 135.4, 
128.8 (2C), 128.3, 126.8 (2C), 104.8 (2C), 97.4, 91.5, 90.7, 71.1, 56.9, 56.6, 40.0, 36.5, 14.4; HRMS (ESI+) 
calcd for [C23H22ClO6]+ 429.1105, found 429.1108. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-5-nitro-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-
ene-4’-one) 7. 
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To a solution of griseofulvin (2.0 g, 5.67 mmol) in acetic anhydride (10 mL) was slowly added a solution of 
nitric acid (2 mL) in acetic anhydride (4 mL) while maintaining the temperature at 0-5 C. The mixture was 
stirred at 20 C for 48 hours and then cooled to 0 C. A 20% HCl solution was added cautiously to the 
mixture until a yellow precipitate began to appear, cooling was continued to complete the precipitation of 
the product and the product was collected by filtration. Additional product was obtained by cautiously 
adding water to the mother liquor and collected by filtration. The residue was purified by column 
chromatography (EtOAc:heptane 1:2) to afford the product 7 which was re-crystallized from EtOAc. Yield: 
744 mg (33%) (yellow needles); Rf (EtOAc:heptane 5:1): 0.76; m.p.: 195-197 C (Litt.3); IR (KBr, cm-1): 
1719, 1669, 1617, 1577 (Litt.3); 1H NMR (300 MHz, CDCl3):  5.59 (1H, s),  4.22 (3H, s),  4.14 (3H, s),  
3.67 (3H, s),  2.99-2.95 (1H, m),  2.90-2.86 (1H, m),  2.49 (1H, dd, J = 14.5, 2.4 Hz),  0.98 (3H, d, J = 
6.4 Hz) (Litt.17); 13C NMR (75 MHz, CDCl3):  196.3, 192.5, 170.0, 169.6, 169.3, 157.4, 149.5, 105.2, 
108.9, 91.2, 91.1, 57.2, 64.5, 63.3, 40.0, 36.6, 14.5; EIMS [C17H16ClNO8] 397, found 397; Anal. 
(C17H16ClNO8) C, H. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-5-amino-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-
2’-ene-4’-one) 8. 
Powdered iron (1.458 g, 26.11 mmol) was added over 3 h to a stirred solution of 5-nitro griseofulvin 7 (744 
mg, 1.86 mmol) in 90% aq. acetic acid (18.6 mL). The mixture was refluxed for 1 h and cooled to 20 C 
where CH2Cl2 (12.6 mL) and then sat. aq. NaHCO3 was added until pH 7. The aqueous phase was extracted 
with CH2Cl2 (4×100 mL). The combined organic phases were dried (Na2SO4) and concentrated. The residue 
was purified by column chromatography (EtOAc:heptane 1:1) to afford the product 8 which was re-
crystallized from EtOAc/heptane. Yield: 369 mg (58%) (yellow crystals); Rf (EtOAc:heptane 5:2): 0.46; 
m.p.: 120-123 C (Litt.3); IR (KBr, cm-1): 3471, 3376, 1706, 1664 (Litt.3); 1H NMR (CDCl3):  5.53 (1H, s), 
4.06 (3H, s), 3.98 (3H, s), 3.84 (2H, s), 3.61 (3H, s), 2.95 (1H, dd, J = 16.2, 13.3 Hz), 2.87-2.75 (1H, m), 
2.41 (1H, dd, J = 16.2, 4.2 Hz), 0.91 (3H, d, J = 6.6 Hz) (Litt.3); 13C NMR (CDCl3):  196.8, 194.4, 171.3, 
162.1, 153.0, 142.5, 129.5, 110.0, 105.5, 105.2, 89.8, 62.5, 60.5, 56.9, 40.2, 36.8, 14.6; EIMS 
[C17H18ClNO6] 367, found 367. 
 
General procedure for the synthesis of enol ethers by solvolysis (10-15).  
CSA (0.1 mmol, 0.1 equiv.) was added to a solution of griseofulvic acid (0.6 mmol, 1 equiv.) in the 
appropriate alcohol (6 mL, 0.1 M). The mixture was stirred at 100 °C for 6 hours, and then cooled to 20 °C. 
EtOAc (20 mL) was added to the solution and the mixture was washed with sat. NaH2PO4 (20 mL) and then 
water (20 mL). The combined aqueous phases were extracted with EtOAc (3×20 mL), dried (MgSO4) and 
then concentrated. The residue was purified by column chromatography (toluene:CH2Cl2:EtOAc 7:7:1) to 
afford the desired product and the isomer. When possible the product was re-crystallized from 
EtOAc/Heptane. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-ethoxy-6’-methyl-cyclohex-2’-en-4’-on) 
10.
Yield: 32 mg (14%) (white crystals); Rf (EtOAc:heptane 5:1): 0.59; m.p.: 202-204 °C (Litt.5); IR(KBr, 
cm1): 1708, 1661, 1614 (Litt.6); 1H NMR(500 MHz, CDCl3):  6.12 (1H, s), 5.51 (1H, s), 4.03 (3H, s), 3.98 
(3H, s), 3.93-3.74 (2H, m), 3.02 (1H, dd, J = 16.7, 13.4 Hz), 2.91-2.76 (1H, m), 2.42 (1H, dd, J = 16.7, 4.7 
Hz), 1.21 (3H, t, J = 7.0 Hz), 0.96 (3H, d, J = 6.7 Hz) (Litt.4); 13C NMR(50 MHz, CDCl3):  197.1, 192.6, 
169.9, 169.6, 164.4, 157.6, 105.1 (2C), 97.1, 90.8, 89.3, 65.3, 56.9, 56.3, 39.9, 36.3, 14.2, 13.6; HRMS 
(ESI+) calcd for [C18H20ClO6]+ 367.0949, found 367.0960; Anal. (C18H19ClO6) C, H. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(6’-methyl-2’-propoxy-cyclohex-2’-en-4’-
on) 11.
Yield: 41 mg (18%) (white crystals); Rf (EtOAc:heptane 5:1): 0.64; m.p.: 151-153 °C (Litt.7) IR(KBr, cm1): 
1706, 1662, 1614 (Litt.6); 1H NMR(500 MHz, CDCl3):  6.13 (1H, s), 5.51 (1H, s), 4.04 (3H, s), 3.98 (3H, 
s), 3.79-3.66 (2H, m), 3.05 (1H, dd, J = 16.7, 13.5 Hz), 2.89-2.80 (1H, m), 2.42 (1H, dd, J = 16.7, 4.7 Hz), 
1.64-1.55 (2H, m), 0.97 (3H, d, J = 6.7 Hz), 0.82 (3H, t, J = 7.4 Hz); 13C NMR(50 MHz, CDCl3):  197.1, 
192.6, 170.0 (2C), 164.4, 157.6, 105.1, 104.8, 96.8, 90.8, 89.3, 70.7, 56.9, 56.3, 39.9, 36.2, 21.5, 14.2, 9.9; 
HRMS (ESI+) calcd for [C19H22ClO6]+ 381.1105, found 381.1105; Anal. (C19H21ClO6) C, H. 
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(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-isopropoxy-6’-methyl-cyclohex-2’-en-
4’-on) 12.
Yield: 50 mg (22%) (off-white crystals); Rf (EtOAc:heptane 5:1): 0.62; m.p.: 194-197 °C (Litt.1); IR(KBr, 
cm1): 1714, 1667, 1615 (Litt.6); 1H NMR(500 MHz, CDCl3):  6.12 (1H, s), 5.51 (1H, s), 4.33 (1H, sept., J 
= 6.1 Hz), 4.03 (3H, s), 3.98 (3H, s), 3.02 (1H, dd, J = 16.7, 13.4 Hz), 2.87-2.77 (1H, m), 2.41 (1H, dd, J = 
16.7, 4.7 Hz), 1.23 (3H, d, J = 6.1 Hz), 1.11 (3H, d, J = 6.1 Hz), 0.95 (3H, d, J = 6.7 Hz); 13C NMR(50 
MHz, CDCl3):  197.2, 192.6, 169.6, 169.0, 164.3, 157.5, 105.4 (2C), 97.0, 90.9, 89.2, 72.4, 56.9, 56.3, 
39.8, 36.2, 21.2, 20.7, 14.3; HRMS (ESI+) calcd for [C19H22ClO6]+ 381.1105, found 381.1119; Anal. 
(C19H21ClO6) C, H. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-butoxy-6’-methyl-cyclohex-2’-ene-4’-
one) 13.
Yield: 72 mg (14%) (white crystals); Rf (EtOAc:heptane 5:1): 0.41; m.p.: 152-154 C (Litt.7); IR (KBr, cm-
1): 1706, 1662, 1614; 1H NMR (300 MHz, CDCl3):  6.11 (1H, s),  5.50 (1H, s),  4.03 (3H, s),  3.97 (3H, 
s),  3.83-3.68 (2H, m),  3.03 (1H, dd, J = 16.5, 13.5 Hz),  2.79 (1H, ddq, J = 13.3, 6.6, 4.7 Hz),  2.41 
(1H, dd),  1.59-1.49 (2H, m),  1.28-1.19 (2H, m),  0.95 (3H, d, J = 6.7 Hz),  0.74 (3H, t, J = 7.4 Hz); 
13C NMR (75 MHz, CDCl3):  197.1, 192.9, 170.4, 169.5, 164.7, 157.9, 105.4, 105.2, 97.2, 91.1, 89.6, 69.5, 
57.2, 56.6, 40.2, 36.5, 30.2, 19.0, 14.5, 13.8; HRMS (ESI+) calcd for [C20H24ClO6]+ 395.1261, found 
395.1263; Anal. (C20H23ClO6) C, H.
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(6’-methyl-2’-pentoxy-cyclohex-2’-ene-4’-
one) 14.
Yield: 392 mg (17%) (white crystals); Rf (EtOAc:heptane 5:1): 0.52; m.p.: 146-148 C (Litt.7); IR (KBr, cm-
1): 1701, 1653, 1613; 1H NMR (300 MHz, CDCl3):  6.11 (1H, s), 5.48 (1H, s), 4.02 (3H, s), 3.96 (3H, s), 
3.79-3.66 (2H, m), 3.03 (1H, dd, J = 16.5, 13.5 Hz), 2.82 (1H, ddq, J = 13.5, 6.8, 4.7 Hz), 2.40 (1H, dd, J = 
16.5, 4.6 Hz), 1.61-1.51 (2H, m), 1.20-1.15 (4H, m), 0.95 (3H, d, J = 6.7 Hz), 0.77 (3H, t, J = 6.8 Hz); 13C 
NMR (75 MHz, CDCl3):  197.2, 192.8, 170.4, 169.9, 164.7, 157.9, 105.4, 105.1, 97.4, 91.1, 89.5, 69.8, 
57.2, 56.6, 40.2, 36.4, 28.0, 27.9, 22.3, 14.5, 14.1; HRMS (ESI+) calcd for [C21H26ClO6]+ 409.1418, found 
409.1412; Anal. (C21H25ClO6) C, H. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-hexoxy-6’-methyl-cyclohex-2’-ene-4’-
one) 15.
Yield: 450 mg (19%) (white crystals); Rf (EtOAc:heptane 5:1): 0.52; m.p.: 152-154 C (Litt.7); IR (KBr, cm-
1): 1701, 1663, 1616; 1H NMR (300 MHz, CDCl3):  6.11 (1H, s), 5.50 (1H, s), 4.03 (3H, s), 3.97 (3H, s), 
3.83-3.66 (2H, m), 3.04 (1H, dd, J = 16.5, 13.5 Hz), 2.83 (1H, ddq, J = 13.3, 6.6, 4.6 Hz), 2.41 (1H, dd, J = 
16.5, 4.6 Hz), 1.61-1.49 (2H, m), 1.25-1.16 (6H, m), 0.96 (3H, d, J = 6.7 Hz), 0.80 (3H, t, J = 6.9 Hz); 13C 
NMR (75 MHz, CDCl3):  197.2, 192.8, 170.4, 169.8, 164.7, 157.9, 105.5, 105.1, 97.6, 91.1, 89.5, 69.7, 
57.2, 56.6, 40.2, 36.4, 31.3, 28.2, 25.4, 22.6, 14.5, 14.0; HRMS (ESI+) calcd for [C22H28ClO6]+ 423.1574, 
found 423.1560; Anal. (C22H27ClO6) C, H. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-chloro-6’-methyl-cyclohex-2’-ene-4’-
one) 18. 
Griseofulvic acid (11.3 g, 31.6 mmol) was mixed with LiCl (4.2 g, 0.101 mol) and added to a solution of 
POCl3 (15.6 mL, 0.168 mol) in dioxane (40 mL). The mixture was stirred at 100 C for 30 min, cooled to 0 
C and sat. aq. Na2CO3 was added carefully to the solution until slightly basic (pH 7-8). The aqueous phase 
was extracted with CH2Cl2 (4×300 mL) and the combined organic phases were dried (MgSO4) and 
concentrated. The residue was purified by column chromatography (toluene:CH2Cl2:EtOAc 35:35:1) 
affording the desired product 18 and the isomer. The product was re-crystallized from CH2Cl2/heptane. 
Yield: 234 mg (44%) (white crystals); Rf (EtOAc:heptane 5:1): 0.51; m.p.: 196-198 C (Litt.8); IR (KBr, cm-
1): 1698, 1615 (Litt.8); 1H NMR (300 MHz, CDCl3):  6.41 (1H, s), 6.14 (1H, s), 4.03 (3H, s), 3.98 (3H, s), 
3.12 (1H, dd, J = 16.7, 13.9 Hz), 2.89 (1H, ddq, J = 13.5, 4.4, 6.7 Hz), 2.45 (1H, dd, J = 16.7, 4.4 Hz), 0.98 
(3H, J = 6.7 Hz); 13C NMR (50 MHz, CDCl3):  195.0, 191.1, 169.3, 165.3, 158.1, 152.9, 131.6, 105.4, 
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97.6, 91.7, 90.0, 57.3, 56.7, 40.3, 37.8, 15.2; EIMS calcd for [C16H14Cl2O5] 356, found 356; Anal. 
(C16H14Cl2O5) C, H. 
 
General procedure for the synthesis of enol ethers by addition-elimination. (19-21).
To a solution of 18 (0.65 mmol, 1 equiv.) in 1,4-dioxane (3 mL, 0.2 M) was added the desired alcohol (1.30 
mmol, 2 equiv.) and DBU (1.63 mmol, 2.5 equiv.). The mixture was heated to 100 C and stirred for 12 h. 
The mixture was then cooled to 20 C and excess reagent was quenched with sat. aq. NH4Cl (30 mL). The 
aqueous phase was extracted with EtOAc (3×30 mL) and the combined organic phases were dried (MgSO4) 
and then concentrated. The residue was purified by column chromatography (heptane:EtOAc 3:2) affording 
the product. When possible the product was re-crystallized from EtOAc/heptane. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(6’-methyl-2’-phenoxy-cyclohex-2’-ene-
4’-one) 19.
Yield: 199 mg (86%); Rf (EtOAc:heptane 5:1); 0.50; IR (KBr, cm-1): 1704, 1665; 1H NMR(300 MHz, 
CDCl3):  7.36-7.29 (2H, m), 7.22-7.16 (1H, m), 7.00-6.95 (2H, m), 6.13 (1H, s), 5.30 (1H, s), 4.01 (3H, s), 
3.99 (3H, s) 3.06 (1H, dd, J = 16.0, 13.5 Hz), 2.99-2.85 (1H, m), 2.42 (1H, dd, J = 16.0, 4.0 Hz), 1.01 (3H, 
d, J = 6.5 Hz); 13C NMR(75 MHz, CDCl3); 197.0, 192.3, 170.9, 169.6, 164.8, 157.8, 152.6, 130.0 (2C), 
126.3, 121.1 (2C), 108.8, 105.2, 97.2, 90.6, 89.5, 57.0, 56.4, 40.3, 36.5, 14.3; HRMS (ESI+) calcd for 
[C22H20ClO6]+ 415.0948, found 415.0941. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-benzyloxy-6’-methyl-cyclohex-2’-en-
4’-one) 20.  
Yield: 30 mg (55%) (white crystals); Rf (EtOAc:heptane 5:1): 0.49; m.p.: 186-188 °C (Litt.1); 1H NMR(300 
MHz, CDCl3):  7.32-7.24 (3H, m), 7.20-7.16 (2H, m), 6.11 (1H, s), 5.60 (1H, s), 4.02 (3H, s), 3.96 (3H, s), 
4.92 (1H, d, J = 12.3 Hz), 4.82 (1H, d, J = 12.3 Hz), 3.06 (1H, dd, J = 16.7, 13.4 Hz), 2.87 (1H, ddq, J = 
13.4, 6.7, 4.8 Hz), 2.44 (1H, dd, J = 16.7, 4.8 Hz), 0.99 (3H, d, J = 6.7 Hz); 13C NMR(50 MHz, CDCl3):  
196.9, 192.3, 169.5 (2C), 164.5, 157.7, 134.6, 128.5 (2C), 128.1, 126.6 (2C), 105.9, 105.2, 97.2, 90.7, 89.4, 
70.6, 56.9, 56.3, 40.0, 36.6, 14.2; HRMS (ESI+) calcd for [C23H22ClO6]+ 429.1105, found 429.1103. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-benzylthio-6’-methyl-cyclohex-2’-ene-
4’-one) 21.
Yield: 349 mg (93%) (white crystals); Rf (EtOAc:heptane 5:1): 0.44; m.p.: 208-210 C (Litt.8); IR (KBr, cm-
1): 1703, 1663 (Litt.8); 1H NMR (300 MHz, DMSO-d6):  7.33-7.27 (5H, m), 6.51 (1H, s), 6.09 (1H, s), 4.17 
(1H, d, J = 12.5 Hz), 4.05 (1H, d, J = 12.5 Hz), 4.03 (3H, s), 3.95 (3H, s), 2.95-2.83 (1H, m), 2.68 (1H, dd, 
J = 17.3, 13.3 Hz), 2.40 (1H, dd, J = 17.2, 5.3 Hz), 0.77 (3H, d, J = 6.6 Hz); 13C NMR (75 MHz, DMSO-
d6):  193.4, 191.1, 168.5, 165.2, 160.5, 158.4, 135.3, 129.8 (2C), 129.4 (2C), 128.4, 122.6, 104.1, 95.8, 
92.3, 92.2, 58.3, 57.3, 49.9, 37.4, 35.4, 14.9; HRMS (ESI+) calcd for [C23H22ClO5S]+ 445.0877, found 
445.0872; Anal. (C23H21ClO5S) C, H. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-en-4’-
ol) 26. 
A solution of griseofulvin (212 mg, 0.6 mmol) in MeOH (3 mL) was cooled to –40 °C. CeCl3 (448 mg, 1.8 
mmol) was added and the solution stirred for 10 min. after which NaBH4 (70 mg, 1.8 mmol) was added. 
After 3 h excess reagent was quenched by the slow addition of acetone (3 mL) and the mixture was allowed 
to reach 20 °C, diluted with EtOAc (10 mL) and washed with water (20 mL). The aqueous phase was 
extracted with EtOAc (5×30 mL) and the combined organic phases were dried (MgSO4) and concentrated. 
The compound 26 was re-crystallized from MeOH. Yield: 209 mg (98%) (white crystals); Rf 
(EtOAc:heptane 5:1): 0.25; m.p.: 110-113 °C. (Litt.9); 1H NMR(300 MHz, CDCl3):  6.08 (1H, s), 5.11 (1H, 
d, J = 1.9 Hz), 4.45 (1H, ddd, J = 9.3, 5.8, 1.9 Hz), 4.00 (3H, s), 3.96 (3H, s), 3.44 (3H, s), 2.37 (1H, ddq, J 
= 13.1, 3.4, 6.8 Hz), 2.10 (1H, dt, J = 9.3, 13.1 Hz), 2.00 (1H, dddd, J = 13.1, 5.8, 3.4, 0.9 Hz), 0.87 (3H, d, 
J = 6.8 Hz); 13C NMR (from gHSQC, gHMBC, 500 MHz, CDCl3):  195.5, 169.6, 164.8, 157.0, 152.6, 
105.8, 105.5, 96.9, 92.0, 88.8, 65.9, 56.5, 56.1, 55.0, 36.3, 35.6, 14.2; EIMS [C17H19ClO6] M+ 354, found 
354. 
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(2S,2’S,4’S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohexan-
4’-ol) 27. 
To a solution of griseofulvin (107 mg, 0.3 mmol) in MeOH (3 mL) was added 5% Pt on charcoal (24 mg). 
The mixture was stirred at 20 C for 12 h under a hydrogen atmosphere. EtOAc (20 mL) was added and the 
mixture was filtered, dried (MgSO4), concentrated and purified by column chromatography (EtOAc:heptane 
1:1). The product 27 was re-crystallized from EtOAc/heptane. Yield: 94 mg (86%) (white crystals); Rf 
(EtOAc:heptane 4:1): 0.27; m.p.: 188-190 C (Litt.10); IR(KBr, cm1): 1696; 1H NMR(500 MHz, CDCl3):  
6.06 (1H, s), 3.99 (3H, s), 3.94 (3H, s), 3.83-3.70 (1H, m), 3.62 (1H, dd, J = 12.0, 5.1 Hz), 3.27 (3H, s), 2.29 
(1H, m), 2.24 (1H, q, J = 12.0 Hz), 2.09 (2H, m), 1.90-1.78 (1H, m), 0.82 (3H, d, J = 6.1 Hz); 13C NMR(50 
MHz, CDCl3):  195.8, 169.0, 163.6, 156.9, 107.7, 96.6, 94.8, 88.6, 81.5, 67.4, 58.4, 56.7, 56.0, 37.4, 35.0, 
34.9, 14.1; Anal. (C17H21ClO6): C, H. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-ene-
4’-one-4’-oxime) 28. 
To a solution of 1 (0.20 mmol, 1.0 equiv.) in EtOH (5 mL, 0.03M) and DMSO (2.5 mL, 0.03M) was added 
hydroxylamine hydrochloride (0.70 mmol, 3.5 equiv.) and sodium acetate (0.86 mmol, 4.3 equiv.). The 
mixture was stirred at 75 C for 24 hours, allowed to reach 20 C and diluted with CH2Cl2 (20 mL). The 
mixture was washed with distilled water (215 mL) and then brine (15 mL). The organic phase was dried 
(MgSO4) and concentrated. The crude mixture was purified by column chromatography 
(toluene:CH2Cl2:EtOAc 2:2:1) to afford the desired product. 
Yield: 988 mg (95%) (white needles); Rf (MeOH:CH2Cl2 1:10): 0.50; IR (KBr, cm-1): 1706, 1590, 1614 
(Litt.3); 1H NMR (300 MHz, CDCl3):  6.26 (0.5H, s), 6.10 (0.5H, s), 6.10 (0.5H, s), 5.59 (0.5H, s), 4.01 
(3H, s), 3.96 (1.5H, s), 3.96 (1.5H, s), 3.61 (1.5H, s), 3.55 (1.5H, s), 3.12 (0.5H, dd, J = 16.6, 4.7 Hz), 2.99 
(0.5H, dd, J = 15.0, 13.1 Hz), 2.70 (0.5H, dd, J = 16.6, 13.0 Hz), 2.64-2.48 (1H, m), 2.40 (0.5H, dd, J = 
15.0, 4.2 Hz), 0.95 (1.5H, d, J = 6.7 Hz), 0.94 (1.5H, d, J = 6.7 Hz) (Litt.3); 13C NMR (75 MHz, CDCl3):  
194.1 (0.5C), 193.9 (0.5C), 169.4 (0.5C), 169.4 (0.5C), 164.3 (0.5C), 164.2 (0.5C), 161.3 (0.5C), 158.6 
(0.5C), 157.5 (0.5C), 157.4 (0.5C), 155.0 (0.5C), 151.8 (0.5C), 105.6 (0.5C), 105.5 (0.5C), 98.9 (0.5C), 
97.1, 92.6 (0.5C), 91.4 (0.5C), 91.3 (0.5C), 89.1, 56.9 (0.5C), 56.9 (0.5C), 56.3, 56.1 (0.5C), 55.9 (0.5C), 
36.4 (0.5C), 35.2 (0.5C), 30.8 (0.5C), 25.5 (0.5C), 14.3 (0.5C), 14.2 (0.5C); HRMS (ESI+) calcd for 
[C17H19ClNO6]+ 368.0901, found 368.0891; Anal. (C17H18ClNO6) C, H. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(3’,3’,6’-trimethyl-cyclohex-2’,4’-dione) 
31. 
To a solution of griseofulvin (514 mg, 1.5 mmol) in THF (10 mL) was added K2CO3 (410 mg, 3.0 mmol) 
and MeI (0.2 mL, 3.1 mmol) and the mixture was heated to 80 °C. The solution was cooled to 20 °C after 12 
h. The reaction was quenched with sat. aq. NH4Cl (30 mL) and the aqueous phase was extracted with EtOAc 
(3×30 mL). The combined organic phases were dried (MgSO4), concentrated and the residue was purified by 
column chromatography (EtOAc:heptane 1:6) affording the product 31. Yield: 75 mg (14%) (yellow oil); Rf 
(EtOAc:heptane 5:1): 0.65; IR(KBr, cm-1): 1695, 1615; 1H NMR(500 MHz, CDCl3):  6.11 (1H, s), 4.02 
(3H, s), 3.94 (3H, s), 3.44-3.39 (1H, m), 2.88-2.77 (2H, m), 1.39 (3H, s), 1.36 (3H, s), 1.05 (3H, d, J = 6.5 
Hz); 13C NMR(75 MHz, CDCl3):  207.2, 201.6, 190.8, 169.2, 164.8, 157.9, 104.5, 97.3, 96.0, 89.6, 60.2, 
57.0, 56.3, 40.4, 32.2, 23.6, 23.5, 14.6; EIMS [C18H19ClO6] 366, found 366. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(3’-benzyl-6’-methyl-cyclohex-2’,4’-
dione) 32. 
A solution of griseofulvic acid (5.0 g, 0.015 mol) in H2O (7.4 mL) containing KOH (0.832 g, 0.015 mol) and 
NaI (2.22 g, 0.015 mol) was heated to reflux with copper powder (188 mg, 2.97 mmol) and benzyl bromide 
(2.54 g, 0.015 mol) for 24 hours. The mixture was cooled to 20 C and the precipitate was filtered off. The 
filtrate was extracted with EtOAc (3×10 mL) and the organic phase was washed with sat. aq. NaHCO3. The 
aqueous phase was acidified with 2M HCl and then extracted with EtOAc (3×50 mL). The combined 
organic phases were dried (MgSO4) and concentrated. The residue was purified by column chromatography 
(toluene:CH2Cl2:EtOAc 10:10:1) to yield the product 32 which was re-crystallized from CH2Cl2/heptane. 
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Yield: 533 mg (8%) (white crystals); Rf (EtOAc:heptane 5:1): 0.33; m.p.: 202-204 C (Litt.11); IR (KBr, cm-
1): 1702, 1616 (Litt.11); 1H NMR (300 MHz, DMSO-d6):  11.6 (1H, s), 7.21-7.16 (2H, m), 7.10-7.05 (3H, 
m), 6.43 (1H, s), 4.01 (3H, s), 3.88 (3H, s), 3.50 (1H, d, J = 14.6 Hz), 3.41 (1H, d, J = 14.6 Hz), 2.92 (1H, 
dd, J = 16.5, 11.5 Hz), 2.81-2.70 (1H, m), 2.63 (1H, dd, J = 16.5, 5.2 Hz), 0.84 (3H, d, J = 6.4 Hz); 13C 
NMR (75 MHz, DMSO-d6):  190.7, 190.6, 174.4, 168.5, 163.5, 156.9, 140.4, 127.5 (2C), 127.4 (2C), 
124.9, 103.8, 95.0, 94.3, 90.4, 90.3, 57.0, 56.0, 34.0, 32.5, 27.3, 13.9; HRMS (ESI+) calcd for 
[C23H22ClO6]+ 429.1105, found 429.1108. 
 
General procedure for the synthesis of 3’ iodo analogues (33-35).
To an ice-cooled solution of griseofulvin (1.4 mmol, 1 equiv.) and N-iodosuccinimide (2.1 mmol, 1.5 equiv.) 
in anhydrous CH2Cl2 (15 mL, 0.1 M) under an argon atmosphere, was added triethylsilyl 
trifluoromethanesulfonate (0.35 mmol 0.25 equiv.). The mixture was stirred at 20 C for 24 h and then 
diluted with CH2Cl2 (60 mL) and washed with sat. aq. NaHCO3 (60 mL). The aqueous phase was extracted 
with CH2Cl2 (50 mL), the combined organic phases were dried (MgSO4) and concentrated. The residue was 
purified by column chromatography (EtOAc:heptane 1:3) to yield the desired product. When possible the 
product was re-crystallized from EtOAc/heptane. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(3’-iodo-2’-methoxy-6’-methyl-cyclohex-
2’-ene-4’-one) 33.
Yield: 126 mg (19%) (white crystals); Rf (EtOAc:heptane 5:1): 0.77; m.p.: 188-190 C (Litt.12); IR (KBr, 
cm-1): 1717, 1664 (Litt.12); 1H NMR (300 MHz, CDCl3):  5.56 (1H, s), 4.10 (3H, s), 4.01 (3H, s), 3.63 (3H, 
s), 2.95 (1H, dd, J = 15.6, 13.3 Hz), 2.90-2.79 (1H, m), 2.46 (1H, dd, J = 15.6, 3.6 Hz), 0.94 (3H, d, J = 6.4 
Hz); 13C NMR (75 MHz, CDCl3):  196.7, 192.5, 170.8, 170.3, 164.6, 157.0, 106.3, 105.4, 97.1, 91.1, 82.1, 
63.1, 61.4, 57.1, 40.1, 36.7, 14.6; HRMS (ESI+) calcd for [C17H17ClIO6]+ 478.9758, found 478.9761. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(3’-iodo-6’-methyl-2’-propoxy-cyclohex-
2’-ene-4’-one) 34.
Yield: 49 mg (19%) (yellow crystals); Rf (EtOAc:heptane 5:1): 0.53; m.p.: 98-100 C (Litt.12); IR (KBr, cm-
1): 1719, 1618 (Litt.12); 1H NMR (500 MHz, CDCl3):  6.13 (1H, s), 4.14-4.11 (2H, m), 4.03 (3H, s), 4.00 
(3H, s), 3.80-3.73 (1H, m), 2.94-2.87 (1H, m), 2.92-2.90 (1H, m), 1.75-1.68 (2H, m), 1.05 (3H, d, J = 5.8 
Hz), 1.00 (3H, t, J = 7.4 Hz); 13C NMR (75 MHz, CDCl3):  196.7, 192.1, 188.0, 172.3, 172.3, 165.5, 158.3, 
112.2, 103.8, 97.9, 90.1, 67.9, 57.4, 56.8, 39.4, 38.2, 22.3, 12.2, 10.8; HRMS (ESI+) calcd for 
[C19H21ClIO6]+ 507.0071, found 507.0069. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(3’-iodo-2’-benzyloxy-6’-methyl-
cyclohex-2’-ene-4’-one) 35.
Yield: 56 mg (17%) (white crystals); Rf (EtOAc:heptane 5:1): 0.88; m.p.: 172-175 C (Litt.12); IR (KBr, cm-
1): 1715, 1666 (Litt.12); 1H NMR (300 MHz, CDCl3):  7.27-7.22 (3H, m), 7.12-7.10 (2H, m), 5.59 (1H, s), 
4.90 (1H, d, J = 12.3 Hz), 4.81 (1H, d, J = 12.3 Hz), 4.07 (3H, s), 3.95 (3H, s), 2.95 (1H, dd, J = 15.5, 13.2 
Hz), 2.88-2.81 (1H, m), 2.44 (1H, dd, J = 15.4, 3.3 Hz), 0.95 (3H, d, J = 6.4 Hz); 13C NMR (75 MHz, 
CDCl3):  196.7, 192.6, 170.9, 168.9, 164.6, 157.0, 134.6, 128.9 (2C), 128.7, 126.9 (2C), 110.4, 106.5, 
106.2, 91.2, 82.0, 71.1, 63.1, 61.4, 40.2, 36.5, 14.6; HRMS (ESI+) calcd for [C23H21ClIO6]+ 555.0071, found 
555.0071; Anal. (C23H20ClIO6) C, H. 
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(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(6’-methyl-cyclohex-2’,4’-dione) 2
1H NMR (500 MHz, DMSO-d6) 
 
 
13C NMR (50 MHz, CDCl3) 
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(2S,6’R)-(7-Chloro-6-methoxy-4-hydroxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-en-4’-one) 4
1H NMR (500 MHz MHz, DMSO-d6) 
 
13C NMR (50 MHz, CDCl3)  
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 S12 
(2S,6’R)-(7-Chloro-4-ethoxy-6-methoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-en-4’-one) 5
1H NMR (500 MHz, CDCl3) 
 
13C NMR (50 MHz, CDCl3) 
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 S13 
(2S,6’R)-(7-Chloro-4-benzyloxy-6-methoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-en-4’-one) 6
1H NMR (500 MHz, CDCl3) 
13C NMR (50 MHz, CDCl3)  
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 S14 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-5-nitro-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-ene-4’-one) 7
1H NMR (300 MHz, CDCl3) 
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 S15 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-5-amino-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-ene-4’-one) 8
1H NMR (300 MHz, CDCl3) 
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ppm (f1)
050100150200
0
500
1000
1500
2000
2500
O
Cl
O
O
O
O
O
H2N
161
177
 S16 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-5-benzylamino-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-ene-4’-one) 9
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (75 MHz, CDCl3) 
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 S17 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-ethoxy-6’-methyl-cyclohex-2’-en-4’-on) 10
1H NMR (500 MHz, CDCl3) 
 
13C NMR (50 MHz, CDCl3) 
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 S18 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(6’-methyl-2’-propoxy-cyclohex-2’-en-4’-on) 11 
1H NMR (500 MHz, CDCl3) 
 
13C NMR (50 MHz, CDCl3) 
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 S19 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-isopropoxy-6’-methyl-cyclohex-2’-en-4’-on) 12 
1H NMR (500 MHz, CDCl3) 
13C NMR (50 MHz, CDCl3) 
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 S20 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-butoxy-6’-methyl-cyclohex-2’-ene-4’-one) 13
1H NMR (300 MHz, CDCl3) 
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 S21 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(6’-methyl-2’-pentoxy-cyclohex-2’-ene-4’-one) 14
1H NMR (300 MHz, CDCl3) 
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 S22 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-hexoxy-6’-methyl-cyclohex-2’-ene-4’-one) 15
1H NMR (300 MHz, CDCl3) 
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 S23 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-cyclopropylmethoxy-6’-methyl-cyclohex-2’-en-4’-one) 16
1H NMR (500 MHz, CDCl3) 
13C NMR (50 MHz, CDCl3) 
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 S24 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-cyclopentoxy-6’-methyl-cyclohex-2’-en-4’-one) 17
1H NMR (500 MHz, CDCl3) 
 
 13C NMR (50 MHz, CDCl3) 
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 S25 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-chloro-6’-methyl-cyclohex-2’-ene-4’-one) 18
1H NMR (300 MHz, CDCl3) 
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 S26 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(6’-methyl-2’-phenoxy-cyclohex-2’-ene-4’-one) 19
1H NMR (300 MHz, CDCl3) 
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 S27 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-benzyloxy-6’-methyl-cyclohex-2’-en-4’-one) 20 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
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 S28 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-benzylthio-6’-methyl-cyclohex-2’-ene-4’-one) 21
1H NMR (300 MHz, CDCl3) 
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 S29 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-(2-phenylethoxy)-6’-methyl-cyclohex-2’-en-4’-one) 22 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
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 S30 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-4-methylbenzyloxy-6’-methyl-cyclohex-2’-ene-4’-one) 23 
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
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 S31 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-(4-biphenylmethoxy)-6’-methyl-cyclohex-2’-ene-4’-one) 24
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
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 S32 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-(1-adamantylmethoxy)-6’-methyl-cyclohex-2’-ene-4’-one) 
25 
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (50 MHz, CDCl3) 
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 S33 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-en-4’-ol) 26 
1H NMR (300 MHz, CDCl3) 
 
Carbon shifts from gHSQC, gHMBC
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 S34 
(2S,2’S,4’S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohexan-4’-ol) 27
1H NMR (500 MHz, CDCl3) 
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 S35 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-ene-4’-one-4’-oxime) 28 
1H NMR (300 MHz, CDCl3) 
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 S36 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-benzyloxy-6’-methylcyclohex-2’-ene-4’-one-4’-oxime) 29
1H NMR (300 MHz, CDCl3) 
 
 
13C NMR (75 MHz, CDCl3) 
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 S37 
(2S,6’R,E)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-2’-ene-4’-one-4’-
dimethylhydrazine) 30
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
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 S38 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(3’,3’,6’-trimethyl-cyclohex-2’,4’-dione) 31 
1H NMR (500 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
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 S39 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(3’-benzyl-6’-methyl-cyclohex-2’,4’-dione) 32
1H NMR (300 MHz, CDCl3) 
 
13C NMR (75 MHz, CDCl3) 
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 S40 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(3’-iodo-2’-methoxy-6’-methyl-cyclohex-2’-ene-4’-one) 33
1H NMR (300 MHz MHz, CDCl3) 
 
13C NMR (50 MHz, CDCl3) 
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 S41 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(3’-iodo-6’-methyl-2’-propoxy-cyclohex-2’-ene-4’-one) 34
1H NMR (500 MHz, CDCl3) 
ppm (f1)
1.02.03.04.05.06.07.0
0
100
200
300
400
500
600
700
O
Cl
O
O
O
O
O I
13C NMR (75 MHz, CDCl3) 
187
203
 S42 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(2’-benzyloxy-3’-iodo-6’-methyl-cyclohex-2’-ene-4’-one) 35
1H NMR (300 MHz, CDCl3) 
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Disparate SAR Data of Griseofulvin Analogs for the Dermatophytes Trichophyton mentagrophytes, T.
rubrum and MDA-MB-231 Cancer Cells 
Mads H. Rønnest, Marc S. Raab, Simon Anderhub, Sven Boesen, Alwin Krämer, Thomas O. Larsen,* Mads 
H. Clausen*
Supporting Information 
S2-S3  Experimental for compounds 3, 39-41 and 44.
S4-S27  NMR spectra of 3, 7, 8, 15, 19, 21, 22, 26, 28-35 and 38-44.
S28-S41  UPLC-DAD chromatograms of all tested compounds. 
S42 Figure S1 and S2. 
S43  References. 
S1
191
207
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(6’-methyl-cyclohex-2’,4’-dione) 2
 
Griseofulvic acid (2) (3.0 mmol, 1 equiv.) was mixed with LiCl (15 mmol, 5 equiv.) and added to a solution 
of POCl3 (15 mmol, 5 equiv.) in dioxane (14 mL). The mixture was stirred at 100 °C for 30 min, cooled to 0 
°C and sat. aq. Na2CO3 was added carefully to the solution until slightly basic (pH 7-8). The aqueous phase 
was extracted with CH2Cl2 (3×20 mL) and the combined organic phases were dried (MgSO4) and 
concentrated. The residue was purified by column chromatography (toluene:CH2Cl2:EtOAc 35:35:1) 
affording the desired products 15 and 16. 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-one)-2-spiro-1’-(4’-chloro-6’-methyl-cyclohex-3’-en-2’-
one) 15 
Yield: 588 mg (55 %) (white crystals); Rf-value (EtOAc/heptane, 5:1): 0.63; m.p. 241-243 C (Litt.1); IR 
(neat, cm-1): 1699, 1677, 1614, 1596, 1581 (Litt.1); 1H NMR (CDCl3, 300 MHz):  6.28 (1H, d, J = 2.2 Hz), 
6.10 (1H, s), 4.01 (3H, s), 3.94 (3H, s), 3.40 (1H, ddd, J = 18.5, 11.2, 2.2 Hz), 2.93 (1 H, ddq, J = 11.2, 5.7, 
6.7 Hz), 2.75 (1H, dd, J = 18.5, 5.7 Hz), 1.04 (3H, d, J = 6.7 Hz); 13C NMR (CDCl3, 50 MHz):  190.3, 
187.0, 169.5, 164.6, 160.0, 157.8, 125.3, 104.7, 97.5, 94.6, 89.6, 57.0, 56.3, 38.6, 36.5, 14.2; []20D = +269° 
(c = 0.5 in CHCl3); HRMS (ESI+) calcd for M+H [C16H14Cl2O5]+ 357,0297, found 357,0304; Anal. Calcd 
for C16H14Cl2O5: C, 53.80; H, 3.95. Found: C, 53.69; H, 3.88. 
General Procedure for the Synthesis of Enol Ethers by Solvolysis (39-41 and 44).
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(4’-methoxy-6’-methyl-cyclohex-3’-en-2’-
one) 3 
 
Yield: 116 mg (22 %) (white crystals); Rf-value (EtOAc/heptane, 5:1): 0.48; m.p. 197-198 C (Litt.5); IR 
(neat, cm-1): 1701, 1657, 1607, 1589; 1H NMR (CDCl3, 300 MHz):  6.07 (1H, s), 5.44 (1H, s, J = 1.5 Hz), 
4.00 (3H, s), 3.91 (3H, s), 3.76 (3H, s), 3.18 (1H, ddd, J = 17.5, 12.0, 1.5 Hz), 2.83 (1H, m), 2.46 (1H, dd, J 
= 17.5, 5.7 Hz), 1.01 (3H, d, J = 6.7 Hz) (Litt.5); 13C NMR (CDCl3, 50 MHz):  191.6, 188.6, 178.8, 169.7, 
164.3, 157.6, 105.1, 99.6, 97.3, 95.1, 89.4, 56.9, 56.2 (2C), 35.1, 32.6, 14.4; []20D = +142° (c = 0.3 in 
CHCl3); HRMS (ESI+) calcd for [M+H]+ [C17H18ClO6]+ 353.0792, found 353.0790; Anal. Calcd for 
C17H17ClO6: C, 57.88; H, 4.86. Found: C, 57.75; H, 4.60. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(4’-ethoxy-6’-methyl-cyclohex-3’-en-2’-
one) 39 
 
Yield: 145 mg (64 %) (white crystals); Rf-value (EtOAc/heptane, 5:1): 0.67; m.p. 167-168 C (Litt.2); IR 
(neat, cm-1): 1703, 1657, 1609, 1589 (Litt.3); 1H NMR (CDCl3, 300 MHz):  6.08 (1H, s), 5.41 (1H, d, J = 
1.2 Hz), 4.00 (3H, s), 3.98 (2H, q, J = 7.0 Hz), 3.92 (3H, s), 3.18 (1H, ddd, J = 17.6, 12.1, 1.2 Hz), 2.84 (1H, 
ddq, J = 12.1, 5.7, 6.7 Hz), 2.45 (1H, dd, J = 17.6, 5.7 Hz), 1.39 (3H, t, J = 7.0 Hz), 1.02 (3H, d, J = 6.7 Hz); 
13C NMR (CDCl3, 50 MHz):  191.7, 188.8, 178.0, 169.6, 164.3, 157.6, 105.1, 99.9, 97.2, 95.0, 89.4, 64.9, 
S2
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56.9, 56.2, 35.1, 33.2, 14.4, 14.0; []20D = +198° (c = 0.4 in CHCl3); Anal. Calcd for C18H19ClO6: C, 58.94; 
H, 5.22. Found: C, 58.78; H, 5.20.  
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(4’-propoxy-6’-methyl-cyclohex-3’-en-2’-
one) 40 
 
Yield: 146 mg (63%) (white crystals); Rf-value (EtOAc/heptane, 5:1): 0.75; m.p. 176-178 C (Litt.4); IR 
(neat, cm-1): 1703, 1657, 1608, 1590 (Litt.3); 1H NMR (CDCl3, 500 MHz):  6.08 (1H, s), 5.41 (1H, s), 4.00 
(3H, s), 3.92 (3H, s), 3.91-3.82 (2H, m), 3.19 (1H, dd, J = 17.6, 12.1 Hz), 2.84 (1H, ddq, J = 12.1, 6.7, 5.7 
Hz), 2.46 (1H, dd, J = 17.6, 5.7 Hz), 1.83-1.74 (2H, m), 1.02 (3H, d, J = 6.7 Hz), 0.99 (3H, t, J = 7.4 Hz); 
13C NMR (CDCl3, 50 MHz):  191.7, 188.8, 178.2, 169.6, 164.4, 157.6, 105.1, 99.9, 97.2, 95.0, 89.4, 70.7, 
56.9, 56.2, 35.1, 33.1, 21.7, 14.4, 10.2; []20D = +192° (c = 0.5 in CHCl3); Anal. Calcd for C19H21ClO6: C, 
59.92; H, 5.56. Found: C, 59.86; H, 5.47 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(4’-isopropoxy-6’-methyl-cyclohex-3’-en-
2’-one) 41 
 
Yield: 109 mg (47%) (white crystals); Rf-value (EtOAc/heptane, 5:1): 0.71; m.p. 186-187 C (Litt.4); IR 
(neat, cm-1): 1704, 1657, 1611, 1589 (Litt.3); 1H NMR (CDCl3, 300 MHz):  6.08 (1H, s), 5.41 (1H, s), 4.49 
(1H, sept., J = 6.1 Hz), 4.00 (3H, s), 3.92 (3H, s), 3.15 (1H, ddd, J = 17.6, 12.1, 1.2 Hz), 2.83 (1H, ddq, J = 
12.1, 6.7, 5.7 Hz), 2.42 (1H, dd, J = 17.6, 5.7 Hz), 1.33 (6H, d, J = 6.1 Hz), 1.01 (3H, d, J = 6.7 Hz); 13C 
NMR (CDCl3, 50 MHz):  191.8, 188.8, 177.0, 169.7, 164.3, 157.6, 105.2, 100.2, 97.4, 95.1, 89.3, 71.9, 
56.9, 56.2, 35.0, 33.6, 21.5, 21.2, 14.4; []20D = +153° (c = 0.4 in CHCl3); Anal. Calcd for C19H21ClO6: C, 
59.92; H, 5.56. Found: C, 59.84; H, 5.50. 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(4’-benzyloxy-6’-methyl-cyclohex-3’-en-
2’-one) 44 
 
Yield: 398 mg (31%) (yellow oil); Rf-value (EtOAc/heptane, 5:1): 0.59; IR (neat, cm-1): 1703, 1658, 1609, 
1589; 1H NMR (CDCl3, 300 MHz):  7.42-7.33 (5H, m), 6.06 (1H, s), 5.53 (1H, s), 4.96 (1H, d, J = 17.2 
Hz), 4.94 (1H, d, J = 17.2 Hz), 3.99 (3H, s), 3.86 (3H, s), 3.25 (1H, dd, J = 17.6, 12.0 Hz), 2.90-2.81 (1H, 
m), 2.53 (1H, dd, J = 17.6, 5.7 Hz), 1.02 (3H, d, J = 6.7 Hz); 13C NMR (CDCl3, 50 MHz):  191.6, 188.8, 
177.7, 169.6, 164.4, 157.6, 134.4, 128.6 (2C), 128.1, 127.8 (2C), 104.9, 100.5, 97.1, 94.9, 89.4, 71.0, 56.9, 
56.1, 35.1, 33.1, 14.4; []20D = +307° (c = 0.5 in CHCl3); HRMS (ESI+) calcd for [M+H]+ [C23H22ClNO6]+ 
429.1105, found 429.1107. 
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Synthesis and single crystal X-ray analysis of two griseofulvin metabolites 
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 S2 
Experimental
1H NMR spectra were recorded using either a Varian Unity Inova 500 MHz spectrometer or a 
Varian Mercury 300 MHz spectrometer. 13C NMR spectra were recorded using a Bruker AC 200 
MHz. Chemical shifts were measured in ppm and coupling constants in Hz. When CDCl3 was used 
as solvent the residual peak was used as internal reference at  7.27 for 1H NMR and  77.00 for 13C 
NMR spectra. When DMSO-d6 was used the values were  2.50 for 1H NMR and  39.43 for 13C 
NMR spectra. 
IR spectra were recorded using a Bruker Alpha ATR and measured in cm1. All melting points are 
uncorrected. TLC was performed on aluminium sheets precoated with silica gel 60 F254 (Merck 
1.05554.0001).  
High-resolution LC-DAD-MS was performed on an Agilent 1100 system equipped with a 
photodiode array detector (DAD) and coupled to a LCT orthogonal time-of-flight mass 
spectrometer (Waters-Micromass, Manchester, UK) with a Z-spray electrospray ionisation (ESI) 
source and a LockSpray probe (M+H 556.2771) and controlled by MassLynx 4.0 software. LC-MS 
calibration from m/z 100-900 was done with a PEG mixture. Standard separation involved a LUNA 
2 column with an acetonitrile (50 ppm formic acid) in water gradient starting from 15% to 100% 
over 25 minutes with a flow rate of 0.3 mL/min. 
Compounds were visualized by charring after dipping in a solution of 1% KMnO4, 6.7% K2CO3 and 
0.08% NaOH in water. UV visualization was done using a Model UVGL-25 Mineralight Lamp. 
LC-MS/MS analysis was performed with an Agilent HP 1100 liquid chromatography system 
(Waldbronn, Germany) coupled to a Quattro Ultima triple mass spectrometer (Micromass, 
Manchester, UK) with ESI source. A Gemini C6-phenyl HPLC column (50 × 2 mm, 3 μm) was 
used with a flow of 0.3 mL/min and H2O/CH3CN (Starting at 80/20, increasing to 0/100 over 9 
minutes) as the mobile phase. Tandem mass spectrometry was performed in ESI+ at a source flow at 
700 L/h nitrogen at 350 °C. Nitrogen was also used as collision gas, and the MS operated in 
multiple reaction monitoring mode at the following transitions for both 2 and 3: daughter ion scan 
of m/z 339, cone 50 V, collision 30. 45 and 60 V, dwell time 50 ms.  
Fluorescence spectra was obtained on an Agilent Series 110 FLD  
 
 
(2S,6’R)-(7-Chloro-4,6-dimethoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-cyclohex-
2’-en-4’-one) 1
 
1H NMR (DMSO-d6, 300 MHz) 6.50 (1H, s), 5.60 (1H, s), 4.05 (3H, s), 3.94 (3H, s), 3.62 (3H, s), 
2.80 (1H, ddq, J = 13.3, 6.6, 4.8 Hz), 2.67 (1H, dd, J = 16.6, 13.3 Hz), 2.35 (1H, dd, J = 16.6, 4.8 
Hz), 0.80 (3H, d, J = 6.6 Hz); 13C NMR(DMSO-d6, 50 MHz)  195.5, 191.1, 170.2, 168.5, 164.4, 
157.6, 104.6, 104.0, 95.2, 91.3, 90.1, 57.5, 57.0, 56.5, 39.2, 35.5, 13.8. 
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(2S,6’R)-(7-Chloro-6-hydroxy-4-methoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-
cyclohex-2’-en-4’-one) 2
 
Method A: 
Griseofulvin (10 mg, 0.03 mmol) and LiI (4.7 mg, 0.04) was dissolved in pyridine (0.5 mL) and 
heated to 115 °C. After 16 H the reaction was allowed to reach 20 °C and sat. aq. NH4Cl was added. 
The mixture was extracted 3 times with EtOAc, dried (MgSO4) and concentrated. Purification was 
performed on a Luna HPLC column (250 × 10 mm, 5 μm, C-18) using 5 mL/min H2O/CH3CN 
(isocratic run at 65/35, for 15 minutes) as the mobile phase to yield 2 (2.8 mg, 29 %) as a yellow 
oil. Rf (CH2Cl2:MeOH:HOAc 96:3:1): 0.32; IR(neat): 1707, 1667, 1610; 1H NMR (DMSO-d6, 500 
MHz) 6.26 (1H, s), 5.59 (1H, s), 3.81 (3H, s), 3.63 (3H, s), 2.78 (1H, ddq, J = 13.4, 6.5, 4.6 Hz), 
2.68 (1H, dd, J = 16.4, 13.4 Hz), 2.33 (1H, dd, J = 16.4, 4.6 Hz), 0.80 (3H, d, J = 6.5 Hz); 1H 
NMR(CDCl3, 500 MHz):  6.25 (1H, s), 5.57 (1H, s), 3.92 (3H, s), 3.63 (3H, s), 3.04 (1H, dd, J = 
16.8, 13.4 Hz). 2.83 (1H, ddq, J = 13.4, 6.5 4.7 Hz), 2.45 (1H, dd, J = 16.8, 4.7 Hz), 0.97 (3H, d, J
= 6.5 Hz); 13C NMR(DMSO-d6, from gHSQC and gHMBC, 500 MHz):  195.6, 190.6, 170.4, 
169.8, 164.5, 156.9, 104.1, 102.9, 94.3, 93.7, 89.8, 56.7, 55.6, 39.2, 35.3, 13.5; 13C NMR(CDCl3, 
from gHSQC and gHMBC, 500 MHz):  197.3, 191.8, 170.6, 169.2, 161.4, 157.9, 105.1, 104.6, 
96.9, 93.1, 91.0, 56.4, 56.2, 39.7, 36.0, 13.9; [] +254° (c = 0.1 in MeOH); HRMS (ESI+) calcd for 
M+H [C16H16ClO6]+ 339.0635, found 339.0634. 
 
Method B: 
Compound S1 (51 mg, 0.16 mmol) was dissolved in MeOH (2.5 mL), CSA was added (1 mg, 0.01 
mmol) and the mixture was refluxed for 20 H. EtOAc was added and the organic phase was washed 
with sat. aq. NaHCO3. The aqueous phase was extracted three times with EtOAc and the combined 
organic phases were dried (MgSO4) and concentrated. The product 2 was isolated on a Luna HPLC 
column (250 × 10 mm, 5 μm, C-18) using 5 mL/min H2O/CH3CN (isocratic run at 65/35, for 15 
minutes) as the mobile phase to yield 2 (1 mg, 2 %) 
 
 
(2S,6’R)-(7-Chloro-6-methoxy-4-hydroxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-
cyclohex-2’-en-4’-one) 3
 
 
A solution of MgI2 was prepared by adding magnesium turnings (31 mg, 1.3 mmol) and iodine (54 
mg, 0.43 mmol) to anhydrous Et2O (2 mL) and toluene (1 mL). This solution was sonicated at 60 
°C for 90 min., ltered and added to griseofulvin (1) (100 mg, 0.29 mmol) and heated to 80 °C. The 
solution was cooled to 20 °C after 20 h. and 0.2 M H2SO4 was added. The mixture was extracted 3 
times with EtOAc, dried (MgSO4) and concentrated. The residue was purified by column 
chromatography (CH2Cl2:MeOH:AcOH 97:2:1), yielding 3, which was recrystallized from 
EtOAc/heptane to afford yellow crystals (95 mg, 98%). Rf (CH2Cl2:MeOH:HOAc 96:3:1): 0.25; 
m.p: 138-140 °C; IR(neat): 1697, 1620, 1449; 1H NMR(DMSO-d6, 500 MHz):  11.53 (1H, s), 6.26 
(1H, s), 5.60 (1H, s), 3.92 (3H, s), 3.63 (3H, s), 2.78 (1H, ddq, J = 13.4, 6.5 4.5 Hz), 2.68 (1H, dd, J
= 16.3, 13.4 Hz), 2.34 (1H, dd, J = 16.3, 4.5 Hz), 0.81 (3H, d, J = 6.5 Hz); 1H NMR(CDCl3, 300 
MHz):  6.18 (1H, s), 5.57 (1H, s), 3.97 (3H, s), 3.65 (3H, s), 2.95 (1H, dd, J = 15.3, 13.1 Hz), 2.92-
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 S4 
2.80 (1H, m), 2.48 (1H, dd, J = 15.3, 3.2 Hz), 0.97 (3H, d, J = 6.4 Hz); 13C NMR(DMSO-d6, 500 
MHz):  195.5, 191.3, 170.4, 168.1, 163.7, 156.8, 104.5, 103.7, 94.1, 93.6, 89.8, 56.9 (2C), 39.4, 
35.6, 13.8; 13C NMR(CDCl3, 50 MHz):  196.8, 195.6, 170.4, 167.3, 165.5, 156.0, 104.8, 103.9, 
96.4, 93.7, 91.2, 57.2, 56.7, 40.0, 36.2, 14.2; [] +310° (c = 0.3 in CCl3); HRMS (ESI+) calcd for 
M+H [C16H16ClO6]+ 339.0635, found 339.0633. 
 
 
(2S,6’R)-(7-Chloro-6-hydroxy-4-methoxy-benzofuran-3-on)-2-spiro-1’-(6’-methyl-cyclohex-2’,4’-
dione) S1
O
O
Cl
MeO
HO
OH
O
 
 
Griseofulvic acid1,2 (300 mg, 0.88 mol) was dissolved in 0.66 M NaOH (10 mL) and heated to 100 
°C for 24 H. The mixture was allowed to reach 20 °C and filtered. The supernatant was acidified 
with 2 M H2SO4 and the precipitate purified on reverse phase silica (MeOH/H2O). The compound 
was re-crystallized from MeOH/H2O to afford S1 (123 mg, 43%) as white crystals. Rf 
(CH2Cl2:MeOH:HOAc 89:10:1): 0.49; m.p: 259-261 °C (decomp.); IR(neat): 3100 (b), 1661, 1632, 
1579, 1538; 1H NMR(DMSO-d6):  11.88 (1H, s), 6.24 (1H, s), 5.30 (1H, s), 3.78 (3H, s), 2.88-2.66 
(2H, m), 2.52-2.40 (1H, m), 0.84 (3H, d, J = 6.1 Hz); 13C NMR(DMSO-d6):  190.7, 187.8, 179.3, 
170.1, 163.7, 156.9, 103.5, 101.5, 94.3 (2C), 93.6, 55.9, 34.4, 32.9 14.3; [] +289° (c = 0.3 in 
MeOH); HRMS (ESI+) calcd for M+H [C15H14ClO6]+ 325.0479, found 325.0467. 
 
1. Rønnest, M. H.; Rebacz, B.; Markworth, L.; Terp, A. H.; Larsen, T. O.; Krämer, A.; Clausen, M. H. J. Med. 
Chem. 2009, 52, 3342.  
2. Arkley, V.; Gregory, G. I.; Attenbur, J.; Walker, T. J. Chem. Soc. 1962, 1260.
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Griseofulvin 1
1H NMR (500 MHz, DMSO-d6) 
 
Figure 1. 1H NMR of 1 in DMSO 
 
13C NMR (50 MHz, DMSO-d6) 
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(2S,6’R)-(7-Chloro-6-hydroxy-4-methoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-
cyclohex-2’-en-4’-one) 2
1H NMR (500 MHz, DMSO-d6) 
 
Figure 2. 1H NMR of 2 in DMSO 
LC-DAD chromatogram 
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(2S,6’R)-(7-Chloro-6-methoxy-4-hydroxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-
cyclohex-2’-en-4’-one) 3
1H NMR (500 MHz, DMSO-d6) 
 
 
Figure 3. 1H NMR of 3 in DMSO, insert showing spectrum after shaking with D2O.
 
13C NMR (50 MHz, DMSO-d6) 
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LC-DAD chromatogram 
 
 
 
244 Supp. Info. - Chapter 5
260
 S9 
(2S,6’R)-(7-Chloro-6-hydroxy-4-methoxy-benzofuran-3-on)-2-spiro-1’-(6’-methyl-cyclohex-2’,4’-
dione) S1
1H NMR (300 MHz, DMSO-d6)
 
13C NMR (50 MHz, DMSO-d6) 
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 S10 
LC-DAD chromatogram 
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Griseofulvin 1
gHMBC (500 MHz, DMSO-d6) 
 
 
Figure 4. gHMBC spectrum of griseofulvin, showing that the two methoxy groups (9 and 10) only have one 
correlation each, which is to the corresponding ipso carbon. 
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(2S,6’R)-(7-Chloro-6-hydroxy-4-methoxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-
cyclohex-2’-en-4’-one) 2
Atom# 1H NMR 13C NMR gHMBC DQF-COSY 
2  89.8   
3  190.6   
3a  102.9   
4  156.9   
5 6.26 (1H, s) 93.7 3, 3a, 4, 6, 7, 7a  
6  164.5   
7  94.3   
7a  169.8   
8 0.80 (3H, d, J = 6.5 Hz) 13.5 2, 4’, 5’, 6’ 6’ 
9 3.81 (3H, s) 55.6 4  
10 3.63 (3H, s) 56.7 2’, 3’  
2’  170.4   
3’ 5.59 (1H, s) 104.1 2, 2’, 4’, 5’  
4’  195.6   
5’ 2.33 (1H, dd, J = 16.4, 4.6 Hz) 2, 3’, 4’, 6’, 8 5’, 6’ 
5’ 2.68 (1H, dd, J = 16.4, 13.4 Hz) 39.2 2, 4’, 6’, 8 5’, 6’ 
6’ 2.78 (1H, ddq, J = 13.4, 6.5 4.6 Hz) 35.3 2, 3, 5’, 8 5’, 5’, 8 
Table 1. 1H NMR as well as gHMBC and DQF-COSY data for 2 (500 MHz, DMSO-d6) 
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(2S,6’R)-(7-Chloro-6-methoxy-4-hydroxy-benzofuran-3-on)-2-spiro-1’-(2’-methoxy-6’-methyl-
cyclohex-2’-en-4’-one) 3
 
gHMBC (500 MHz, DMSO-d6) 
 
 
Figure 5. gHMBC of 3. By increasing the intensity, a correlation can be seen from the phenol (4) to the carbon 
shift 103.7, which corresponds to the 3a position, indicating the position of the phenol. 
 
 
Atom# 1H NMR 13C NMR gHMBC DQF-COSY 
2  89.8   
3  191.3   
3a  103.7   
4 11.53 (1H, s) 156.8 3a  
5 6.26 (1H, s) 94.1 3, 3a, 4, 6, 7, 7a  
6  163.7   
7  93.6   
7a  168.1   
8 0.81 (3H, d, J = 6.5 Hz) 13.8 2, 4’, 5’, 6’ 6’ 
9 3.92 (3H, s) 56.9 6  
10 3.63 (3H, s) 56.9 2’, 3’  
2’  170.4   
3’ 5.60 (1H, s) 104.5 2, 2’, 4’, 5’  
4’  195.5   
5’ 2.34 (1H, dd, J = 16.3, 4.5 Hz) 2, 3’, 4’, 6’, 8 5’, 6’ 
5’ 2.68 (1H, dd, J = 16.3, 13.4 Hz) 39.4 2, 4’, 6’, 8 5’, 6’ 
6’ 2.78 (1H, ddq, J = 13.4, 6.5 4.5 Hz) 35.6 2, 2’, 3, 5’, 8 5’, 5’, 8 
Table 2. 1H and 13C NMR as well as gHMBC and DQF-COSY data 3 (500 MHz, DMSO-d6) 
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UV spectrum of 2
 
UV spectrum of 3
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Fluorescence data 
Excitation Emission (2) Emission (3) 
215 nm 420 nm 424 nm 
237 nm 424 nm 430 nm 
295 nm 427 nm 434 nm 
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MS-MS spectra of 2 and 3 (collision 30 V)
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MS-MS spectra of 2 and 3 (collision 45 V) 
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 S18 
MS-MS spectra of 2 and 3 (collision 60 V) 
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S1 
 
A technique for selective ipso-substitution of ortho-, meta- or para-aryl trimethylsilyl groups with 
radioactive iodide in quantitative yields. 
 
Mads H. Rønnest, Felix Nissen, Thomas Ostenfeld Larsen, Walter Mier, Mads H. Clausen* 
 
Supporting Information 
S2-S10  NMR spectra of 3, 4, 5, 7, 8, 9, 10, 11 and 12. 
S11  UPLC-DAD chromatograms of compounds 7, 8, 9, 10, 11 and 12. 
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1H NMR (300 MHz, CDCl3) 3 
 
13C NMR (75 MHz, CDCl3) 3 
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1H NMR (300 MHz, CDCl3) 4 
 
13C NMR (75 MHz, CDCl3) 4 
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S4 
 
1H NMR (300 MHz, CDCl3) 5 
 
13C NMR (75 MHz, CDCl3) 5 
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1H NMR (300 MHz, CDCl3) 7 
 
13C NMR (50 MHz, CDCl3) 7 
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1H NMR (300 MHz, CDCl3) 8 
 
13C NMR (50 MHz, CDCl3) 8 
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1H NMR (300 MHz, CDCl3) 9 
 
13C NMR (50 MHz, CDCl3) 9 
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1H NMR (300 MHz, CDCl3) 10 
 
13C NMR (50 MHz, CDCl3) 10 
 
1H NMR (300 MHz, CDCl3) 11  
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S9 
 
 
13C NMR (50 MHz, CDCl3) 11 
 
1H NMR (300 MHz, CDCl3) 12 
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S10 
 
 
13C NMR (50 MHz, CDCl3) 12 
 
UPLC-DAD 7 
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S1 
 
(+)-Geodin from Aspergillus terreus 
Mads H. Rønnest, Morten T. Nielsen, Blanka Leber, Uffe H. Mortensen, Alwin Krämer, Mads H. Clausen, 
Thomas O. Larsen, Pernille Harris* 
 
Supplementary data 
 
S2  Experimental 
S3-S4 1D NMR spectra of 1 and UPLC-DAD chromatogram 
S5 References  
269
285
S2 
 
Experimental 
1H NMR spectra were recorded using either a Varian Unity Inova 500 MHz or a Bruker Avance 800 MHz 
spectrometer. 13C NMR spectrum were recorded using a Bruker Avance 800 MHz spectrometer. Chemical shifts 
were measured in ppm and coupling constants in Hz. When benzene-d6 was used as solvent the residual peak was 
used as internal reference at 7.15 for 1H NMR and δ 128.0 for 13C NMR spectra. For DMSO-d6 the value were δ 
2.50 for 1H NMR. The IR spectrum was recorded using a Bruker Alpha ATR and measured in cm−1. The melting 
point is uncorrected. High-resolution LC-DAD-MS was performed on an Agilent 1100 system equipped with a 
photodiode array detector (DAD) and coupled to a LCT orthogonal time-of-flight mass spectrometer (Waters-
Micromass, Manchester, UK) with a Z-spray electrospray ionisation (ESI) source and a LockSpray probe (M+H 
556.2771) and controlled by MassLynx 4.0 software. LC-MS calibration from m/z 100-900 was done with a PEG 
mixture. Standard separation involved a LUNA 2 column with an acetonitrile (50 ppm formic acid) in water 
gradient starting from 15% to 100% over 25 minutes with a flow rate of 0.3 mL/min. 
Purity was assessed by UPLC-DAD on a Dionex ultimate 3000 system. The column used was a Kinetex (150 × 
2.10 mm, 2.6 μm, C-18) at 357 °K with a flow of 0.8 mL. The following gradient was used: 
 
Time (min.) MeCN % 
0 15 
0.5 25 
6.0 65 
7.0 100 
8.5 100 
9.0 15 
12.0 15 
 
A. terreus (IBT 28226, culture collection at center for microbial biotechnology (Lyngby, Denmark)) was cultured 
on 50 plates of yeast extract sucrose agar at 298 °K for 7 days and extracted with ethyl acetate (2L) then 
concentrated to afford 1.2 g raw extract. The raw extract was dissolved in 10% H2O in MeOH (50 mL) and the 
aqueous phase was extracted with heptane (50 mL). The water content was increased to 50% by adding 40 mL 
H2O and shaken with CH2Cl2 (90 mL). The CH2Cl2 phase was concentrated (0.86 g) and further purification was 
performed on a Luna HPLC column (250 × 10 mm, 5 μm, C-18) using 5 mL/min H2O/CH3CN (isocratic run at 
50/50 for 15 minutes) as the mobile phase to yield 1 (11.6 mg as yellow oil). Geodin (1) was crystallized from 
EtOAc/heptane to afford yellow crystals. 
 
(R)-Methyl 5,7-dichloro-4-hydroxy-6'-methoxy-6-methyl-3,4'-dioxo-spiro[benzofuran-2,1'-cyclohexa-2',5'-diene]-
2'-carboxylate I (geodin) 
 
m.p.: 527-529 °K. (in agreement with litt. (Raistrick & Smith, 1936)). IR(neat): 3396, 1724, 1659, 1610, 1461, 
1440; 1H NMR (800 MHz, benzene-d6):  7.04 (1H, d, J = 1.0 Hz), 5.43 (1H, d, J = 1.0 Hz), 2.91 (3H, s), 2.53 
(3H, s), 2.00 (3H, s); 13C NMR (200 MHz, benzene-d6):  194.3, 184.8, 167.8, 166.4, 163.9, 150.4, 147.1, 137.9, 
137.7, 115.5, 110.0, 110.0, 105.1, 85.4, 56.3, 52.5, 18.5; 1H NMR (800 MHz, CDCl3):  7.14 (1H, d, J = 1.5 Hz), 
5.82 (1H, d, J = 1.5 Hz), 3.74 (3H, s), 3.70 (3H, s), 2.58 (3H, s) (in agreement with litt. (Sato et al., 2005)); 1H 
NMR (500 MHz, DMSO-d6):  7.05 (1H, d, J = 1.0 Hz), 6.05 (1H, d, J = 1.0 Hz), 3.72 (3H, s), 3.68 (3H, s), 2.52 
(3H, s); HRMS (ESI+) calcd for M + H [C17H13Cl2O7]+ 399.0038, found 399.0041. [∝] +129° (c = 1.16, CHCl3) 
(in agreement with litt. (Raistrick & Smith, 1936)). 
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S3 
 
1H NMR (800 MHz, benzene-d6) 
 13C NMR (200 MHz, benzene-d6) 
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S4 
 
UPLC-DAD chromatogram and UV spectrum 
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